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DIABETES MELLITUS: PATHOPHYSIOLOGY AND CONSEQUENCES 
In people with diabetes mellitus, commonly abbreviated as diabetes, β-cells in the pancreas 
are unable to produce sufficient insulin which is needed for the uptake of glucose in body 
tissues [1]. This might co-occur with body tissues being resistant to insulin and thereby not 
being able to use insulin effectively [1]. Thereby untreated diabetes results in high blood 
glucose levels (hyperglycaemia).
 Hyperglycaemia is associated with acute symptoms such as increased hunger and 
thirst, frequent urination and an increased risk of infections [2]. Long-term consequences 
of high blood glucose levels are macrovascular (cardiovascular disease) and microvascular 
complications such as damage to the small blood vessels of the eyes (retinopathy), kidneys 
(nephropathy), and nerves (neuropathy) [3]. In an advanced stage, these complications 
could result in blindness, the need for dialysis, or an amputation of a foot or a leg [3]. 
 The most common types of diabetes are type 1 and type 2 diabetes. In people with type 
1 diabetes, damaging and destruction of β-cells caused by an auto-immune response results 
in an absolute insulin deficiency [1]. A recent study has shown, however, that (inactive) 
β-cells might still be present in the pancreas in persons with type 1 diabetes [4]. A feature 
of type 1 diabetes is its rapid onset which generally occurs in childhood or adolescence, but 
can occur at any age [2]. 
 The majority of people with diabetes have type 2 diabetes (approximately 90%) [3]. Type 
2 diabetes – the focus of this thesis – generally has a gradual onset and is characterised by 
insulin resistance (reduced response of body tissues to insulin) and insufficient production 
of insulin by β-cells to meet the heightened needs, either of which may predominate [1]. 
The onset is usually in (late) adulthood [2]. A person’s risk of developing type 2 diabetes can 
be estimated using a combination of genetic predisposition factors, overweight and lifestyle 
factors, such as low levels of physical activity and an unhealthy eating pattern including a 
high intake of saturated fat and high caloric intake [5]. 
 Worldwide, about 382 million people have diabetes [3]. In the Netherlands, approximately 
one million people have this condition [6]. The prevalence of diabetes has rapidly increased 
since the year 2000 in the Netherlands. From 2001 to 2011 the prevalence has doubled 
in men and increased more than 60% in women [6]. Explanations for this increase are 
improved detection of type 2 diabetes, longer life expectancies, but also a trend towards a 
more unhealthy lifestyle resulting in more obesity [6]. With more children and adolescents 
being obese type 2 diabetes is not exclusively diagnosed in adults anymore. Although exact 
numbers of children and adolescents with type 2 diabetes in the Netherlands are unknown, 




 Because of the gradual onset of type 2 diabetes, this condition might stay unnoticed 
for years [3]. Approximately one quarter to half of the people with type 2 diabetes are not 
diagnosed [3,6]. Because of this delay in diagnosis, many people have already developed 
micro- or macrovascular complications at time of diagnosis. For example, a Dutch study 
among people diagnosed by their general practitioner between 1998 and 2005 in the area 
of Nijmegen found that 24% had a (history of) macrovascular disease (e.g., stroke) at time 
of diagnosis and also 24% already had microvascular complications (e.g., nephropathy) [7]. 
Another Dutch study, ‘The Hoorn study’ in West-Friesland, among people diagnosed by their 
general practitioner between 1999 and 2001, also found high percentages of complications 
at time of diagnosis, with up to half of all new cases having reduced sensibility in feet and 
a quarter having ischaemic heart disease [8,9]. Because the detection of type 2 diabetes 
has improved during the last decennium [10], the percentage of people already having 
complications at time of diagnosis has probably decreased.
TREATMENT OF TYPE 2 DIABETES
The main treatment goal of diabetes care is to prevent or delay long-term vascular 
complications. The UK Prospective Diabetes Study (UKPDS), a landmark, randomised, 
multicentre trial has found that following a strict treatment regimen that strives towards 
near normal blood glucose levels and optimal glycaemic control resulted in a 25% reduction 
in microvascular complications and a 6% reduction in all-cause mortality over 10 years 
in people with type 2 diabetes [11]. Diabetes care generally aims at reducing glycated 
haemoglobin level (HbA1c; which indicates the average blood glucose level in the previous 
three months) to 53 mmol/mol (7%), although in elderly in some cases a higher HbA1c level is 
recommended (58 or 64 mmol/mol) [12]. In Dutch primary care, HbA1c levels are determined 
in the laboratory at least once a year [12]. An additional treatment aim is reducing other 
(modifiable) cardiovascular risk factors by optimising cholesterol levels and blood pressure 
and advising to quit smoking [12,13]. 
 In order to reach or maintain good glycaemic control and prevent or delay complications, 
people with type 2 diabetes have to regulate their blood glucose level and other 
cardiovascular risk factors by monitoring their food intake, engaging in regular physical 
activity, using medication to lower their blood glucose levels and to optimise cholesterol 
levels and blood pressure (if indicated), and maintaining normal body weight [14]. Besides, 
patients need to stop smoking (if applicable), and inspect their feet [14]. Treatment of 
hyperglycaemia generally follows a stepwise approach [12,15,16]. The first step is to engage 
in a healthier lifestyle (weight loss, healthier eating pattern, increase exercise levels, and quit 
smoking), followed by the use of the oral agent metformin to lower blood glucose [12,15]. 




the next step is, usually, to add a sulfonylurea derivate (another oral agent). If that is not 
sufficient, insulin therapy is indicated [12]. Type 2 diabetes is characterised by progressive 
β-cell dysfunction, hence during the course of diabetes treatment intensification is generally 
necessary [16]. On a yearly basis, insulin is initiated in about six percent of people with type 
2 diabetes using oral agents [17]. 
 In the Netherlands, approximately 90% of people with type 2 diabetes are treated in 
general practice (primary care), and even an increasing number of those who need insulin 
treatment are treated in primary care instead of secondary care. Usually, they are seen by 
a practice nurse in the general practice every three months and once a year by the general 
practitioner [12]. Consultations include lifestyle advice, improving self-management, 
monitoring blood glucose level and other risk factors for complications, such as a high level 
of low-density lipoprotein (LDL) cholesterol, elevated blood pressure, overweight, and 
monitoring signs of complications, such as reduced sensibility of feet, microalbuminuria, 
and signs of retinopathy. 
 In some cases people are referred to specialised diabetes care in hospitals (secondary 
care; approximately 10% of people with type 2 diabetes). Referral is indicated when glucose 
levels remain suboptimal despite the efforts of the person with diabetes and the primary 
care team, when cardiovascular risk factors, such as hypertension and high cholesterol 
levels, do not respond to treatment, when comorbidities or treatment of complications, 
such as nephropathy or painful neuropathy, requires specialised care, or when a women 
with type 2 diabetes wishes to become pregnant [18].
DIABETES AND EMOTIONAL DISTRESS  
Diabetes-specific and emotional distress
Having a chronic condition such as diabetes can be burdensome. Diabetes treatment relies 
for a large part on self-care, such as adherence to a healthy diet, regular physical activity, 
foot care, and taking medication. This focus on self-care might induce feelings of guilt when 
glucose levels are suboptimal, or guilt related to being overweight. Furthermore, people 
with diabetes are confronted with the possibility of developing complications or with the 
further progression of existing complications. Also feelings of loneliness and lack of support 
related to diabetes have been reported by this group [19].
 These negative emotions specifically related to living with diabetes and its self-
management are referred to as ‘diabetes-specific emotional distress’ (shortened as diabetes 
distress). The prevalence rate of high diabetes distress depends on the questionnaire used, 
the definition of ‘elevated levels of’ or ‘severe’ diabetes distress and the sample in which it is 
assessed. For example, a study in the US among people with type 2 diabetes in primary care 
(n = 506, mean age 58 ± 10 years) found a prevalence of 18% of moderate diabetes distress 
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which was defined as a mean item score on the Diabetes Distress scale (range 1-5) of ≥ 3 
[20]. A much higher percentage was found in a recent Australian study among young adults 
with type 2 diabetes (< 40 years old, n = 149). They found that 63% reported severe diabetes 
distress which was defined as a total score of ≥ 8 on the 5-item Problem Areas in Diabetes 
scale (range 0-20) [21]. Several factors have been related to elevated diabetes distress, such 
as suboptimal HbA1c levels [22-25], using insulin [26] and having complications [26,27].
Diabetes and depression
Another emotional problem that has been linked to diabetes is depression. The two core 
symptoms of a major depressive disorder are (1) feeling down (dysphoria) and (2) diminished 
interest or pleasure (anhedonia) [28]. Other symptoms of depression may include change in 
appetite (eating more or less than usual), sleep disturbance or excessive sleeping, fatigue, 
feelings of worthlessness or guilt, diminished ability to concentrate or to make decisions, 
being agitated or lethargic, and recurrent thoughts of death [28]. For a diagnosis of major 
depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders 
fourth edition (DSM-IV) a person should have at least one of the two core symptoms and 
in total at least five out of the nine depression symptoms. In addition, the symptoms have 
to be present for at least two weeks almost every day, cause significant impairment in 
functioning, for example, work or social life, and cannot be explained by normal grief or a 
medical condition [28].
 The prevalence of depression in people with diabetes depends on the method of 
assessment [29]. In a meta-analysis of Anderson et al. it was found that when depression 
was assessed by a clinical diagnostic interview (tool to assess a depressive disorder) the 
prevalence was 11%, but the prevalence was 31% when assessed by a self-reported symptom 
questionnaire (tool to assess elevated symptoms of depression and symptom severity) [29]. 
Independently of the way it is assessed, the prevalence of depression in people with type 2 
diabetes is almost twice as high as people without this condition [29,30]. 
 There is convincing evidence that the relationship between type 2 diabetes and 
depression is bidirectional [31-33]. Depression has been related to a 37% increased risk of 
developing type 2 diabetes [31], and type 2 diabetes appeared to be associated with a 24% 
increased risk of developing depression [33]. Several behavioural and biological mechanisms 
could explain the heightened incidence of type 2 diabetes in people with depression. For 
example, depression is related with an unhealthy and inactive lifestyle [34], which in turn 
is a risk factor for developing type 2 diabetes [5]. A pathophysiological mechanism that 
could explain the heightened incidence of diabetes in people with depression is increased 
activation of the hypothalamic-pituitary-adrenocortical (HPA) axis and sympathetic nervous 
system in this group. This results in increased glucose production, decreased insulin release, 




of noradrenergic antidepressants and tricyclic antidepressants, which has been associated 
with adverse metabolic outcomes [36]. 
 A mechanism that could explain the heightened incidence of depression in people with 
diabetes is the ‘psychological burden hypothesis’ [37,38]. The burden of knowing that you 
have a chronic disease, which requires daily self-care and coping with complications could 
induce feelings of depression. Moreover, diabetes complications can result in functional 
limitations, which can also have a negative impact on mood [39]. Support for this hypothesis 
was found in a meta-analysis by Nouwen and colleagues [38]. They showed that people 
who know that they have diabetes had higher odds of experiencing depression than people 
with undiagnosed diabetes, impaired glucose metabolism (‘pre-diabetes’), or persons with 
normal glucose metabolism [38].
 Having depression is not only associated with a heightened incidence of diabetes, but 
also with adverse outcomes when having diabetes, such as an increased risk of developing 
diabetes related complications [40], an increased mortality risk [41], and decreased quality of 
life [42]. Less treatment adherence and poor lifestyle habits are associated with depression 
which could be an explanation for adverse outcomes [43,44].
Diabetes and anxiety
In persons with diabetes, the prevalence of anxiety is relatively high. The odds of having an 
anxiety disorder were found to be 25% higher in people with diabetes, compared with the 
general population, and the odds of having elevated anxiety symptoms were 48% higher 
[45]. In a systematic review by Grisby et al. it was found that 14% of people with diabetes 
had a generalised anxiety disorder (based on six studies with a total n = 850) and 40% had 
elevated symptoms of anxiety (based on 7 studies with a total n = 1283) [46]. Similar to 
depression, anxiety has been associated with increased activation of the HPA-axis which 
negatively influences glucose metabolism [47], and with unhealthy lifestyle factors, such 
as physical inactivity and obesity [48], which are known risk factors for the development 
of diabetes [3]. However, the question whether anxious persons are at increased risk for 
developing type 2 diabetes is currently unclear [49]. Preliminary findings among 1920 
people in the United States did not find a statistically significant association between anxiety 
disorders and an increased incidence of type 2 diabetes [48].
 The consequences of anxiety for diabetes outcomes are less clear than for depression. 
This could be due to the fact that only a few studies have investigated the potential role of 
anxiety, but also because a certain amount of anxiety might actually have beneficial effects 
on health [50]. A meta-analysis including 11 cross-sectional studies found that anxiety was 
related to suboptimal glycaemic control [51]. However, this relation was only found for 
anxiety disorders, not in studies investigating symptoms of anxiety [51]. Studies investigating 




Treatment of emotional distress in people with diabetes
The heightened prevalence of emotional distress – an umbrella term for problems such 
as anxiety, depression, and diabetes distress – and its negative consequences for diabetes 
outcomes and quality of life has prompted several guideline committees to recommend 
attention for psychosocial problems in diabetes care in national [12,55,56] and international 
diabetes guidelines [13,15,57]. Though emotional problem are frequently overlooked in 
people with diabetes [58], a strong focus on detection (e.g., screening) is not sufficient 
to reduce levels of emotional distress [59,60]. Detection should be embedded in a more 
intensive care program to improve outcomes [59]. For example, general guidelines on 
the treatment of depression and anxiety, such as the Dutch multidisciplinary guidelines 
and British guidelines by the National Institute for Health and Clinical Excellence (NICE), 
recommend using a stepped care treatment program [61-64]. The stepped care treatment 
model is considered to ensure a cost-effective treatment; the first step is the least costly and 
intensive though effective treatment, and a more intensive treatment is started only when 
necessary [65]. By assessing symptoms during or after the intervention, it can be evaluated 
whether it is necessary to continue with more intensified treatment [65]. Also the NICE 
guideline on depression in people with a chronic disease recommends using a stepped care 
model, despite limited studies examining the effectiveness of this model in people with a 
chronic disease. The extended collaborative stepped care model, that includes besides the 
stepped care treatment a multidisciplinary team across care settings and a care manager 
[66], showed promising results in treating symptoms of depression in people with diabetes 
[67-69]. This model has been predominantly evaluated in US primary care settings. A 
collaborative care treatment investigated by Williams et al. [69] yielded moderate to large 
effects after 12 months (Cohen’s d = 0.67, n = 417). The Pathways study found that more 
people in the intervention group had a 50% decrease in depressive symptoms (41% vs 32%) 
after 12 months, compared with the usual care group [68]. Although this difference was 
not statistically significant (adjusted odds ratio 1.47, 95% confidence interval 0.90-2.39, n = 
288), the mean difference in depression scores was statistically significant. 
 While guidelines recommend using a stepped care treatment model, a basic stepped care 
treatment model for people with a chronic disease in primary care has to our knowledge not 
been studied. Therefore, we developed the Disease Management program for Comorbid 
Depression and Anxiety (DiMaCoDeA) to evaluate a basic stepped care treatment in people 
with a chronic disease in primary care.
DiMaCoDeA intervention
The DiMaCoDeA intervention involved a stepped care intervention targeting symptoms of 
depression and anxiety in people with type 2 diabetes, asthma, and/or chronic obstructive 




self-report questionnaires, people were identified with elevated symptoms of depression 
or anxiety. Because depression and anxiety are often recurrent [70-72], the DiMaCoDeA 
intervention also included monitoring of symptoms after remission. Regularly assessing 
symptoms and intervening when symptoms recur could prevent development of a major 
depressive disorder or an anxiety disorder [73]. 
 The DiMaCoDeA study was conducted in general practices allied to the primary care 
organisation PoZoB located in the south of the Netherlands (Southeast-Brabant). PoZoB 
started with a managed care program for people with type 2 diabetes in 2005 (DIAZOB: 
DIAbetes care ZuidOost Brabant) [74]. Besides practice nurses, this primary care organisation 
also employs diabetes nurses. Diabetes nurses treat people with type 2 diabetes who are 
using insulin and support practice nurses. In 2008, PoZoB also started with a managed care 
program for people with asthma and COPD (ASCOZOB: Asthma and COPD care ZuidOost 
Brabant) [75]. The design of a randomised controlled trial investigating the effectiveness 
of the DiMaCoDeA intervention (stepped care treatment including continued monitoring 
of symptoms after remission) for people with type 2 diabetes is described in Chapter 2. 
Because of the small number of people with type 2 diabetes being eligible and willing to 
participate in the trial, we had to combine the sample of people with diabetes and the 
sample of people with asthma and/or COPD to be able to evaluate the DiMaCoDeA study 
(in the General Discussion, Chapter 7, this is discussed in more detail). Chapter 3 describes 
the results of the randomised controlled trial for both people with diabetes and those with 
asthma or COPD. 
Screening for emotional distress and subsequent trial participation
One of the findings of the trial was that the number of people willing to participate was 
much lower than initially expected. This induced several additional research topics for the 
present thesis, including the flow from screening for symptoms of anxiety and depression 
to participation in the DiMaCoDeA trial. The low inclusion rate led to questions about the 
characteristics of people who actually responded to the screening questionnaire and people 
who decided to participate in a subsequent treatment trial. 
 Several (inter)national diabetes guidelines recommend screening for emotional distress. 
While this seems reasonable given the increased prevalence, the under recognition, and the 
negative consequences of emotional distress in people with diabetes, this recommendation 
has also been debated. Opponents of the recommendation to screen for emotional distress 
(e.g., depression) in people with a chronic disease or in the general population argue that 
evidence for the effectiveness of screening is lacking and that screening for depression is 
unlikely to be cost-effective [59,76-79].
 A Dutch study in outpatient care has evaluated the effectiveness of a screening procedure 
for depression in people with diabetes using a randomised controlled trial design. In the 
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screening group, written feedback, including diagnosis and treatment advice, were provided 
to both the person with diabetes and the physician in case of an anxiety or mood disorder. In 
case no disorder was detected, only the person with diabetes received written feedback. This 
screening procedure did not result in decreased symptoms of depression or an increased 
initiation of treatment compared with the usual care group [60].
 Few studies have investigated the actual reach of a screening procedure for emotional 
distress in primary diabetes care. Two studies in people with diabetes in secondary care 
found that younger age, suboptimal HbA1c levels and cholesterol levels, smoking, and 
not coming to diabetes appointments in the hospital were related with not completing a 
screening questionnaire [80,81].
 Being screened positive does not automatically mean that someone would like to be 
referred to psychosocial health care or start psychological treatment. Two studies in hospital 
care settings (secondary or tertiary care) found that only about a third of identified cases 
with depression or diabetes distress accepted a referral to psychosocial care [81,82]. A 
Dutch study by Baas et al. reported that screening in a high risk group for depression (but 
not necessarily having diabetes) did rarely result in treatment initiation (4% (17/826) of 
people who filled out the screening questionnaire; 24% of people with newly diagnosed 
major depressive disorder) [83]. This low rate of acceptance of a regular care treatment 
offer might also occur when participation in a treatment trial is offered. A study in secondary 
diabetes care found that 58% of eligible people (reporting depressive symptoms and a need 
for help) participated in their treatment trial. Participants had on average a more optimal 
body mass index and triglycerides level, than eligible people who did not participate [80]. 
 The reach of screening for emotional distress in people with type 2 diabetes in primary 
care is not yet known, neither are the characteristics of people responding to screening or 
characteristics related to participation in a subsequent treatment trial. This is investigated 
in Chapter 4. 
Diabetes-specific emotional distress and care setting
The second research question triggered by the lower-than-expected participation rate in 
the treatment trial was the question whether the scope of the problem (emotional distress) 
was less pronounced in primary care compared with secondary care. There is evidence that 
depression is less prevalent in primary than in secondary care in the Netherlands [71,84]. 
A similar difference could be hypothesised to exist with regard to diabetes distress. As 
mentioned previously, Dutch people with type 2 diabetes are generally treated in primary 
care (90%), but more complex cases are treated in secondary care [18]. One might expect that 
diabetes distress levels are higher in secondary care, as factors known to be more common 
in secondary care, such as suboptimal HbA1c levels, insulin use, and having complications, 




comparison of diabetes distress levels between care settings within one country has never 
been made. Chapter 5 describes a study investigating levels of diabetes distress in Dutch 
people with type 2 diabetes in primary versus secondary care and factors that could explain 
possible differences in diabetes distress levels.
Psychosocial health care needs
A third study prompted by the low participation rate in the treatment trial focused on the 
actual psychosocial health care needs of people with type 2 diabetes in primary care. We 
also examined factors related to having an open attitude towards psychosocial health care 
and factors related to addressing psychosocial issues by the health care provider. These 
topics have not received much scientific attention. The international Monitoring Individual 
Needs in Diabetes (MIND) study in people with diabetes in secondary care found that only 
15% reported that they wished to discuss mood or stress with their diabetes health care 
provider during the next consultation [82]. However, a qualitative study conducted in 34 
people with type 2 diabetes in the USA found that 19 out of 20 persons who indicated 
that their diabetes health care provider did not inquire about their emotional well-being, 
wanted their health care provider to inquire about this. They considered knowledge about 
their emotional struggles necessary for providing personalised care [85]. Although they 
expressed the desire that the health care provider listened to what bothered them and 
knew about their situation, they did not expect him/her to treat their problems [85]. A 
parallel qualitative study in 19 diabetes health care providers (general practitioners and 
endocrinologists) identified barriers for the health care providers in delivering psychosocial 
support to people with type 2 diabetes. Some health care providers noted difficulties 
with referral, for example, finding a therapist in the neighbourhood of the patient; were 
overwhelmed when having to deal with emotional problems; felt exhausted themselves 
when these issues were addressed; or reported lack of expertise in providing proper 
support [86]. Unfortunately, these short reports only focused on patients’ and health care 
providers perspectives with respect to addressing emotional problems in diabetes care, and 
did not investigate the full range of psychosocial health care needs or factors related to 
open attitude towards psychosocial health care in people with type 2 diabetes. A study 
that examined patient barriers in accepting care for anxiety or depression in general (not 
specifically in people with diabetes) reported the existence of several barriers including 
the desire to handle problems on one’s own, fear of being stigmatised, or lack of time for 
treatment [87]. 
 Given the small number of previous studies and their limitations, we conducted a 
qualitative focus group study with people with type 2 diabetes and with health care 
providers in a Dutch primary care setting to explore the following topics in more detail: (1) 
psychosocial health care needs in people with type 2 diabetes in primary care, (2) factors 
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that facilitate or impede having an open attitude towards a psychosocial health care offer, 
and (3) factors that facilitate or impede addressing psychosocial issues by the health care 
provider. The perspectives of people with type 2 diabetes and primary health care providers 
were investigated (Chapter 6).
OUTLINE OF THIS THESIS
The present thesis focuses on emotional distress in people with type 2 diabetes treated in 
primary care.
• Chapter 2 describes the design of the DiMaCoDeA trial for people with type 2 diabetes, 
a randomised controlled trial testing the effectiveness of a stepped care intervention to 
treat symptoms of depression and anxiety.
• In Chapter 3 the results of the DiMaCoDeA trial are described for people with type 2 
diabetes, asthma, and/or COPD.
• In Chapter 4 the flow towards the DiMaCoDeA trial is examined. In this study the 
response to a screening questionnaire assessing symptoms of anxiety and depression is 
evaluated in people with type 2 diabetes, as are demographic and clinical characteristics 
that are associated with (non-)response. Secondly, it is examined which demographic, 
clinical and psychological characteristics are associated with subsequent participation in 
the DiMaCoDeA trial.
• In Chapter 5 diabetes distress levels of people with type 2 diabetes treated in primary 
care and those treated in secondary care are compared, as are factors that could explain 
possible differences in distress levels between the care settings.
• Chapter 6 reports the psychosocial health care needs of people with type 2 diabetes 
treated in primary care from the perspective of patients and health care providers. 
Also the attitudes of people with diabetes regarding psychosocial help and factors that 
facilitate or impede addressing psychosocial health issues by the health care provider 
are explored in this focus group study.
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Background: Depression and anxiety are common comorbid health problems in people with 
type 2 diabetes. Both depression and anxiety are associated with poor glycaemic control 
and increased risk of poor vascular outcomes and higher mortality rates. Results of previous 
studies have shown that in clinical practice, treatment of depression and anxiety is far from 
optimal as these symptoms are frequently overlooked and undertreated.
Methods/Design: This randomised controlled trial will examine the effectiveness of a 
disease management program treating symptoms of depression and anxiety in people with 
type 2 diabetes treated in primary care. Participants will be randomised to the intervention 
group or control group in equal ratio (1:1). Random block sizes of 2 and 4 are used. The 
disease management program consists of screening, stepped treatment and monitoring of 
symptoms (n = 80). This will be compared with care as usual (n = 80).
Discussion: The disease management model for comorbid depression and anxiety in 
people with diabetes treated in primary care is expected to result in reduced symptoms 
of depression and anxiety, improved quality of life, reduced diabetes specific distress, and 
improved glycaemic control, compared with care as usual.




Diabetes mellitus is a common chronic disease affecting more than 220 million people 
worldwide, with approximately 90% having type 2 diabetes [1]. People with type 2 diabetes 
often have comorbid affective symptoms such as depression and anxiety. Results of recent 
studies show that 10-30% of people with type 2 diabetes suffer from major depressive 
disorder or sub-threshold depression [2-4], about 14% suffers from generalised anxiety 
disorder and up to 40% has an elevated level of anxiety symptoms [5]. A meta-analysis of 
longitudinal studies showed that people with diabetes are also at a 24% increased risk of 
developing depression [6]. 
 The high prevalence of depression and anxiety in people with type 2 diabetes has 
significant negative implications. It is associated with poorer quality of life, impaired self-
care activities, higher health care costs, a higher risk for the development of diabetes 
complications, and increased mortality rates [7-13]. Despite these known adverse effects 
and the high prevalence of depression and anxiety in people with type 2 diabetes, and 
the fact that effective treatments are available, there is a considerable underdetection 
and subsequent undertreatment of these conditions [14,15]. Less than half of people 
with diabetes and comorbid depression and/or anxiety are recognised as such [14,15]. In 
order to prevent the negative consequences of anxiety and depression, early detection and 
enhanced treatment thus seem crucial.
 Meta-analyses have shown that treating depression and anxiety in people with type 2 
diabetes results in reduced psychological distress, but also in improved glycaemic control 
[16,17]. For example, a meta-analysis by Ismail et al. showed that psychological interventions 
resulted in a statistically significant better glycaemic haemoglobin, with an absolute 
difference of 0.76% (or 8.3 mmol/mol) [16]. A study by Bogner et al. has shown that the 
all-cause mortality risk decreased when treating depression in primary care patients with 
diabetes mellitus [7]. However, the study by Bogner et al. has been criticised by Thombs 
and Ziegelstein [18]. Given the high prevalence of depression and anxiety in people with 
type 2 diabetes, and the fact that these emotional problems are often overlooked and 
undertreated, while effective treatments are available, current guidelines recommend 
screening for depression and anxiety [19-21]. A recent randomised controlled trial showed, 
however, that screening alone did not improve depression outcomes in secondary diabetes 
care [22]. It seems crucial that screening efforts should be embedded in a managed care 
approach for depression and anxiety [23]. 
 A large American randomised controlled trial, The Pathways Study, tested the 
effectiveness of a collaborative care approach consisting of screening, stepped care 
intervention and collaboration between several health professionals (multidisciplinary 
team) [24]. The collaborative care approach was more effective in reducing depressive 
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symptoms after 6 months compared with usual care (z = 2.84, p = 0.004). It was also cost-
effective [25]. However, no effect on glycaemic control was found [24]. Another randomised 
controlled trial has been conducted in the Netherlands in elderly primary care patients 
with diabetes or chronic obstructive pulmonary disease and comorbid depression [26]. 
The intervention, provided at home by trained nurses, was based on cognitive behavioural 
therapy principles and self-management. While the intervention was effective in reducing 
depressive symptoms (Beck Depression Index improvement rate odds ratio = 3.22 [1.31 – 
7.89]), it was not cost-effective [27].
 Most research focused on treating depression, and less research investigated a treatment 
for anxiety in people with type 2 diabetes. The randomised controlled trials investigating 
anxiety treatment in people with diabetes showed less consistent results compared with the 
depression trials; some studies showed a beneficial effect while other studies did not [5,28].
 In the present study, we therefore aim to test the effectiveness of a disease management 
intervention. It will be tested whether and to what extend the Disease Management 
intervention for Comorbid Depression and Anxiety in people with type 2 diabetes 
(DiMaCoDeA-DM2) can significantly reduce symptoms of depression and anxiety. Using 
a randomised controlled trial design, we will compare the new intervention to care as 
usual. Our primary objective is to investigate the effectiveness of the disease management 
approach on symptoms of depression and/or anxiety. Our secondary objectives are to 
investigate whether this approach results in improved quality of life, reduced diabetes-




Inclusion criteria are having type 2 diabetes mellitus, aged 18 or over, and having elevated 
symptoms of depression (PHQ-9 score > 7) and/or anxiety (GAD-7 score  > 8; see ‘assessment’ 
for more information about the PHQ-9 and GAD-7). People will be excluded if they currently 
receive psychological treatment for their symptoms of depression or anxiety, experience 
major psychiatric problems, such as schizophrenia and suicidal ideation, are addicted to 
alcohol, drugs or gambling, are cognitively impaired, or are unable to read or speak Dutch 
sufficiently.
Study setting and sample recruitment
The study will be conducted in primary care practices that are affiliated to a large primary 
care organisation PoZoB. Over 200 general practitioners and approximately 150 practise 
nurses in a southern region of the Netherlands are associated with PoZoB with approximately 
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12,000 people with type 2 diabetes. The general practitioners together with the practice 
nurse are responsible for the primary care of people with chronic diseases such as type 2 
diabetes. People with type 2 diabetes are seen by the practice nurse every three months.
 People with type 2 diabetes from the general practices that agreed to participate will 
be screened for symptoms of depression and anxiety with the PHQ-9 and GAD-7. Eligible 
people will be invited for an interview. During this interview the baseline questionnaires will 
be administered. After providing written informed consent, they will be randomised into the 
intervention group or the care as usual group.
Randomisation
Participants will be randomised to the intervention or control group in equal ratio (1:1). 
Block randomisation will be used with block sizes of 2 and 4. These block sizes are chosen to 
enhance the chance that in each general practice participants will be in both study conditions. 
An independent researcher will generate a random sequence by randomization.com
and will fill envelopes with the sheets describing the group allocation. These opaque 
envelopes will be sealed and sequentially numbered by the independent researcher. When 
a participant is enrolled in the study, the person who enrols the participant will open the 
envelope and disclose the group allocation. The allocation sequence will be concealed until 
a participant is irreversibly registered. 
Power
Assuming an α of 0.05 and a 1-β (power) of 0.90, 64 participants are needed in each condition 
to be able to detect a moderate effect of 0.5 standard deviation on the PHQ-9 and GAD-7. 
We anticipate a drop out of 20% and therefore we will need to include 80 participants in 
both groups.
Intervention
The DiMaCoDeA-DM2 intervention will continue for a year and will consist of active 
screening, stepped care treatment, and monitoring of symptoms of depression and anxiety 
(see Figure 1).
 Screening. People with diabetes in the collaborating general practices will be screened 
for symptoms of depression and anxiety using the PHQ-9 and GAD-7.
 Stepped care. A stepped care model has been used to design the intervention. This 
means that a basic treatment will be provided firstly, followed by intensified treatment when 
needed, i.e. in case of non-remission or worsening of symptoms. The DiMaCoDeA-DM2 
stepped care treatment will comprise of the following three steps: (1) psycho-education, 
(2) the course “Coping with depression and anxiety”, and (3) elongation of the course and 
discuss the option for antidepressant or antianxiety medication. The first step, psycho-
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education, will consist of four 30-minute lessons provided by trained psychologists. At the 
end of the fourth lesson, the participant will fill out the PHQ-9 and GAD-7. If the participant 
scores below the cut-off score on both questionnaires (PHQ-9 < 7 and GAD-7 < 8), the 
treatment will be stopped and the participant will enter a phase in which symptom severity 
of depression and anxiety will be monitored. If the participant still suffers from significant 
depression and/or anxiety, as indicated by scores above the cut-off score, the participant 
will enter step 2. In the second step the course “Coping with depression and anxiety” will 
be offered to the participant. The course is based on the “Coping with depression” course 
by Lewinsohn [29] and a “Coping with anxiety” course [30]. The course consists of a self-
help book and coaching. Coaching will be provided in the general practice office by trained 
psychologists and will take place once a week for half an hour. Depending on the most 
prominent complaints and on the preference of the participant either the “Coping with 
depression” course or the “Coping with anxiety” course will be provided. A combination of 
the two courses is also possible. The course takes 10 weeks to complete. Halfway through 
the course and at the end of the course, the participant will fill out the PHQ-9 and GAD-7. If 
during the course the symptoms worsen, the participant will be offered the opportunity to 
start with step 3, even though step 2 has not been finished. In step 3, the general practitioner 
will discuss the option of using antidepressant or antianxiety medication. If medication is 
indicated, the general practitioner will have contact with the participant to discuss side 
effects and monitor the effect of the medication. Moreover, the course will be elongated 
with a maximum of six sessions in six months. 
Figure 1 DiMaCoDeA intervention
PHQ = 9-item Patient Health Questionnaire, GAD = 7-item General Anxiety Disorder questionnaire.
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 Monitoring. A crucial element of the intervention will be the frequent monitoring of 
depression and anxiety. During the DiMaCoDeA intervention, participants will fill out the 
PHQ-9 and GAD-7 every three months. If the participant has a score PHQ-9 ≥ 7 and/or GAD-
7 ≥ 8, treatment will be offered; if step 1 has been completed, step 2 will be offered, and if 
step 2 has been completed, step 3 will be offered.
Control group
The control group will receive care as usual. During the assessments (see below) the 
participants will fill out the PHQ-9 and GAD-7. If a participant in the control group has 
two consecutive PHQ-9 scores ≥ 15 or two consecutive GAD-7 scores ≥ 15, the general 
practitioner will be notified.
Assessments
All participants will fill out questionnaires at 7 time points: at baseline, 3, 6, 9, 12, 18 and 
24 months. The primary outcomes are symptoms of depression and anxiety as measured 
by the PHQ-9 and GAD-7 [31,32]. The PHQ-9 is a screening tool that has nine items that 
correspond to the nine DSM-IV criteria of depression [31]. The PHQ-9 assesses how often 
in the last two weeks a participant was bothered by nine problems such as “Little interest 
or pleasure in doing things”. Each item can be scored from 0 “not at all” to 3 “nearly every 
day”. The total score on the PHQ-9 ranges from 0-27. This score indicates the severity of the 
depressive symptoms, with higher scores reflecting higher levels of depressive symptoms 
[31]. A study with primary care patients with diabetes found an optimal cut-off score for 
depression screening of 7 [33]. The cut-off point of 7 on the PHQ-9 was the most optimal 
cut-off score to predict major depressive disorder measured by a diagnostic interview [33]. 
Therefore the cut-off of PHQ-9 ≥ 7 will be used in this study. The GAD-7 will be used to assess 
anxiety symptoms. This questionnaire has been developed to assess generalised anxiety 
disorder, but can also be used as a screener for several anxiety disorders [32]. A cut-off 
score of 8 has been found to be the most optimal cut-off score, when used as a screener for 
several anxiety disorders [32]. Therefore, people with a score GAD-7 ≥ 8 are considered as 
having significant anxiety symptoms. 
 During the baseline interview the Mini-International Neuropsychiatric Interview (MINI) 
is administered to assess major depression and general anxiety disorder. The MINI will not 
be used as a selection criterion.
 Secondary outcomes are quality of life, health status, diabetes-specific emotional 
distress, self-management, medication adherence, and cost-effectiveness. Baseline and 12, 
24 months HbA1c will be obtained from the participants’ medical charts, to evaluate the 
effect on blood glucose. Furthermore, we will gather data regarding demographics (age, 
gender, marital status, and education), exercise (measured with SQUASH [34]), smoking and 
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alcohol use, body mass index, psychiatric history and Type D (distressed) personality (DS-
14 [35]). Type D is a personality type that is characterised by negative affectivity and social 
inhibition. Research on Type D personality has been mostly conducted in cardiac patients. 
In this population, it has been found that persons with Type D personality have a three-fold 
risk of adverse cardiac outcomes [36].
Blinding
The nature of the study does not allow blinding of participants, therapists and researchers.
Statistical analyses
The data will be analysed using intention to treat approach. This means that participants 
are analysed in the group to which they are allocated, even though the participant did not 
start the intervention or did not complete the intervention. To test whether the intervention 
group differs from the control group in terms of demographical and clinical data, T-tests and 
Chi-squared analyses will be used. To test the effectiveness of the intervention in achieving 
favourable outcomes, ANCOVA’s will be conducted. The analyses will be adjusted for the 
possible confounding variables age and sex.
Ethics
The study has been approved by the medical ethical committee of the St. Elisabeth Hospital, 
the Netherlands NL3363.008.10. The trial is registered in the Dutch Trial Register NTR2626.
DISCUSSION
This randomised controlled trial will test the effectiveness of a disease management 
model of anxiety and depression symptoms in Dutch people with type 2 diabetes who are 
treated in primary care. We expect that the managed care intervention will contribute to 
enhanced treatment of depression and/or anxiety and a reduction of symptoms of anxiety 
and depression. We hypothesise that the intervention will also result in improved quality of 
life, reduced diabetes-specific distress, better glycaemic control and lower health care cost. 
A first strength of the intervention is that it will largely take place in the general practice 
office. This will make it easier for people to participate, because they do not have to travel 
to specialised mental health care institution. A second strength of the intervention is the 
stepped care approach. This means that the people receive as much treatment as needed. 
Providing only the most intensive treatment to a selected group of people, will reduce the 
costs of the intervention. A third strength of the intervention is the monitoring of symptoms 
of anxiety and depression. It is known that anxiety and depressive symptoms often do recur, 
but are overlooked. It is therefore important to continue monitoring to detect recurring 
DIMACODEA – DESIGN OF A RANDOMISED CONTROLLED TRIAL
31
2
anxiety and depressive symptoms and offer treatment if needed. A fourth strength is the 
randomised controlled trial design. By randomising participants, possible confounders will 
be distributed randomly over the groups. Thereby, a possible different outcome between 
the two groups is most likely to be attributed to the intervention.
 A possible limitation in the design is that the general practitioner will be informed when 
a participant of the control group has two consecutive high scores. As a consequence the 
general practitioner may start an intervention and this might interfere with care as usual. 
However, several studies have shown that focusing on detection of depression, does not 
automatically lead to improved psychological care [22,23,37]. 
 In conclusion, this trial will compare a disease management model with usual care. This 
model will improve detection of symptoms of depression and anxiety and will provide an 
easily accessible service to people with diabetes to improve their well-being. In the long-
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Background: Depression and anxiety are common comorbidities in people with a chronic 
disease. Although guidelines recommend treatment using a stepped care model, the 
effectiveness of this approach in primary care has not been evaluated in people with 
diabetes, asthma or COPD.
Methods: In a randomised controlled trial, a 12-month disease management program which 
involved screening, stepped care treatment and monitoring of symptoms was evaluated. 
3559 people were invited for screening (41% response). Of 286 persons with elevated 
symptoms of anxiety and/or depression (Generalised Anxiety Disorder questionnaire (GAD-
7) total score ≥ 8 and/or Patient Health Questionnaire (PHQ-9) total score ≥ 7), 46 were 
randomised. Main outcomes were symptoms of anxiety and depression at the end of the 
12-month program and six months later (18-month measurement). Analysis of covariance 
(ANCOVA) was first adjusted for condition (diabetes or lung disease) and baseline GAD-7/
PHQ-9 scores, and subsequently also for age, sex and education.
Results: Compared with the control group receiving usual care and monitoring, the 
intervention group showed a significant reduction in symptoms of anxiety at the end of the 
12-month program (GAD-7 6 ± 6 vs 9 ± 6; Cohen’s d = 0.61). This effect was still present at 
the 18-month measurement. The intervention group also showed a greater reduction in 
symptoms of depression than the control group at the end of the 12-month program (PHQ-
9 6 ± 4 vs 9 ± 6; Cohen’s d = 0.63); however, this difference was only statistically significant 
in the partly adjusted model (p = 0.03), but not in the fully adjusted model (p = 0.10). At 
the 18-month measurement the difference in symptoms of depression between the two 
groups was not statistically significant in either the partly or fully adjusted model, despite 
the medium effect size. 
Conclusions: The stepped care treatment with monitoring resulted in a clinically relevant 
reduction in symptoms of anxiety and depression. 




Symptoms of depression and anxiety are common in people with a chronic disease such 
as asthma, chronic obstructive pulmonary disease (COPD) or diabetes [1-4]. Besides their 
negative impact on quality of life and disease burden [4,5], these symptoms are also related 
to the development of complications and higher mortality rates [3,5-8]. However, depression 
and anxiety are often not recognised by health care providers [9-11]. 
 Not surprisingly, international guidelines have recommended heightened awareness 
of psychosocial problems in people with a chronic disease [12-16]. For example, several 
diabetes guidelines and guidelines for cardiovascular disease prevention advocate standard 
screening and monitoring of psychosocial well-being/distress [12,13,16]. While screening 
may facilitate recognition, higher recognition rates do not necessarily lead to increased 
treatment initiation and improved patient outcomes [17,18]. Hence it is crucial that 
screening is embedded into comprehensive care for mental health problems such as anxiety 
and depression [19].
 In anxiety and depression guidelines, the use of a stepped care intervention model is 
recommended [20-23]. The rationale behind the stepped care model is that (a) treatment 
is started with a low-intensity, cheap though effective intervention (e.g., psycho-education) 
and (b) via systematic reassessments it is evaluated whether the treatment goal is met or 
the following step needs to be initiated comprising a more intensive treatment [24]. Hence 
it is assumed that this intervention model provides adequate cost-effective care [24].
 The guideline on treatment and management of depression in adults with a chronic 
physical health problem developed by the National Institute for Health and Clinical 
Excellence (NICE) also recommends using a basic stepped care model despite the fact that 
this model has rarely been evaluated in this group [14]. They argue that “the stepped-care 
model remains the best developed system for ensuring access to cost-effective interventions 
for a wide range of people with depression and a chronic physical health problem, 
particularly if supported by systems for routine outcome monitoring” [14]. Several studies, 
mainly conducted in the USA primary care setting, found that the extended collaborative 
stepped care model was effective in treating symptoms of depression or anxiety in people 
with a chronic disease [25-30]. In addition to stepped care treatment, the collaborative 
care treatment incorporates a multidisciplinary team across care settings (e.g., including 
a psychiatrist) and a care manager [31]. However, the effectiveness of a basic stepped care 
model for treating symptoms of anxiety and/or depression in people with a chronic disease 
in primary care has not been evaluated [14].
 Therefore, the aim of the current study was to evaluate the effectiveness of a stepped 
care model in reducing symptoms of anxiety and/or depression in people with a chronic 





Participants and procedure of inclusion
Twenty-four primary care practices took part in the current study. All participating general 
practices were allied to the large primary care organisation PoZoB, located in the south 
of the Netherlands, and employed a practice nurse for mental health. People who were 
treated within the framework of the somatic managed care programs for type 2 diabetes 
(DIAZOB) or asthma and COPD (ASCOZOB) were considered for participation [32,33]. The 
general practitioner excluded those who were already receiving psychological treatment, 
or fulfilled one of the other exclusion criteria: (a) experiencing psychiatric problems (e.g., 
schizophrenia, addiction); (b) having cognitive disabilities; and (c) insufficient mastery of the 
Dutch language. Eligible people were sent a screening questionnaire assessing symptoms 
of anxiety and depression. People scoring above the cut-off score on the anxiety and/or 
depression questionnaire were invited for an interview. Exclusion criteria were double 
checked by the screening questionnaire and during the interview. During this interview, the 
aims and procedures of the trial were explained and a clinical interview was administered 
for diagnosing major depressive disorder and generalised anxiety disorder. The presence 
of a mood or anxiety disorder according to the diagnostic interview was not used as an 
inclusion criterion for the trial. After providing written informed consent, participants were 
randomly assigned to the intervention group or the control group in equal ratio (1:1). The 
first six participants were part of a pilot group and not randomised. These persons were not 
included in the present analyses. Block randomisation with block sizes of 2 and 4 were used 
and randomisation was stratified for diabetes and lung diseases (i.e. asthma and COPD). 
An independent researcher generated a random sequence using http://randomization.com, 
filled sequentially numbered opaque envelopes with the group allocation and sealed the 
envelopes. Participants were recruited between January 2011 and April 2012. The design of 
the trial has been described in detail elsewhere [32,33].
 The trial has been registered in the Dutch Trial Register NTR2626, and was approved by 
the medical ethical committee of the St. Elisabeth Hospital, the Netherlands NL3363.008.10.
Measures
All participants filled out a questionnaire 3, 6, 9 and 12 months post screening (the end of 
the disease management program) and a follow up measure after 18 months (6 months 
after the end of the disease management program).
 The 7-item General Anxiety Disorder questionnaire (GAD-7) was used to assess 
symptoms of anxiety [34]. Although the scale has originally been developed to screen for 
generalised anxiety disorder, it has been shown to be a sensitive screener for other anxiety 
disorders (e.g., panic disorder, social anxiety, or posttraumatic stress disorder) [34]. The scale 
measures symptoms in the past two weeks, and each item can be answered on a 4-point 
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Likert scale ranging from 0 “not at all” to 3 “nearly every day”. The total score ranges from 
0-21, with higher scores reflecting higher levels of anxiety symptoms. To detect any anxiety 
disorder, the cut-off point of ≥ 8 has shown the most optimal sensitivity and specificity in 
primary care populations [34]. A cut-off point of ≥ 15 represents severe symptoms [34].
 The 9-item Patient Health Questionnaire (PHQ-9) was used to assess symptoms of 
depression [35]. The nine items are based on the nine symptoms of major depressive 
disorder as defined by the Diagnostic and Statistical Manual 4th Edition (DSM-IV) [36]. 
Similar to the GAD-7, this questionnaire measures symptoms during the last two weeks 
and uses the same 4-point Likert scale. The total score ranges from 0-27, with higher 
scores reflecting higher levels of symptoms of depression. A cut-off ≥ 7 has shown the most 
optimal sensitivity and specificity in a primary care sample of people with type 2 diabetes 
and COPD [37]. A cut-off point of ≥ 15 represents moderately severe symptoms [35]. For 
the outcome evaluation, a maximum of three missing items on the GAD-7 or PHQ-9 were 
imputed using mean imputation; i.e. the missing items were replaced by the mean of the 
individual’s completed items. Several demographic variables were assessed in the screening 
questionnaire including age, sex and level of education (with low education defined as 
having completed no more than primary school or lower vocational training).
 Two modules of the Mini-International Neuropsychiatric Interview (MINI) were used 
to assess the presence of major depressive disorder and generalised anxiety disorder. The 
MINI is a diagnostic interview following the DSM-IV criteria [38]. 
Intervention
The intervention consisted of a 12-month Disease Management program for Comorbid 
Depression and Anxiety (DiMaCoDeA) which involved stepped care treatment followed by 
monitoring of symptoms of anxiety and depression in case of remission (Figure 1). Because 
anxiety and depression are often recurrent [39-41], monitoring of symptoms after remission 
was included in the model to be able to quickly intervene when a relapse occurred. Step 1 
consisted of four weekly individual meetings focusing on psycho-education. Step 2 included 
an individual course of ten weekly meetings targeting either depressive symptoms [42] or 
anxiety symptoms [43]. The “Coping with depression” course was originally developed by 
Lewinsohn and has been shown to be effective in diverse settings and countries and easy to 
adapt to specific target groups [42]. The course is based on principles of cognitive behavioural 
therapy, behavioural activation, social skills training, and relapse prevention [42]. The 
“Coping with anxiety” course is an adapted version of the “Coping with depression” course 
[43]. Step 3 consisted of an advice to meet the general practitioner to discuss antidepressant 
or antianxiety medication options and booster sessions (six times during a maximum of six 




 The decision to change from one step to a higher level was based on the scores on the 
PHQ-9 and GAD-7 completed at the end of each step. In case of no remission (PHQ-9 ≥ 7 
and/or GAD-7 ≥ 8; Figure 1) participants were referred to the next level. Moreover, in step 2 
(lasting for ten weeks) the PHQ-9 and GAD-7 were also completed half way and those with 
high scores (PHQ-9 or GAD-7 ≥ 15) were offered step 3 before step 2 was finished. In case of 
remission, the participant entered the monitoring phase. During the monitoring phase, the 
scores on the PHQ-9 and GAD-7 were assessed every three months. When relapse occurred 
(PHQ-9 ≥ 7 and/or GAD-7 ≥ 8) continuation with the next stepped care treatment level was 
offered (Figure 1).
Monitoring symptoms of anxiety and depression every three months
Step 1: Psycho-
education (4 weeks)







    No
Yes





Figure 1 Design of the stepped care intervention
Control group
The control group received usual care plus monitoring by filling in a postal questionnaire 
every three months to assess symptoms of anxiety and depression for research purposes. 
For ethical reasons, the general practitioner (GP) was notified when two consecutive scores 
were ≥ 15 on either questionnaire.
Suicidal thoughts
With informed consent of the participants, the GP was informed when a participant in 
either the intervention or control group had possible suicidal thoughts (a score of ≥ 1 on the 
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ninth item of the PHQ-9). In addition, the participant received a phone call and was advised 
to meet their GP. This was the case for 5 to 7 persons on each time point with no difference 
seen between the intervention and control group.
Data analyses
Statistical analyses were performed using the IBM Statistical Package for Social Sciences 
(SPSS version 19, IBM, Chicago, Illinois, USA). To compare the intervention and control 
group on demographic and psychological variables and type of disease at time of screening, 
independent T-tests and Chi-square tests were used. ANCOVA was performed to evaluate the 
outcomes of the disease management program, using the intention-to-treat principle. The 
outcome variables were the PHQ-9 and GAD-7 total scores 12 months post screening (which 
corresponds with the end of the 12-month disease management program) and 18 months 
post screening. Group allocation (intervention or control group) was the independent 
variable. The analyses were performed while controlling for stratum (diabetes or lung 
disease) and baseline PHQ-9 or GAD-7 values, as appropriate. These analyses were repeated 
while additionally adjusting for age, sex and education. In addition to statistical significance 
(p < 0.05), clinical significance in terms of the effect size (Cohen’s d) was calculated by 
subtracting the mean score of the intervention group from the mean score of the control 
group and dividing the difference by the pooled standard deviation. Cohen’s d >|0.20| was 
considered a small effect, >|0.50| a medium effect, and >|0.80| a large effect [44].
RESULTS
The 24 participating practices had 4094 people in the chronic disease care management 
programs of whom 3559 individuals were eligible and therefore invited to complete the 
screening questionnaire (Figure 2). The response to the screening was 41% (n = 1465), with 
1336 people completing the PHQ and GAD-7. Of these 1336 individuals, 286 (21%) had an 
elevated score on the depression or anxiety questionnaire, of whom 215 consented to be 
invited for an interview. However, only 122 individuals attended this interview. After the 
interview, 76 individuals declined participation in the randomised controlled trial. Because 
the first six participants were included in the pilot period to test the logistics of the design 
and three persons fulfilled one of the exclusion criteria, 46 people were randomised (23 in 
the intervention group and 23 in the control group; Figure 2). The people who participated 
in the trial did not significantly differ from people who were eligible but did not participate 
regarding baseline symptoms of anxiety and depression and demographic variables (data not 
shown). Of the participants, 16% fulfilled the criteria for a general anxiety disorder and 30% 
the criteria of a major depressive disorder on the MINI. The intervention and control group 
did not differ regarding baseline symptoms of anxiety and depression, type of condition, and 
demographic variables except for age (64 ± 12 years vs 55 ± 14 years, respectively; Table 1). 
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4094 in managed care 
programs
3559 invited for screening
1465 response
1336 completed PHQ / 
GAD questionnaires
286 eligible for treatment 
(PHQ ≥ 7 and/or GAD ≥ 8)





2094 screeners not 
returned
49 excluded (currently 
receiving psychological 
treatment)a
81 incomplete PHQ / GAD 
questionnaires
1050 no elevated score




23 intervention 23 control
12 months after 
screening (n = 20)
12 months after 
screening (n = 18)
18 months after 
screening (n = 18)
18 months after 
screening (n = 18) 
Figure 2 Flow chart from screening to participation in the trial. 
a Based on information in the screening questionnaire. COPD = Chronic obstructive pulmonary disease, 
PHQ = 9-item Patient Health Questionnaire, GAD = 7-item General Anxiety Disorder questionnaire.
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Table 1 Baseline characteristics of the participants in the randomised controlled trial 
Control group Intervention group Total group
n % M SD n % M SD sig. n % M SD
Age, years 23 54.83 13.9 23 64.22 11.7 0.02* 46 59.52 13.6
Women 10/23 46.5 13/23 56.5 0.38 23/46 50.0
Low Education 9/23 39.1 14/22 63.6 0.10 23/45 51.1
Chronic illness 1.00
  Diabetes 12/23 52.2 12/23 52.2 24/46 52.2
  Asthma/COPD 11/23 47.8 11/23 47.8 22/46 47.8
Baseline symptoms 
of anxiety (GAD-7 
total score)




23 11.9 4.0 23 10.6 5.2 0.34 46 11.3 4.7
GAD diagnosis 
(MINI) 3/23 13.0 4/21 19.1 0.69 7/44 15.9
Major Depressive 
disorder (MINI) 7/23 30.4 7/22 31.8 1.00 14/45 30.4
*p < 0.05. MINI = Mini-International Neuropsychiatric Interview. GAD = Generalised anxiety disorder. COPD = 
Chronic obstructive pulmonary disease, PHQ = 9-item Patient Health Questionnaire, GAD = 7-item General Anxiety 
Disorder questionnaire.
Completion of the intervention 
Of the 23 people allocated to the intervention group, 22 started with the treatment (Step 1). 
Four persons did not complete the first step. Reasons for not completing Step 1 were finding 
it too strenuous (n = 1), treatment did not meet expectations (n = 1), not experiencing 
symptoms of anxiety or depression anymore (n = 1), or having cognitive problems (n = 1). 
After completing Step 1, seven people had elevated scores. Of these seven people, six started 
with Step 2. During the monitoring phase, additionally thirteen people experienced relapse 
and Step 2 was indicated. Of those thirteen people, three started with Step 2. All people 
who started Step 2 completed the course. Reasons for not starting Step 2 after relapse were 
having an alternative explanation for their complaints (n = 3), cognitive problems (n = 1), 
having started with specialised mental health care (n = 1), having difficulties with reading (n 
= 1), not being interested or thinking that the intervention would not help (n = 4). Two out 
of three people eligible for step 3 followed the last step (Figure 3). The person not starting 
step 3 was not interested in booster sessions and was already using antianxiety medication.
Attrition
Three persons in the intervention group and five persons in the control group did not fill 
out the questionnaires at the end of the 12-month intervention program (stepped care 
treatment and monitoring) and at six-month follow-up (18 months post screening). At the 
follow-up measure there were also an additional two persons from the intervention group 
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n = 6 + 1
Figure 3 Flow through the intervention
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Effectiveness of the intervention
Symptoms of anxiety and depression over time are shown in Figure 4 and 5. At the end 
of the intervention program (12 months post screening) the intervention group reported 
less symptoms of anxiety than the control group (GAD-7 total score of 6 ± 6 vs 9 ± 6, 
Cohen’s d = 0.61). This difference was statistically significant both in the analysis controlled 
for stratum and baseline GAD-7 value (F(3, 33) = 5.71, p = 0.02) and in the analysis with 
additional adjustment for age, sex and education (F(6, 29) = 4.24, p = 0.048). The difference 
in depressive symptoms between the intervention and control group was moderate, with 
Cohen’s d being 0.63 (PHQ-9 total score of 6 ± 4 vs 9 ± 6). This difference was statistically 
significant in the analysis controlled for stratum and baseline PHQ-9 value (F(3, 34) = 4.8, p = 
0.03), but only significant at a 90% level in the fully adjusted analysis (F(6, 30) = 2.89, p = 0.10).
 Eighteen months post screening, there was still a difference between the intervention 
and control group with respect to GAD-7 total scores, with the intervention group reporting 
less symptoms of anxiety compared with the control group (GAD-7 total score 4 ± 3 vs 8 ± 
6, Cohen’s d = 0.74; analysis controlled for stratum and baseline value F(3, 31) = 10.10, p = 
0.003; fully adjusted analysis F(6, 28) = 8.52, p = 0.007). Although the intervention group also 
reported lower symptoms of depression than the control group 18 months post screening 
(PHQ-9 total score 5 ± 3 vs 8 ± 5, Cohen’s d = 0.61), this difference was not statistically 
significant (analysis controlled for stratum and baseline value F(3, 32) = 3.47, p = 0.07; fully 



















Figure 4 Total score of the GAD-7 anxiety scale for the control and intervention group over time. 





















Figure 5 Total score of the PHQ-9 depression scale for the control and intervention group over time. 
DiMaCoDeA = Disease Management for Comorbid Depression and Anxiety.
DISCUSSION
The present study showed that a stepped care treatment with additional monitoring after 
remission was effective in reducing symptoms of anxiety and depression in people with a 
chronic disease treated in a primary care setting. The effect sizes were moderate to large for 
both anxiety and depression immediately after the 12-month disease management program 
and also 6 months later (18 months post screening; Cohen’s d between 0.61 and 0.74). After 
adjustment for age, sex, educational level, stratum and baseline scores, the intervention 
group had lower scores on anxiety (p = 0.048) and at a 90% significance level for depression 
(p = 0.10) directly post treatment. Six months later (18 months post screening), the difference 
in symptoms of anxiety remained statistically significant (p = 0.007), but the difference 
in symptoms of depression between intervention and control group was not statistically 
significant anymore, which may be due to insufficient power given the moderately large 
effect size (Cohen’s d = 0.61).
 Other studies investigating a basic stepped care treatment for depression and/or anxiety 
in primary care (not specifically in people with a chronic condition) showed inconclusive 
results. A Dutch study by Van ‘t Veer et al. found that stepped care treatment for elderly 
people with symptoms of depression and/or anxiety halved the 12-month incidence 
of depressive and anxiety disorders [45]. In contrast, a study of Van der Weele et al. on 
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stepped care treatment in elderly with depressive symptoms showed that stepped care was 
less effective than usual care [46]. An important difference between the studies was the 
number of participants of the intervention group who actually started the treatment, which 
was 100% and 18%, respectively [45,46]. Another Dutch study including people with major 
and minor depression and/or anxiety disorder in primary care did not find a significant 
difference between stepped care and usual care [47], but in their study the drop-out rate 
was substantial during and after the first step comprising a self-help intervention (52%). 
In our study, the initial uptake of the first step was 96% (22/23) with 18 persons (82%) 
completing the first step.
 An additional element of our intervention was monitoring of symptoms of depression 
and anxiety after remission. This might have been a crucial element of the intervention. In 
the monitoring phase, people were offered treatment again when symptoms recurred. In our 
study we found that the majority experienced recurrent symptoms during the monitoring 
phase. These persons received a phone call and were invited for stepped care treatment 
again. It has to be noted, though, that a minority accepted the treatment offer. However, 
a study that has specifically investigated the effects of regular monitoring of psychological 
well-being in people with diabetes in secondary care found that monitoring and subsequent 
discussion of the test results with the diabetes nurse had favourable effects on mood [48]. 
 
Strengths and limitations
A strength of the present study is that we contacted a representative large sample of people 
treated in primary care for their chronic somatic disease (n = 3559). Furthermore, we have 
followed the participants during a substantial period of time (18 months). The control 
group in this study received, apart from care as usual, monitoring whereby in case of severe 
symptoms or in case of possible suicidal ideation the GP was informed. This was also done in 
the intervention group. Additionally, in the intervention group monitoring was also used to 
decide whether treatment intensification was needed, or in case of relapse that treatment 
needed to be continued again. Despite the fact that the control group received care as usual 
plus a form of monitoring, the difference between the intervention and control group was 
large, which strengthens the finding that the intervention was effective. 
 A limitation of the study is that although a large number of people were screened, 
less than 2% participated in the trial, which was substantially lower than initially expected 
[32,33]. However, participants and non-participants did not significantly differ on baseline 
symptoms of anxiety and depression, age, sex, or education level. The low participation rate 
might suggest that the perceived need for an intervention was low. Other studies in primary 
care using general screening (instead of, for example, case finding or referral by the GP) 
found quite similar results, with participation rates in the intervention trials ranging from 
0.3% to 4% of those screened [28,45-47]. A suggestion for future research is to investigate 




The intervention including stepped care treatment and monitoring after remission was 
effective in reducing symptoms of anxiety and depression, showing large effect sizes, 
although most findings for depression were not significant at the 95% significance level. The 
effectiveness of the current stepped care model suggests that a basic stepped care model 
could be an efficient alternative for the extended collaborative stepped care model. Future 
studies should compare these two approaches directly using a RCT design. Additionally, 
future studies should test the cost-effectiveness of this stepped care approach.
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Aims: The primary aim of this study was to investigate (factors related to) the response to 
a screening procedure for depression and anxiety in people with type 2 diabetes in primary 
care. The secondary aim was to investigate (factors related to) participation in a subsequent 
randomised controlled trial targeting depressive or anxiety symptoms.
Methods: People with type 2 diabetes (n = 1837) received a screening questionnaire including 
the Patient Health Questionnaire (PHQ-9, depressive symptoms) and the Generalised 
Anxiety Disorder questionnaire (GAD-7, anxiety symptoms). Eligible persons who scored 
above the cut-off score (PHQ-9 ≥ 7 or GAD-7 ≥ 8) were offered to participate in a trial testing 
the effectiveness of a stepped care treatment targeting depressive and anxiety symptoms. 
Results: In total, 798 people (43%) returned the screening questionnaire. Non-responders 
were more often female (53% vs 44%, p < 0.001), had higher LDL cholesterol levels (Cohen’s 
d = 0.17, p = 0.001), and a higher albumin/creatinine ratio (Cohen’s d = 0.08, p = 0.01). In 
total, 130 people (18%) reported elevated depressive or anxiety symptoms. Twenty-seven 
persons agreed to participate in the trial (21% of those with an elevated score; 1.5% of 
the total people who received the screening questionnaire). Factors related to participation 
were a high education level, a higher level of diabetes distress, and a history of psychological 
problems. 
Conclusions: Using screening as recruitment resulted in a small number of participants in 
a treatment trial for anxiety and depression. Research is needed to investigate whether 
screening is also followed by a low uptake of treatment in primary care outside a RCT setting. 
 




People with type 2 diabetes have approximately 20% higher odds of having an anxiety 
disorder [1], 20-60% higher odds to experience depression [2], and 24% higher odds to 
develop depression than people without diabetes [3]. Apart from the negative impact on 
quality of life [4], depression is associated with the development of diabetes complications 
and higher mortality rates in this group [5-7]. Pharmacological or psychological treatments 
for people with type 2 diabetes and emotional problems, such as depression and anxiety, 
appear to be effective [8,9], but underrecognition of emotional problems by health care 
providers has been reported in up to 75-80% of the cases [10].
 This evidence convinced several diabetes guideline committees to include a 
recommendation to integrate screening for emotional distress into regular diabetes care 
[11,12]. However, this recommendation has been subject to debate [13-15]. The key 
points of this debate are first of all that there is a lack of evidence that screening, which is 
assumed to enable early recognition and treatment of psychological problems, results in 
better outcomes (e.g., increased well-being) than when no screening has been used [13-
15]. Studies on the (cost-) effectiveness of screening are scarce. One study investigating a 
screening procedure, including written feedback to people with diabetes and their physician 
about screening outcome and treatment advice, found that this procedure did not result in 
a higher rate of psychological treatment initiation or a reduction in depressive symptoms 
compared with a control group [14]. Second, for a screening procedure to be effective, the 
treatment following positive screening should be effective. However, in a meta-analysis 
it has been shown that the success rate of depression treatment is significantly lower in 
people identified through screening than in people referred by their physician (Cohen’s d = 
0.13 vs Cohen’s d = 0.43) [16]. Third, it is crucial that the participation rate is high in both the 
screening program and subsequent treatment, which is often not the case [15]. 
 However, few studies have investigated which factors are related to participation in a 
screening program. In outpatient diabetes clinics, non-participation in a screening program 
was associated with younger age, suboptimal HbA1c levels, and higher LDL cholesterol levels 
[17,18]. In studies investigating the effect of a treatment program for people with diabetes 
and comorbid emotional problems, only a very small minority of people invited for screening 
were taking part in the trial (4-6%), which was either due to not completing the screening 
procedure, not being eligible, or not accepting the offer to participate in the treatment trial 
[19-21]. It seems that a rather selected group is participating in treatment trials targeting 
emotional distress. However, whether and how participants differ from non-participants is 
still unclear. 
 In people with type 2 diabetes in primary care, the willingness to participate in a screening 
procedure for depression and anxiety has not yet been investigated. Therefore, the first 
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objective of the current study was to investigate (a) the response to a screening procedure 
for detecting depressive and anxiety symptoms in people with type 2 diabetes in primary 
care and (b) demographic and clinical variables associated with response. The second 
objective was to examine (a) how many people with a positive screen would participate in 
a randomised controlled trial (RCT) investigating a treatment program targeting depressive 
and anxiety symptoms and (b) demographic, clinical and psychological factors associated 
with participation. 
METHODS 
Setting, sample and procedure
This study was conducted in general practices allied to the primary care organisation PoZoB 
located in the southeast of The Netherlands, currently consisting of 200 general practitioners 
(GPs) who offer managed care to people with type 2 diabetes (DIAZOB; Diabetes care 
Zuidoost-Brabant) [22]. Practices are mainly located in rural and semi-rural areas. People 
with type 2 diabetes taking part in the DIAZOB managed care program were considered for 
study participation. The GP was asked whether individuals met one of the following exclusion 
criteria for screening: (a) aged younger than 18 years; (b) currently receiving psychological 
treatment for depression or anxiety symptoms, or experiencing major psychiatric problems, 
such as schizophrenia and suicidal ideation; (c) being addicted to alcohol, drugs, or gambling; 
(d) being cognitively impaired; (e) being severely ill; or (f) being unable to read or speak 
Dutch sufficiently. The use of pharmacotherapy (e.g., antidepressants or anxiolytics) was not 
an exclusion criterion. The remaining subjects were sent a screening questionnaire. People 
who scored above the cut-off on either the depression or anxiety questionnaire and agreed 
to being contacted for follow-up were phoned by the researcher to invite them for a face-
to-face interview. During this interview a diagnostic clinical interview was administered for 
diagnosis of a major depressive episode and generalised anxiety disorder, and a last check 
for exclusion criteria for the trial was done. Furthermore, the randomised controlled trial 
(RCT) investigating a stepped care treatment for anxiety and depression was explained to 
them. Details about the trial have been described elsewhere [23]. Subjects who attended 
the interview (irrespective of diagnostic interview outcome) were invited to participate in 
the RCT and those who gave informed consent were randomly allocated to the intervention 
or control group [23]. The reason of non-participation was noted, but people were not 
obliged to give a reason. The study has been approved by the medical ethical committee 
of the St. Elisabeth Hospital, The Netherlands NL3363.008.10. The trial is registered in the 
Dutch Trial Register NTR2626.




Depressive symptoms were assessed using the Patient Health Questionnaire 9-item scale 
(PHQ-9) [24]. This questionnaire assesses symptoms during the previous two weeks 
on a 4-point Likert scale ranging from 0 “not at all” to 3 “every day” with higher values 
indicating more depressive symptoms (total score range 0-27). While the developers of the 
questionnaire recommend a cut-off of ≥ 10, the optimal cut-off has been found to vary 
across samples [24-26]. In the present study, a PHQ-9 total score ≥ 7 was used to indicate 
the presence of elevated depressive symptoms [25]. This cut-off has been found to be most 
optimal for detecting major depressive disorder in a primary care sample of people with 
type 2 diabetes [25].
 Anxiety symptoms in the last two weeks were assessed by the Generalised Anxiety 
Disorder 7-item questionnaire (GAD-7) [27], using a 4-point Likert scale ranging from 0 “not 
at all” to 3 “every day” with higher values indicating more anxiety symptoms (total score 
range 0-21). The cut-off score used to indicate the presence of elevated anxiety symptoms 
was a GAD-7 total score ≥ 8 [27]. This cut-off has been found to be most optimal to detect 
any anxiety disorder in a primary care sample in the USA [27].
 When only one item was missing, the total scores of the PHQ-9 and GAD-7 were calculated 
using mean imputations. Elevated symptoms of depression and anxiety were then defined 
using the above mentioned cut-offs. If there was more than one missing item, but the total 
score of the remaining items was above the cut-off, the respondent was registered as having 
an elevated score. When there were two missing items and when it was not possible to 
score above the cut-off if these missing items received the maximum score, the respondents 
were registered as having no elevated score. 
 Diabetes-specific emotional distress, which is emotional distress caused by having 
diabetes and by its management, was assessed using the validated 20-item Problem Areas 
in Diabetes (PAID) questionnaire [28]. Each item is answered on a 5-point Likert scale 
ranging from 0 “not a problem” to 4 “serious problem”. The sum score of the 20 items 
was transformed into a total score ranging from 0-100, with higher scores indicating higher 
levels of diabetes distress [28]. The PAID total score was calculated when participants had 
no more than three missing items. The missing items were replaced by the individual’s mean 
score on the completed items. A cut-off of ≥ 40 was used to indicate elevated levels of 
diabetes distress [29]. 
 Furthermore, the screening questionnaire included a question to assess a history of 
psychological problems “During your lifetime, have you ever had psychological problems 
such as depression, anxiety, or burn-out?” (no/yes) and a question to assess a history of 
treatment for psychological problems “Have you ever been treated for psychological 




 In addition to the above psychological measures, some background measures were 
added to the questionnaire, namely demographics (sex, age, marital status, education, 
and nationality), health behaviours (alcohol use (no/yes), smoking (no/yes)), and diabetes 
treatment (insulin no/yes). 
 To assess the presence of a major depressive disorder and generalised anxiety disorder, 
two parts of the Mini-International Neuropsychiatric Interview (MINI), a diagnostic clinical 
interview, were used [30].
 Apart from age and gender, diabetes duration and the following clinical variables (most 
recent value) were derived from the large PoZoB diabetes database: HbA1c (mmol/mol and 
%), LDL cholesterol (mmol/l), triglycerides (mmol/l), body mass index (BMI, kg/m2), systolic 
blood pressure (mm Hg), and albumin/creatinine ratio (mg/g). 
Data analyses
Statistical analyses were performed using the IBM Statistical Package for Social Sciences 
(SPSS version 19, IBM, Chicago, Illinois, USA). Descriptive statistics were used to describe the 
number of people (a) responding to the screening questionnaire, (b) having an elevated score 
on the depression and/or anxiety measure, (c) accepting the invitation for an interview, and 
(d) participating in the trial. Chi-square tests and independent samples T-tests, or in case of 
non-normality the Mann-Whitney U test, were used to compare the following groups on 
demographic, clinical and - if available - psychological characteristics: (a) responders versus 
non-responders to the screening questionnaire, and (b) people who scored positive on 
screening and consented to participate in the RCT versus the positive screened cases who 
did not want to participate in the RCT (‘participants’ versus ‘non-participants’).
 Besides determining statistical significance of group differences (p < 0.05, two-sided), 
effect sizes were calculated to provide an indication of clinical significance. Cohen’s d was 
calculated for continuous variables; a Cohen’s d of >|0.20| is considered a small effect, 
>|0.50| a medium effect, and >|0.80| a large effect [31]. For binary variables, the risk ratio 
(RR) was calculated. The more the risk ratio deviates from 1 the larger the effect. 
RESULTS 
Of the 2113 people taking part in the diabetes managed care program, 276 (13%) were 
excluded as described in Figure 1, leaving 1837 people to be invited for screening.
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2113 in diabetes care 
programs
1837 invited for screening
798 response
734 completed PHQ / GAD 
questionnaires
130 eligible for treatment 
(PHQ ≥ 7 and/or GAD ≥ 8)




Known severe psychological 
problems or treatment (n = 82)
Severe illness (n = 10)
Language (n = 38)
Cognitively impaired (n = 48)
Other (n = 98)
1039 screeners not returned
21 excluded (currently receiving 
psychological treatment)a
43 incomplete PHQ / GAD 
questionnaires
604 no elevated score
39 had no interview:
Too strenuous (n = 10)
Not interested (n = 12)
Unable to reach (n = 6)
Unable to come (n = 5)
Other (n = 3)
32 declined participation:
Will receive other psychological 
help shortly (n = 1)
Language problems (n = 1)
Cognitive impairment (n = 3)
Too strenuous (n = 10)
Did not want help (n = 15)
Not able to come to future 
appointments (n = 2)
Figure 1 Flow chart of the screening procedure for symptoms of anxiety and depression leading to 
participation in a treatment trial in people with type 2 diabetes.
a Based on information in the screening questionnaire. PHQ = 9-item Patient Health Questionnaire, 
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Screening questionnaire - responders versus non-responders 
Of the 1837 invited people, 798 (43%) returned the questionnaire. Responders were more 
often male (Χ2(1) = 16.04; p < 0.001, RR = 0.82). Age did not differ statistically significantly 
between the two groups (p = 0.21; Table 1). Non-responders had a higher albumin/creatinine 
ratio (4.1 ± 15.4 vs 2.9 ± 11.6, p = 0.01, d = -0.08, clinically not relevant), and had slightly 
higher LDL levels (2.4 ± 0.9 vs 2.3 ± 0.8, p = 0.001, d = -0.17). Other clinical variables did 
not statistically significantly differ between both groups (Table 1). Of the 798 responders, 
21 persons fulfilled an exclusion criterion and 43 persons returned an incomplete screening 
questionnaire (Figure 1). In total, 130 people (18%) reported elevated depressive or anxiety 
symptoms; 8% experienced elevated depressive as well as elevated anxiety symptoms, 3% 
only elevated anxiety symptoms, and 7% only elevated depressive symptoms. 
Participants versus non-participants in the RCT
Of the group with an elevated score, 98 /130 (75%) agreed with being contacted for follow-up 
and were invited for an interview. Of these 98 people, 59 (60%) were interviewed (Figure 1). 
Reasons for not coming to the interview were finding it too strenuous to come (n = 10), not 
being interested (n = 12), being unable to come (n = 3), or being deaf (n = 1). Additionally, 
six persons could not be reached after several attempts, one person was deceased, and one 
invitation was cancelled by the general practitioner who found the person too old to come 
to the interview. In total, 27 persons consented to participate in the RCT after the interview, 
which is 21% of the 130 subjects with an elevated depression or anxiety score and 1.5% 
of all people with type 2 diabetes who received the screening questionnaire (n = 1837). 
Reasons for not participating in the trial were finding it too strenuous (n = 10), receiving 
other psychological help shortly (n = 1), not being interested in receiving help (n = 15), having 
cognitive problems (n = 3), having language problems (n = 1), or not being able to come to 
future appointments (n = 2). During the MINI interview, 9/27 (35%) fulfilled the criteria for 
a diagnosis of current major depressive disorder and 5 (19%) currently had a generalised 
anxiety disorder. One third of the participants did not have a score ≥ 10 (the commonly used 
cut-off) on the depression (PHQ-9) and anxiety (GAD-7) questionnaire.
 Participants in the trial appeared to have a higher level of education (p = 0.03, RR = 0.67; 
Table 2), reported statistically significantly higher levels of diabetes-specific emotional distress 
(p = 0.02, d = 0.56), and reported more often previous psychological problems (74% vs 48%; 
p = 0.01, RR = 1.56) than people with an elevated score who did not participate. Although 
participants reported on average more symptoms of depression and anxiety, these differences 
were not statistically significant. Health behaviours were not statistically significantly related 
to participation status (Table 2), neither did participants and non-participants significantly 
differ on HbA1c levels, systolic blood pressure, and albumin/creatinine ratio. Although 
participants more often used insulin (30% vs 19%, p = 0.21, RR = 1.59), this difference was 
not statistically significant. The duration of diabetes and LDL cholesterol levels differed at a 




























































































































































































































































































































































































































































































































































































































































   

































































































































































































































































































































































































































































































































































This study investigated the response to screening for depression and anxiety and subsequent 
participation in a treatment trial, and factors related to response and participation in people 
with type 2 diabetes in primary care. The response rate to the screening questionnaire for 
depression and anxiety was 43% (798/1837). Eighteen percent of responders reported an 
elevated level of depression and/or anxiety symptoms (n = 130) of which only one fifth 
(n = 27) accepted the offer to participate in a trial investigating a stepped care approach 
for treatment of depression and anxiety. This is 1.5% of the total group (n = 1837) who 
were initially sent a screening questionnaire. Factors related to non-response to the 
screening questionnaire were being female, having a higher albumin/creatinine ratio, and 
a higher LDL cholesterol level. The differences on these clinical variables were statistically 
significant although with small effect sizes (d < 0.20). HbA1c levels did not significantly differ 
between responders and non-responders. The difference in LDL cholesterol level between 
responders and non-responders to the screening questionnaire is in the same direction as it 
was in the study by Ajduković et al., and is somewhat in line with their finding that people 
with sub optimally controlled diabetes are less likely to respond to a screening program for 
depression [17]. 
 Those who participated in the RCT after positive screening had a significantly higher 
educational level, higher levels of diabetes-related distress, and reported significantly 
more often previous psychological problems. Although participants on average reported 
more depressive symptoms and symptoms of anxiety, this difference was not statistically 
significant, possibly due to the low power (n = 27 RCT participants). An explanation for the 
association between diabetes distress and participation being larger than the association 
between anxiety or depression and participation could be related to the setting (diabetes 
care) in which people were invited. Although the treatment offered in the trial was not 
specifically aimed at treating diabetes distress, it might be that people who experience 
symptoms of anxiety or depression in relation to their diabetes are more inclined to view the 
treatment suitable for them than people whose symptoms are not related to the diabetes. 
 Other RCTs in primary diabetes care also found that a minority of people invited for 
depression screening participated (4-6%) [19-21]. The main reasons given for not participating 
in the present trial were not being interested in receiving help and finding it too strenuous. 
Although not participating in a treatment trial does not necessarily mean that someone is 
not interested in receiving any help, these reasons given for non-participation are likely to 
be associated with not accepting a regular treatment offer as well. There is some evidence 
that the uptake of regular treatment after a screening procedure for emotional distress 
is also low. Two studies in outpatients with diabetes found that 7% of those invited for 
screening [18] and 9-10% of people actually screened were referred [18,32]. In a study in 
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people at high risk of depression in primary care (not having diabetes), 1% of those invited 
for screening initiated treatment [33]. Moreover, a meta-analysis has found that treatment 
of people identified through a screening procedure is less often effective than treatment 
of people referred by their health care provider; the numbers-needed-to-treat to have one 
person with a successful outcome were 13.5 and 4, respectively [16]. This calls into question 
whether screening all people with type 2 diabetes in primary care is an efficient tool for 
reducing emotional distress. 
 What could be an alternative to general screening? Instead of systematically screening all 
people with type 2 diabetes, health care providers could be alert on symptoms of anxiety and 
depression in a high risk subgroup (case finding). As shown by our study, having experienced 
psychological problems in the past is a correlate of accepting treatment targeting current 
psychological problems. Because research has shown that previous psychological problems 
are also highly predictive of current emotional problems, with 66% of people with previous 
depressive symptoms having persistent or recurrent depression at follow-up (1.5 or 2.5 
years later) [34], it could be useful to be particularly alert in this group. This is in line with 
the recommendation of the NICE guideline to be alert on depression especially in a high 
risk group (with a history of depression or with functional impairment associated with 
chronic disease) [35], but opposed to the IDF and ADA guidelines that advocate screening 
for emotional problems in all people with diabetes [11,12]. Furthermore, rather than using 
full questionnaires, the NICE guideline suggests two simple screening questions that can be 
asked: ‘During the last month, have you often been bothered by feeling down, depressed 
or hopeless?’ and ‘During the last month, have you often been bothered by having little 
interest or pleasure in doing things?’ [35]. These two questions are based on the first two 
items of the PHQ-9. For anxiety, the first two items of the GAD-7 can be used [36].
  The threshold of the PHQ-9 (≥ 7) used in our study was based on a Dutch study with 
people with diabetes or COPD treated in primary care, as this sample most closely matched 
our sample [25]. Other studies with a different composition of the sample have suggested a 
higher cut-off: ≥ 10 or ≥ 12 [24,37]. In the present study one third of the participants did not 
have a score of 10 or above on the depression or anxiety questionnaire. These people who 
did have a need for help would not have been reached when a higher threshold had been 
used.
Strengths and limitations
The major strength of this study is the availability of clinical data, even from non-
responders, to explore the characteristics of people not reached by a screening procedure 
and characteristics associated with participation in a treatment trial.
 A limitation of the study is that we do not have information about symptoms of anxiety 
and depression in the non-responders to the screening questionnaire. Another limitation 
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is that the treatment offered in this study was part of a trial. This means that the results 
regarding participation cannot automatically be extrapolated to acceptance of regular 
treatment. People who refused to take part in the trial were still able to receive treatment 
in regular care. However, when looking at the reasons for not participating, it became 
evident that on the one hand a substantial group was not interested in receiving help, but 
on the other hand a substantial group regarded coming to an interview or participating 
in a treatment program as too strenuous. For future research it would be interesting to 
investigate mental health care needs in people with type 2 diabetes in more detail, to be 
able to offer treatment that matches preferences optimally.
CONCLUSION
In a sample of people with type 2 diabetes in primary care, those who were not reached by 
the depression/anxiety screening procedure were more often female and had a slightly less 
optimal lipid profile and albumin/creatinine ratio compared with responders. The screening 
procedure resulted in a low number of people actually participating in a trial investigating 
an intervention targeting depression/anxiety. Taken together, these findings question 
whether screening for depression and anxiety symptoms in people with type 2 diabetes in 
primary care is the best way to identify trial participants. Future research should focus on 
alternatives for screening with questionnaires and investigate the actual health care needs 
expressed by people with type 2 diabetes in primary care. Furthermore, research is needed 
to investigate whether screening is also followed by a low uptake of treatment in primary 
care outside a RCT setting. 
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Aims The present study aims to compare levels of diabetes distress in people with type 2 
diabetes treated in primary and secondary care and to examine demographic and clinical 
correlates that may explain potential differences in level of distress between care settings. 
Methods People with type 2 diabetes from 24 primary care practices (n = 774) and 
three secondary care clinics (n = 526) completed the Problem Areas In Diabetes (PAID) 
questionnaire. Data on HbA1c and diabetes complications were derived from medical charts. 
Hierarchical ordinal regression analysis was used to investigate which correlates could 
explain the potential differences in level of diabetes distress between care settings.
Results Diabetes distress levels and the prevalence of elevated diabetes distress were 
considerably lower in participants treated in primary care (mean (SD) 8(11); 4% of participants 
with a PAID score ≥ 40) than in secondary care (mean (SD) 23(21); 19% of participants with 
a PAID score ≥ 40, p < 0.001). In addition to care setting, the following variables were also 
independently related to diabetes distress: younger age, ethnic minority status, using insulin, 
having a higher HbA1c, having a higher body mass index, and the presence of neuropathy. 
Other diabetes complications were not independently associated with diabetes distress.
Conclusions In primary care, lower levels of diabetes distress were reported than in 
secondary care. The difference in diabetes distress between care settings can be largely, 
but not fully, explained by specific demographic and clinical characteristics. These results 
need to be interpreted with caution as they are based on two separate studies, but do call 
into question the need for screening for diabetes distress in people with type 2 diabetes in 
primary care.




Self-management, including healthy eating, physical activity and proper use of medication, is 
a key factor in the treatment of type 2 diabetes. This daily responsibility can be burdensome 
and the complications of the disease, such as cardiovascular disease, retinopathy, neuropathy 
and nephropathy can result in functional limitations that seriously impair quality of life [1]. 
Having diabetes can also result in uncomfortable social interactions around diabetes with 
family, friends or colleagues at work. Problems may include subjective perceptions of family 
or friends being over-concerned or not supportive regarding diabetes management efforts 
[2]. Not surprisingly, having type 2 diabetes can be rather stressful, with 19-63% of people 
with this condition reporting high levels of diabetes-specific emotional distress (from this 
point onwards referred to as diabetes distress) [3-5]. 
 In many European countries, the majority of people with type 2 diabetes are treated 
in primary care. In the Netherlands, for example, this is the case for approximately 90% 
of people with type 2 diabetes [6]. According to guidelines, indications for referral include 
uncontrolled glucose levels, therapy resistant cardiovascular risk factors (e.g., persistent 
dyslipidaemia or hypertension), difficulties with the treatment of complications, such as 
nephropathy or painful neuropathy, or comorbidities that require specialised care [7]. 
Several factors that are usually more prevalent in people with type 2 diabetes treated in 
secondary care have been found to be related to diabetes distress. These include the use 
of insulin [8], the presence of complications [5,8], and having a higher HbA1c level [4,9-
11]; hence, it is likely that levels of diabetes distress differ across care settings, being more 
pronounced in secondary (hospital) care settings. 
 Studies directly comparing levels of diabetes distress across care settings are currently 
lacking. Most studies in primary care have been conducted in the USA [4,5,9,10,12] and 
studies in secondary care include people with type 1 and type 2 diabetes, without stratifying 
results by diabetes type [2,13-15], thus precluding reliable comparisons. European data on 
diabetes distress in type 2 diabetes in primary care are scarce, or have focused on specific 
groups of people with type 2 diabetes, for instance people who were recently diagnosed 
[16]. 
 The aims of the present study were to investigate whether the level of diabetes distress 
and the prevalence of diabetes distress in people with type 2 diabetes are higher in 
secondary care compared with primary care using two large samples, and to investigate 
whether demographic and clinical variables can explain possible differences in diabetes 




Data were derived from baseline assessments (screening data) of two randomised controlled 
trials (for details see [17] and [18]):
 Primary care setting. The first trial was designed to investigate the effects of a disease 
management intervention for comorbid depression and anxiety in people with diabetes 
treated in a primary care setting [17]. People with type 2 diabetes from 24 collaborating 
general practices located in the South-East part of the Netherlands were invited to 
participate. People were excluded if they: (a) were not able to read Dutch sufficiently, (b) 
had cognitive disabilities, (c) had a severe psychiatric or somatic illness, or (d) were currently 
receiving psychological treatment. From the 1840 screening questionnaires sent out, 803 
(44%) were returned. Using anonymised data from primary care registries, we found that 
people who did not return the questionnaire were more often female (53% vs 44%, p < 
0.001), but did not significantly differ in age or HbA1c levels from those who did return 
the form. Participants who had more than three missing values on the diabetes distress 
questionnaire (n = 29) were excluded. This resulted in a sample of 774 people with type 2 
diabetes from a primary care setting.
 Secondary care setting. The second randomised controlled trial investigated whether 
screening for depression and providing feedback to both the person with diabetes and the 
physician would improve depression outcomes [18]. People with type 1 or type 2 diabetes 
treated in two university hospitals with specialised diabetes clinics (the VU University 
Medical Centre in Amsterdam, the Radboud University Medical Centre in Nijmegen) and 
one general hospital (Haaglanden Medical Centre in The Hague) were invited to participate. 
They were all receiving ambulatory care. People were excluded when (a) they were not able 
to read Dutch sufficiently, (b) they were not willing to give consent to inform the internist/
endocrinologist and/or general practitioner of their affective status (following depression 
assessment), or (c) any of the following applied: having a history of suicide attempt(s), more 
than one hospital admission for depression, and/or electroconvulsive therapy. Of the 2055 
people invited, 966 (47%) returned the questionnaire. No information was available about 
the characteristics of people who did not return the questionnaire. In the current study, only 
people with type 2 diabetes were included (n = 549). Participants who had more than three 
missing values on the diabetes distress questionnaire were excluded from the analyses (n = 
23). This resulted in a final sample of 526 people with type 2 diabetes from a secondary care 
setting.
 Both studies were approved by the local medical ethics advisory committees.
 




Demographics. The following socio-demographic characteristics were collected using a self-
report questionnaire that was completed by the participants: sex, age, education (middle/
high vs low education, where low education was defined as having completed no more than 
primary school or lower vocational training), having a partner (no/yes), and belonging to an 
ethnic minority group (no/yes).
 Diabetes-specific emotional distress (diabetes distress). In both studies, the validated 
Dutch version of the Problem Areas in Diabetes (PAID) scale was used to measure diabetes 
distress [19]. This self-report measure consists of 20 items concerning negative emotions 
specifically related to living with diabetes and its self-management such as “worrying about 
the future and the possibility of serious complications”, “feelings of guilt or anxiety when 
you get off track with your diabetes management”, and “uncomfortable social interactions 
around diabetes” that are scored on a five-point scale ranging from 0 “not a problem” to 
4 “a serious problem”. The sum score of the 20 items was transformed into a total score 
ranging from 0-100, with higher scores indicating more diabetes distress [19]. A cut-off of 
≥ 40 is generally used to indicate seriously elevated diabetes distress. This cut-off score 
corresponds to one standard deviation above the mean based on European studies [20]. The 
PAID total score was calculated when participants had no more than three missing items. 
The missing items were imputed by replacing them with the mean score of the remaining 
items.
 Clinical variables. Diabetes duration and insulin use were self-reported. The following 
complications were derived from the medical charts: retinopathy (no/yes), nephropathy 
(no/yes), neuropathy (no/yes), and cardiovascular disease (no/yes). In primary care, the 
International Classification for Primary Care codes are used and the codes corresponding 
to the diabetes related complications were extracted from the medical chart. In secondary 
care, no codes were used at the time of the study, and therefore the medical charts were 
searched for diagnoses of diabetes complications. Body mass index (kg/m2; BMI) was self-
reported and HbA1c values were derived from the medical charts. 
Statistical analyses 
Statistical analyses were performed using PASW statistics version 18 (SPSS Inc., Chicago, IL., 
USA). To investigate whether demographics, clinical variables and the PAID score differed 
between people with type 2 diabetes in primary and secondary care, independent T-tests 
were performed when the variable was continuous, and Chi-square tests were performed 
for categorical variables. When continuous data were not normally distributed, the Mann-
Whitney U test was used. 
 Hierarchical ordinal regression analysis was used to investigate which variables 
attenuated the association between care setting and diabetes distress. Ordinal regression 
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was performed because the outcome variable (PAID score) was too skewed to perform 
multivariate linear regression (in primary care 32% scored 0, and in secondary care 7% scored 
0 on the PAID questionnaire). When using decile questionnaire scores as the dependent 
variable, the assumption of proportional odds was not met [21], and therefore quintile 
scores were used as the dependent variable. Multicolinearity was assessed by a correlation 
table of all independent variables (r > 0.80 indicates multicolinearity) and variance inflation 
factor statistics (a value > 10 indicates multicolinearity) [22]. In the first step, the unadjusted 
association between care setting and diabetes distress was investigated (model 1). In 
additional steps, it was examined whether this association was attenuated by adjustment 
for demographic variables (model 2: sex, age, being single, having a low education level, 
belonging to an ethnic minority group); the clinical variables diabetes duration, using 
insulin, BMI, and HbA1c level (model 3: demographic variables and diabetes duration, using 
insulin, BMI, and HbA1c), and having complications (model 4: demographic variables and 
nephropathy, neuropathy, retinopathy, and cardiovascular disease). In the final step, the 
fully adjusted model was examined (model 5). The differences in odds ratios between the 
steps (ΔOR) were calculated.
RESULTS
The demographic and clinical characteristics of the primary and secondary care samples 
are shown in Table 1. With respect to demographic variables, participants with type 2 
diabetes treated in a secondary care setting were significantly younger, were more likely to 
be single and to belong to an ethnic minority group, and less likely to a have low education 
level than participants with type 2 diabetes treated in primary care setting. Regarding the 
clinical variables, participants with type 2 diabetes in secondary care had significantly longer 
duration of diabetes, were more often using insulin, had a higher prevalence of complications, 
had a slightly higher BMI and had higher HbA1c levels. The number of participants with 
cardiovascular disease, however, did not differ significantly between primary and secondary 
care (Table 1).
Prevalence of diabetes distress
The mean (SD) total score of diabetes distress was considerably lower in primary care than 
in those treated in secondary care (8 (11) vs 23 (21); median = 2.6 vs median = 16.3, U = 
100105, p < 0.001, effect size r = 0.43). The percentage of participants experiencing elevated 
diabetes distress (PAID-score ≥ 40) was almost five times higher in participants treated in 
secondary care than those treated in primary care (19% PAID-score ≥ 40 vs 4% PAID-score ≥ 
40; Χ2(1) = 84.60, p < 0.001; Table 1). 
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Table 1 Characteristics of the sample of people with type 2 diabetes treated in primary care compared 
with those treated in secondary care
Primary care (n = 774)a Secondary care (n = 526)a Total group (n = 1300)a
Age (years) 68 [61-75] (n = 774) 61 [53-69]*** (n = 522) 65 [58-73] (n = 1296)
Female 43% (335/774) 47% (249/526) 45% (584/1300)
Ethnic minority 1% (8/770) 26% (125/491)*** 11% (133/1261)
Single status 24% (188/768) 31% (163/521)** 27% (351/1289)
Low education level 48% (375/774) 41% (210/516)** 45% (585/1290)
Body mass index (kg/m2) 28 [25-31] (n = 760) 29 [26-33] ***(n = 502) 28 [26-32] (n = 1262)
Diabetes duration 5 [3-8] (n = 764) 12 [6-17] *** (n = 456) 7 [4-12] (n = 1220)
Using insulinb 16% (123/757) 76% (397/521)*** 41% (520/1278)
HbA1c (mmol/mol) 49 [44-53] (n = 738) 58 [51-68]*** (n = 443) 51 [45-59] (n = 1181)
HbA1c (%) 6.6 [6.2-7.0] (n = 738) 7.5 [6.8-8.4]*** (n = 443) 6.8 [6.3-7.5] (n = 1181)
Complications
   Cardiovascular disease 31% (240/740) 36% (160/446) 34% (400/1186)
   Nephropathy 6% (45/740) 28% (125/451)*** 14% (170/1191)
   Neuropathy 3% (22/740) 27% (119/448)*** 12% (141/1188)
   Retinopathy 4% (34/740) 28% (125/445)*** 13% (159/1185)
People with complications (%) 40% (297/740) 56% (252/449)*** 46% (549/1189)
Diabetes-specific distress
   PAID total scores 3 [0-11] (n = 774) 16 [6-34]*** (n = 526) 8 [1-20] (n = 1300)
   PAID score ≥ 40 4% (29/774) 19% (102/526)*** 10% (131/1300)
a Values are median [interquartile range] or % (n/N). b Insulin with and without oral medication included. PAID = 
Problem Areas In Diabetes scale.  *p < 0.05, **p < 0.01, ***p < 0.001
Factors explaining differences in levels of diabetes distress between care settings
A pooled analysis of the two samples was performed to investigate which variables 
attenuated the association between care setting and diabetes distress after statistical 
adjustment and thus could explain differences in distress levels between care settings (Table 
2; n = 1009, cases are missing because of missing values on correlates). The multicolinearity 
statistics indicated no statistical significant multicolinearity between the independent 
variables. The first model (unadjusted model) showed that care setting was strongly related 
to diabetes distress, with participants in secondary care having an 4.51 (95% CI 3.51-5.81) 
higher odds of experiencing higher levels of diabetes distress than those in primary care. 
The second model showed that this association was attenuated after adding demographic 
variables (ΔOR = 1.54). Adding the clinical variables years since diabetes diagnosis, BMI, 
insulin use, and HbA1c (model 3) further attenuated the association between primary vs 
secondary care and diabetes distress (ΔOR = 1.26; OR of care setting in model 3 compared 
with model 2). Adding complications instead of the previous clinical variables attenuated 
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The fully adjusted model, model 5, showed that the higher odds of experiencing diabetes 
distress in secondary care compared with primary care were strongly reduced by 
demographic and clinical variables. The odds of experiencing higher levels of diabetes 
distress in secondary care compared with primary care remained statistically significant 
(fully adjusted odds ratio = 1.53, 95% CI 1.05-2.22, p = 0.03). 
 The following variables were also independent correlates of diabetes distress: younger 
age, belonging to an ethnic minority group, insulin use, BMI, HbA1c, and current neuropathy. 
The presence of other diabetes-related complications (retinopathy, nephropathy and 
cardiovascular disease) was not independently associated with diabetes distress. 
Explorative analysis
An explorative analysis was performed to investigate diabetes distress among different ethnic 
minority groups in secondary care, because of the relatively high percentage of participants 
belonging to an ethnic minority group in secondary care compared with primary care and 
the high odds ratio of having higher levels of diabetes distress observed in these minority 
groups. This analysis revealed that the prevalence of a PAID score ≥ 40 was 13% for native 
Dutch participants and 38% for participants belonging to an ethnic minority group (Χ2(1) 
= 36.90, p < 0.001; 55% (16/29) for participants with a Turkish background, 40% (21/52) 
for participants from Suriname, and 23% (10/44) for participants with a different ethnic 
background). The prevalence of elevated levels of diabetes distress in participants with a 
native Dutch background treated in a secondary care setting remained significantly higher 
than native Dutch people treated in a primary care setting (13% vs 4%; Χ2(1) = 33.47, p < 
0.001, r = 0.38).
 The proportion of participants from an ethnic minority was very low in the primary 
care sample (1%) compared with the secondary care sample (26%), which may result in 
multicolinearity problems; however, these participants from ethnic minorities were being 
treated in the three secondary care settings, and excluding them from the main analysis 
may also have resulted in biased results. We therefore decided to follow the advice of 
the statistical reviewer by conducting a secondary analysis in the total group (primary 
and secondary care sample), excluding those from the ethnic minority groups. The results 
(shown in Table 3) appeared to be fairly similar to the results of the primary analysis in 
the total group that included participants from an ethnic minority (Table 2); however, in 
model 3 and 4 (Table 3), having neuropathy was no longer a statistically significant correlate 
of diabetes distress, while the association between having cardiovascular disease and 
diabetes distress became statistically significant. Nevertheless, when looking at the size of 
the associations, the odds ratio (effect size) for neuropathy remained larger than the odds 































































































































































































































































































































































































































































































































































































































































































































The present study clearly shows that people with type 2 diabetes treated in secondary care 
experienced considerably higher levels of diabetes distress compared with those treated 
in primary care. Moreover, the percentage of participants who had high levels of diabetes 
distress was fivefold higher in secondary care than in primary care. Although this finding 
confirms our hypothesis, the observed percentage of those with elevated diabetes distress 
was rather high compared with previously described findings from secondary care samples 
in two general hospitals in the north of the Netherlands [23,24]. In those studies, in spite 
of the use of a lower cut-off point on the PAID questionnaire to define elevated levels, only 
6-9% of participants fulfilled these criteria. One explanation for this difference could be 
that two out of the three participating hospitals in the present sample were university 
hospitals with specialised diabetes centres, serving people with the more complex diabetes. 
It might be hypothesised that the lowest prevalence of high diabetes distress levels would 
be seen in primary care, higher levels in general hospitals and the highest levels in university 
hospitals; however, no statistically significant differences in mean levels of diabetes distress 
of patients from different hospitals were observed in the present study (data not shown). 
Another explanation could be the relatively high proportion of participants belonging to an 
ethnic minority group in the secondary care sample of the present study, who experienced 
substantially higher levels of distress than native Dutch participants.
 The association between care setting and diabetes distress was substantially attenuated 
after adjustment for several demographic and clinical factors. With respect to demographic 
factors, participants with type 2 diabetes treated in secondary care were younger than 
participants in primary care. Younger age was a correlate of distress, even when controlling 
for factors such as ethnic minority status, BMI and HbA1c. The association of younger age 
and diabetes distress has been a consistent finding in previous literature [4,5,8,12]. Similarly 
to young age, belonging to an ethnic minority group resulted in higher levels of diabetes 
distress, which was not explained by clinical variables such as BMI, using insulin, HbA1c, 
or having complications. Alternatively, unmeasured factors related to ethnic origin, such 
as migration stress, low socioeconomic status, language problems, health illiteracy, and 
cultural differences could all potentially contribute to diabetes distress [25,26]. 
 In addition to the demographic variables, the clinical variables diabetes duration, insulin 
use, BMI, and HbA1c further attenuated the association between care setting and diabetes 
distress. This is consistent with previous literature [4,9-11] and with our initial hypothesis 
that people with type 2 diabetes treated in secondary care would experience more diabetes 
distress, because of the more complex nature of their condition as well as its management. 
Interestingly, diabetes duration was not statistically significantly associated with diabetes 
distress, which has been found previously as well [4,5].
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 Surprisingly, diabetes-related complications status only slightly attenuated the 
association between care setting and diabetes distress, even without including other clinical 
variables in the model. Only the presence of neuropathy was statistically significantly related 
to diabetes distress, whereas other diabetes-related complications including retinopathy, 
nephropathy as well as cardiovascular disease were not. While this might suggest that 
functional limitations could be an important factor in explaining this difference in the 
association of the distinct diabetes-specific complications with diabetes distress, we cannot 
derive firm conclusions from these findings, as the severity of and particularly the functional 
limitations ensuing from these complications were not evaluated. Adding severity grading 
and a validated questionnaire on functional limitations would be worthwhile in future 
research.
 The demographic and clinical variables could not fully explain the difference in 
diabetes distress levels between primary and secondary care. This could be attributable 
to unmeasured factors, but it is also possible that a high diabetes distress level itself is an 
independent predictor for seeking secondary care.
 The present study has several strengths, including its large sample size and the inclusion 
of several demographic and clinical correlates. Furthermore, it directly compared diabetes 
distress across care settings in the Netherlands and showed the importance of taking care 
setting into account when investigating diabetes distress. These results could have important 
implications. Currently, several (international) diabetes guidelines recommend screening 
for emotional problems, such as diabetes distress, in all people with diabetes [27,28]. 
Our findings call into question whether it is justified to spend limited health resources on 
screening for diabetes distress in all people with type 2 diabetes in primary care, given the 
low prevalence found. Nevertheless, from a population perspective it should be noted that 
most people with type 2 diabetes (about 90%) are treated in primary care [6], and thereby, 
in terms of absolute numbers, the majority of people with high diabetes distress levels will 
be found in primary care, even with a fivefold lower prevalence of high distress levels. The 
size of the problem of emotional distress in primary diabetes care should, therefore, not 
be underestimated on the basis of the prevalence rate; instead, awareness among health 
care providers is suggested, especially in a selected sample of people with type 2 diabetes 
who have a higher risk of diabetes distress. In addition to those in a secondary care setting, 
people at increased risk for diabetes distress are those who are younger, who belong to an 
ethnic minority group, are using insulin, have a higher BMI, a higher HbA1c, or who have 
neuropathy. 
 The present study has several limitations. First, data from two different studies were 
combined to answer our research questions. Neither study was originally designed for this 
purpose. Differences in data collection between primary and secondary care settings might 
have an influence on the results. For example, the data in secondary care were collected 
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several years before the primary care data. Furthermore, the exclusion criteria in primary 
and secondary care were slightly different. In the primary care sample participants receiving 
currently psychological treatment were excluded, while this was not an exclusion criterion in 
secondary care; however, this concerned a small group (< 4% of total group considered for 
study inclusion).
 Second, data of the care settings were collected in different areas in the Netherlands; the 
hospitals were situated in larger cities, whereas the general practices were situated mostly 
in rural and semi-urban areas. Previous studies examining differences in the prevalence of 
emotional disorders between rural and urban areas have found conflicting results [29,30]. 
Hence, the influence of region on our results is not known. Related to this limitation is the 
fact that only a few participants in our primary care sample belonged to an ethnic minority 
group compared with our secondary care sample. This may be attributable to the fact that 
people belonging to an ethnic minority more often live in cities in which the hospitals are 
based, rather than in rural areas [31]. Additionally, it is possible that people belonging to 
an ethnic minority group are more easily referred to secondary care. It has indeed been 
found that people from an ethnic minority group had more outpatient care visits [32] and 
more frequently had suboptimal glycaemic control [33]. This relatively low representation of 
ethnic minority groups may have led to an underestimation of the occurrence and severity 
of diabetes distress in primary care settings in general, but when people belonging to an 
ethnic minority group were excluded in an explorative analysis, levels of diabetes distress 
remained significantly higher in secondary care compared with primary care.
 Third, while HbA1c and complications were derived from medical charts, BMI, insulin 
use and diabetes duration were self-reported. It is known that self-reported BMI is highly 
correlated with objective BMI measures, although BMI values are generally slightly 
underestimated (e.g., average difference of 0.7 in a Dutch sample, [34]), particularly in obese 
people or elderly [35]. We cannot exclude the possibility that self-reported BMI might lead 
to slightly bias. Regarding self-reported diabetes duration, it is likely that a recall bias has 
occurred. Therefore, self-reported diabetes duration should be interpreted with caution. 
Diabetes related complications were extracted from medical charts; however, these data 
were registered for medical reasons, not for research purposes. It is possible that differences 
exist between the methods used by health care providers in different care settings in the 
recording of complications.
 Fourth, about half of the people invited for screening did not return the screening 
questionnaire. The response rate was similar between primary and secondary care and, in 
the primary care sample, responders and non-responders were rather similar, for example, 
they did not significantly differ in HbA1c levels. We do not have information about non-
responders in the secondary care sample. Another Dutch study in people with diabetes 
treated in secondary care found that non-responders to a screening questionnaire for 
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depression and diabetes distress were less adherent to treatment and had a less optimal 
glycaemic control (i.e., higher HbA1c values) [24]. We have found that higher HbA1c values 
were related to higher levels of diabetes distress and that the mean HbA1c value in non-
responders was comparable to that of the responders in primary care. This may indicate 
that the mean diabetes distress level we have found might be an underestimation of the real 
level of diabetes distress.
 To conclude, diabetes distress is considerably more prevalent in people with type 2 
diabetes in secondary care than in primary care. This can be largely explained by differences 
in clinical and demographic factors between these groups. These results, and especially 
the low prevalence of diabetes distress in primary care, call into question the efficiency of 
screening for emotional distress in people with type 2 diabetes in primary care, at least in 
the Netherlands. 
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Aim: International diabetes guidelines advocate attention for the psychological well-being 
of people with diabetes, including those in primary care settings. However, there are very 
few studies on the actual psychosocial health care needs of this particular group. This 
qualitative study examined these needs from the perspective of people with type 2 diabetes 
and diabetes health care providers (HCPs) in primary care. 
Methods: Three focus groups were conducted in people with type 2 diabetes (n = 20) and 
three focus groups in HCPs (n = 18).
Results: Opinions differed considerably on whether there was a need for psychosocial 
health care. Psychosocial needs focused mainly on diabetes-specific issues and ranged from 
a need for extra diabetes education to attention and support within generic diabetes care. 
Some participants reported a need for specialised psychosocial help. In general, people with 
type 2 diabetes were satisfied with the current attention given to them by their HCP with 
regard to psychosocial issues. HCPs often considered it their task to address psychosocial 
issues, but they also recognised barriers, such as health care policies focusing on somatic 
targets, lack of confidence when discussing these issues, and a lack of time. An open attitude 
towards psychosocial health care in the case of people with type 2 diabetes appeared to be 
influenced by the setting in which the care was given (e.g., within regular diabetes care or 
in specialised mental health care), accessibility of care, proactive discussion of psychosocial 
issues with, and referral by HCPs, and attitudes towards or previous experiences with 
psychosocial health care. 
Conclusions: Although only a few participants expressed a need for specialised psychosocial 
care, attention for psychosocial well-being in general diabetes care was generally appreciated.




Having diabetes may result in diabetes-specific emotional problems, such as worries about 
complications and uncomfortable social interaction with regard to self-care activities [1]. 
Moreover, diabetes is related to 60% higher odds of experiencing depression compared 
with persons without diabetes [2] and to 20% higher odds of an anxiety disorder [3]. In 
general, emotional distress in diabetes, particularly depression, has been shown to have 
a negative effect on diabetes self-care [4,5] and the outcome of diabetes, such as a higher 
risk of developing complications [6-8], and is also related to higher mortality rates [9] and 
decreased quality of life [10]. 
 Several diabetes guidelines have recommended that addressing psychosocial issues 
should be a regular part of diabetes care [11,12]. It might be expected that heightened levels 
of distress often indicate a higher need for psychosocial help. However, studies in outpatient 
care have shown that about 30-40% of those with elevated levels of emotional distress 
accept referral or treatment [13,14]. Furthermore, there is also a group not exhibiting high 
distress scores in whom a need for discussing stress and mood is indicated [14]. However, 
there are very few studies on the actual psychosocial health care needs in this particular 
group.
 When examining these needs it is important to differentiate between care settings. For 
example, a recent study reported considerably lower levels of diabetes-specific distress in 
people with type 2 diabetes in primary care compared with secondary care (4% vs 19%) 
[15]. Similar differences have also been reported for depressive symptoms [16,17]. As a 
consequence, the needs for psychosocial health care may also differ across care settings. In 
the Netherlands, the vast majority of people (90%) with type 2 diabetes are treated in primary 
care [18]. Therefore, our study will focus on the primary care setting. In a primary health care 
setting in the Netherlands, the general practitioner is responsible for the treatment policy of 
people with type 2 diabetes. The three-monthly consultations are generally managed by a 
practice nurse and the annual consultation by the general practitioner. In addition, primary 
care diabetes nurses treat people with type 2 diabetes who make use of insulin, and are 
there to support practice nurses. 
 The aims of this study are to examine: (a) the psychosocial health care needs of 
people with type 2 diabetes from the perspective of both people and diabetes health care 
providers (HCPs) in primary care; (b) the factors that impede or facilitate the extent to which 
psychosocial issues are currently addressed by health care providers; and (c) the factors 






Participants were selected from general practices affiliated with the managed care 
organisation PoZoB, located in the southeast of the Netherlands. PoZoB currently organises 
the diabetes care of over 15,000 people with type 2 diabetes who are monitored in a 
structural way during their lifetime [19,20]. The sampling frame included those who 
completed screening questionnaires on emotional distress and consented to being 
contacted [21]. The questionnaires assessed symptoms of anxiety (7-item General Anxiety 
Disorder questionnaire, GAD-7 [22]), depression (9-item Patient Health Questionnaire, 
PHQ-9 [23]), and diabetes distress (20-item Problem Areas In Diabetes survey, PAID [24]). 
We used a purposive sampling strategy (in contrast to a random sampling strategy) in order 
to ensure that a diversity of participants, and thereby possibly a wide variety of experiences, 
was represented [25,26]. The purposive sampling strategy was based on factors that we 
expected to be related to psychosocial health care needs, namely age (less than age 65, or 
age 65 and over), sex, diabetes treatment (whether or not using insulin), and symptoms of 
emotional distress (whether having or not having a heightened score: GAD ≥ 8 [22], PHQ ≥ 
7 [27], or PAID ≥ 15; corresponding to the 80th percentile). People were approached by the 
first author (CS) by telephone and, if they showed interest, received a letter of information 
providing details of the qualitative study.
 The HCPs were also selected using purposive sampling [25,26], based on profession 
(general practitioner (GP), practice nurse, or diabetes nurse), years of work experience in 
the current profession, and participation (yes/no) in a study investigating the effectiveness 
of intervention in people with a chronic disease and comorbid anxiety and/or depression 
[21,28]. For the purposes of the present study, both CS and PoZoB staff members approached 
HCPs by mail, telephone or face-to-face contact. Interested HCPs received a letter of 
information explaining the purpose of the focus group study. In order to facilitate an open 
discussion, HCPs within a particular focus group all worked for different general practices. 
All participants provided written informed consent. 
Data collection
An important advantage of working with a focus group compared with individual interviews 
is that group interaction can stimulate the in-depth exploration of a topic [29]. The size of a 
focus group should be small enough for participants to feel enough at ease to be able to share 
their opinions and experiences, and large enough to reap the benefits of group interaction 
and, as such, have a diversity of opinions and experiences. According to Kitzinger, optimal 
group size is between four and eight participants [29], however, group sizes of between six 
and 12 participants have also been proposed [30]. Our target was focus groups consisting of 
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between five and ten participants each. Three separate focus group sessions were held for 
people with type 2 diabetes, each lasting from one and a half to two hours. Likewise, three 
sessions with HCPs were also organised, with these lasting approximately one hour. After 
these six focus group sessions, saturation point was reached [31]. 
 However, a possible downside of focus groups is that the group may head towards a 
consensus, and any possible diversity of views may be lost [29]. In order to minimise this 
effect, at the start of each focus group session, the moderator (CS) explained that the 
answers would be treated confidentially, that there were no right or wrong answers, and that 
we were interested in all opinions, even when these opinions or experiences differed from 
those of other participants. Moreover, all participants had a form in front of them containing 
the key questions (see below). They were encouraged first to write down their thoughts on 
the form before commencing the group discussion. After the discussion, participants were 
encouraged to write down any thoughts on the topic that had occurred to them that they 
had not shared with the group. We noted that the participants used the forms in order to 
help themselves formulate answers or discussion points. Some details were only reported 
on the forms. However, no new themes emerged from the forms in addition to the group 
discussion.
 During the focus group sessions, an observer (LvT, mentioned in Acknowledgements) 
was present to assist the moderator (CS) and take notes. All the focus group sessions 
were audio-recorded and fully transcribed by the observer and subsequently checked by 
the moderator against the audio recordings. In order to ensure anonymity, participants’ 
names were replaced by consecutive participant numbers and place of residence was not 
transcribed.
Interview guide
The key topics explored in all focus groups were: (1) psychosocial health care needs; and (2) 
the attitude of people with type 2 diabetes with regard to psychosocial help. In addition, 
people with type 2 diabetes were asked to what extent psychosocial issues were currently 
being addressed by their diabetes HCPs. 
Participant characteristics
Information on the sex, age and emotional distress levels of participating people with type 
2 diabetes was available from the screening questionnaire they had completed earlier. 
Before the start of the focus group discussions, they completed additional questions on 
the burden of diabetes (10-point Likert-scale ranging from 1 “not at all burdensome” to 10 
“very burdensome”), diabetes treatment, diabetes complications, and history of treatment 
for psychological problems. HCPs were asked to report their sex, date of birth, function, and 




Data were analysed using the constant comparison method [31]. Two researchers (CS and 
GN) independently coded the transcripts in order to identify themes [25]. Firstly, open 
coding was carried out inductively in order to identify the different responses. Secondly, 
responses (codes) were compared within and between focus groups and grouped together 
into categories (axial coding). These categories were grouped in a hierarchical structure and 
themes were derived from the data (selective coding) [30,31]. Themes emerging from the 
focus groups were compared between the ones held by people with type 2 diabetes and 
the ones held by HCPs (triangulation) [31]. Paper and pencil, Word, Excel and Visio were 
used during these various phases. On several occasions during the process, analyses were 
discussed. Coding disagreements were resolved by discussion. Both CS and GN selected 
quotes illustrative of the themes. Factors that facilitate or impede the addressing of 
psychosocial problems by HCPs, and the extent to which people with diabetes have an open 
attitude towards psychosocial health care were categorised into organisational factors, HCP 
factors, and factors related to people with diabetes (individual factors) [32]. 
 In the Results section, the term ‘participants’ is used to indicate that both people with 
diabetes and HCPs mentioned a particular theme. When a theme was only mentioned by 
people with diabetes or only by HCPs, the specific group is mentioned explicitly.
RESULTS
Participants
In total, 107 people with type 2 diabetes were invited to participate, of whom 20 (19%) 
accepted and were able to join a focus group. Each focus group consisted of between six 
and seven persons. Reasons for not participating included: not experiencing diabetes as 
a burden; being satisfied with the care received from their diabetes HCPs and therefore 
not feeling the need to participate; not regarding participation as a priority in their busy 
schedule; not being able to come to focus group meetings (either due to mobility problems, 
or because of the date and time the focus group was held); not feeling confident enough to 
talk about diabetes in a group setting; and having no interest (no reason specified). A total 
of 18 HCPs participated in the HCP focus groups (between five and seven in each group): 
ten general practitioners (50% female), six practice nurses, and two diabetes nurses (100% 
female). Reasons for not participating among HCPs were: too busy; maternity leave; unable 
to attend on the given date and time; having no interest; or no specified reason. Participant 
characteristics are shown in Table 1.
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Table 1 Characteristics of participants
People with type 2 diabetes (n = 20) Health care providers (n = 18)
n (%) or Mean ± SD [min.-max.] n (%) or Mean ± SD [min.-max.]
Age, years 67 ± 6 [55-79] 47 ± 10 [24-62]
Sex, female 7 (35%) 13 (72%)
Using insulin 7 (35%) -
Diabetes complication(s)a 8 (40%) - 
Burden diabetes 4.6 ± 2.7 [1-10] -
Elevated symptoms of anxiety, 
depression, and/or diabetes 
distressb
7 (35%)
Clinical experience, years - 12 ± 9.5 [2-30]
a Cardiovascular (n = 5), neuropathy (n = 3), and/or retinopathy (n = 4). No-one had self-reported nephropathy. 
b Elevated anxiety symptoms were defined as a Generalised Anxiety Disorder questionnaire (GAD-7) total score ≥ 8, 
elevated depressive symptoms as a Patient Health Questionnaire (PHQ-9) total score ≥ 7, and diabetes distress as 
a Problem Areas In Diabetes (PAID) total score ≥ 15.
Is there a need for psychosocial health care?
There was a considerable difference of opinion as to whether psychosocial support is 
necessary. Several people with diabetes did not experience psychosocial problems and, 
moreover, several HCPs did not recognise any particular heightened needs in this group. 
However, other participants did express or identify needs.
Factors related to experiencing psychosocial health care needs
Participants raised several specific issues as being (potentially) distressing (Table 2), mainly 
focusing on the burden of living with diabetes. For example, some participants noted that 
difficulties were experienced in connection with being diagnosed and having to accept 
having this condition (Quote (Q) 1, 2). Distress was also related to the severity of diabetes, 
such as suboptimal glycaemic control (Q3, 4), (fear of) complications (Q5, 6), and the 
fear of future insulin use (either due to fear of the actual use, or because insulin use was 
taken to signify a loss of control over one’s own body or having a severe and invalidating 
illness; Q7, 8). In addition, diabetes treatment was considered a source of emotional 
distress, including adhering to recommendations on lifestyle (Q9, 10), side effects of insulin 
(hypoglycaemia, skin irritations) and other medications (Q11, 12), and difficulties incurred 
with fitting recommendations into a person’s daily life (Q13, 14). Participants also mentioned 
experiencing feelings of embarrassment, for example, having to inject in public places, or 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 A stress factor only mentioned by people with diabetes was frustration with regard 
to health care providers; including: (a) not feeling supported by the HCP; (b) receiving 
unrealistic, unattainable advice; (c) feeling that the HCP did not take the personal situation 
into consideration when interpreting lab data or when giving advice (Q17); (d) receiving 
contradictory advice from different HCPs; (e) practical difficulties with regard to diabetes 
care appointments (e.g., HCPs not keeping their appointments; a mismatch in the timing of 
receiving lab results and having an appointment with a HCP); or (f) not receiving adequate 
care (e.g., because the HCP has insufficient knowledge, or does not take (somatic) complaints 
seriously). For example, one person was frustrated that her diabetes was diagnosed late 
despite frequent visits to her GP with her complaints. This lead to chronically elevated blood 
glucose levels already having damaged body tissues at the time of diagnosis. Psychosocial 
problems solely mentioned by HCPs were those of addiction (food or alcohol) and sexual 
complications. 
 Participants noted that not just diabetes and its treatment could cause distress and induce 
a need for psychosocial health care, but also personality and having experienced negative 
life events (Q18, Q19). Furthermore, it was reported that the combination of diabetes- and 
non-diabetes-related factors, such as work and family-related issues, comorbidities, and a 
lack of social support, could lead to an increased burden and, therefore, to an increased 
need of psychosocial health care (Q20, Q21). 
 
Factors related to not experiencing psychosocial health care needs
Approximately half the participants with type 2 diabetes did not experience a need for 
psychosocial health care, or felt burdened by their diabetes, or had the feeling that diabetes 
had an impact on their mood. Moreover, several HCPs did not see a heightened need for 
psychosocial health care in this group, although some HCPs wondered whether this was 
due to underrecognition by HCPs (Table 2; Q22). Participants mentioned that not (yet) 
experiencing diabetes as a serious disease and not feeling constrained by the diabetes 
regimen were related to not having psychosocial needs. Some HCPs labelled this as ‘denial’ 
or ‘lack of understanding’ (Q2).
 People with diabetes also described coping styles that helped them to be less affected 
by their condition, for example, having a positive view about their future (Q23), using an 
avoidant coping style, for example, not talking or reading about diabetes (Q24), or using 
an active problem-solving coping style, for example, actively searching for information 
on diabetes or finding a way to incorporate food restrictions into their daily lives (Q25). 
Moreover, accepting and taking responsibility, thereby trying hard to prevent the worsening 
of diabetes, was described, combined with an attitude of acceptance, for example, it was 
stated that, regardless of any efforts to the contrary, not all misfortunes could be prevented 
from happening in life (Q26). Being supported by a partner who cooked healthy meals, helped 
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to remember when medicine should be taken, or there to assist when a hypoglycaemic 
event occurred, was considered helpful (Q27).
Who should provide psychosocial health care?
Following these reflections, participants discussed who should provide psychosocial 
health care when people with diabetes expressed a need for it (Table 3). The majority 
of participants stated that the support provided within current diabetes health care was 
experienced as sufficient (Q28, 29). However, other suggestions were: (1) having a more 
specialised diabetes health care provider (e.g., diabetes nurse; this was only mentioned 
by people with diabetes), especially when the distress was related to diabetes (Q30); (2) 
specialised psychosocial health care, for example, when problems were not specifically 
related to diabetes, for example, in case of life events or when psychosocial problems were 
complex (Table 2, Q18); HCPs considered specialised mental health care particularly useful 
in the case of bariatric surgery or when they were not confident about being sufficiently 
competent to handle psychosocial issues (Table 3, Q31); (3) peer groups (including internet 
forums; Q32); and (4) people should help themselves or talk to a family member or friend 
(Q33). HCPs also mentioned a need for specialised psychosocial care professionals to aid 
in lifestyle advice. Some HCPs stated that they would prefer a psychosocial health care 
provider, such as a mental health care nurse, to provide support to people with diabetes in 
the case of psychosocial problems, rather than it being an additional task left to them.
Table 3 Who should provide psychosocial health care?
Q28 Pt15: No, I don’t need that, I don’t need a psychologist for that any more. That’s what I have my practice 
nurse for. Pt20: yes, but she is not always your psychologist. […] and definitely not in my case. Pt15: No 
but she’s like a psychologist, at least mine is.
Q29 HCP14: It seems to me that in general there doesn’t seem to be that much need for mental support 
by a psychologist in particular, but as you get to know the people better […] they tend to share a lot of 
their problems. These could, for instance, [lead to] a suboptimal glycaemic control. But there still is the 
need to talk about it, but that can be done at the general practice, I wouldn’t actually say solved, but 
still people are not often referred.
Q30 Pt9: When I’m feeling a bit down due to the diabetes I’d like the cause to be treated and then I’d rather 
go to the diabetes nurse than to a specialised mental health care setting. 
Q31 HCP13: But you also need to have a certain expertise. Not every practice nurse has to have that. That’s 
not necessary, when it’s about accepting, learning to accept, dealing with a chronic disease, or with loss 
or sorrow. In that case a mental health care practice nurse may be able to do more.
Q32 HCP16: At such a forum, and in particular when it’s about Victoza, people share a huge amount
Q33 Pt1: What have you already done to overcome your worries, and perhaps we’re exposing ourselves too 
readily to the professionalism of someone else.
Q = Quote. Pt = person with type 2 diabetes. HCP = health care provider
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Attention to psychosocial issues by diabetes HCPs
During the discussions between people with type 2 diabetes regarding the current attention 
being given to psychosocial issues by their primary diabetes HCP, opinions differed regarding 
whether the current level of attention was sufficient for their needs. They were generally 
satisfied with the time and attention received from their HCP, although a few persons felt a 
lack of support (Table 4; Q34). In the same way, several people with diabetes were satisfied 
with the education they received, while others had the feeling that not all their questions 
were being dealt with satisfactorily during a consultation, or that treatment advice was not 
being tailored to their personal situation. 
 Several participants considered attention for psychosocial well-being a task for the 
diabetes HCP, for the following reasons: (1) diabetes can cause distress (as outlined above); 
and (2) psychosocial problems could have an impact on self-management behaviour and 
diabetes outcomes (Q35, 36). It was also noted that HCPs should be aware of the negative 
impact some psychotropic medication can have on glycaemic control. 
 Several ways were described by participants (both HCPs and people with diabetes) 
by means of which emotional distress could be diminished by the diabetes HCP. These 
solutions were predominantly related to diabetes care, and included: (1) meeting a need 
for additional diabetes education when the condition and its management made people 
with diabetes insecure; (2) helping with the acceptance process; (3) supporting the carrying 
out of treatment recommendations in daily life; and (4) increasing self-reliance. Because 
participants felt that the social environment, in particular the partner, could play a significant 
role in successful diabetes care, they emphasised that: (5) HCPs should consider involving 
the partner in the treatment process (Q37, Q38). In addition, people with diabetes thought 
that HCPs could prevent distress by having up-to-date knowledge of diabetes, for example, 
regarding the prevention of irritated skin due to insulin use, comorbidities, and the interaction 
between stress and diabetes outcomes. They also recommended that advice and care 
should be tailored to a person’s personal situation, including well-being and comorbidities, 
since these factors could influence diabetes outcomes, such as glucose level (Q35), and the 
possibility of achieving advice (Q36). Apart from diabetes-related skills, participants also 
indicated that the general communication skills of HCPs could help to reduce distress, such 
as taking enough time, giving their full attention, listening to emotional struggles, and asking 
the right questions (Q39). Another desire expressed by people with diabetes was the HCP’s 
assistance in finding the correct (psychosocial) health care professional for referral. 
 HCPs considered it helpful if they could proactively address psychosocial issues, 
especially in the case of sensitive topics, such as sexual problems. They felt that this might 
reduce the barrier for people with diabetes for mentioning a psychosocial problem, such as 
sexual difficulties, as and when this occurs.
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Table 4 Important considerations with respect to addressing psychosocial problems by the diabetes 
HCP 
Q34 Pt4: There’s no-one you can go to for advice on what you should do. I’ve just deliberately registered 
with a new GP.
Q35 Pt20: Diabetes can affect your life negatively and a practice nurse should pay attention to that too (Pt18: 
right) and not just to the glucose levels.
Q36 HCP13: Yes, also since it [depression] does have consequences for the disease itself: the diabetes is 
getting worse of course, people […] don’t stick to your advice, or they don’t take any exercise.
Q37 Pt6: I’ve sometimes seen on television people who have fallen into a coma, and to start with, you don’t 
know how to deal with it. And that’s exactly what happened to me, which is why I think it’s so important 
to receive special care, to know what you should do, how you should deal with it, while you’re losing 
consciousness. I was lucky enough to receive decent support from the hospital, but they did ask me to 
bring my wife to every consultation, so that if it [hypoglycaemia] happens at home she’ll know what to 
do.
Q38 HCP16: I still ask that now and then, especially of older men, who say they’ll be fine as long as they get 
their pills. I sometimes ask to them bring their wives, because they are usually the ones who do the 
shopping and who decide on what they’re going to eat. 
Q39 HCP12: I think that, the beter they get to know you, the greater the need to tell their story. I’m sure the 
fact that we listen to them will help them.
Q = Quote. Pt = person with type 2 diabetes. HCP = health care provider 
Factors that facilitate or impede addressing psychosocial issues by diabetes HCPs
Although most people with diabetes and HCPs noted that HCPs paid attention to psychosocial 
well-being, several facilitating and impeding factors were identified that influenced the 
extent to which psychosocial issues were addressed. These barriers and facilitators were 
categorised into organisational factors, HCP factors, and factors related to the person with 
diabetes (Table 5).
 Organisational factors. Great differences in policy and structure between the 
general practices were noted. Some GPs allowed their practice nurses to schedule extra 
consultations for discussing psychosocial issues (Q40), while others did not. Moreover, the 
managed-care organisation policy was experienced as a barrier for addressing psychosocial 
issues, because somatic diabetes indicators had to be addressed and, therefore, some HCPs 
felt that there was no time left to address the issue of emotional well-being (Q41). HCPs 
reported that having easily-accessible psychosocial health care (e.g., a practice nurse for 
psychosocial health care working in the practice) made it easier to address psychosocial 
issues and to refer someone to this specialised nurse. Productive collaboration between the 
practice nurse and GP was also described as being helpful. For example, the possibility for 
the practice nurse to discuss the next steps with the GP, or, when necessary, the possibility 
to quickly refer a person with diabetes to the GP. Time pressure was a barrier for people 
with diabetes (Q42). According to some people with diabetes, a ten-minute consultation 
with a GP, and the notion that only one issue could be discussed within this time frame, 
hampered addressing psychosocial issues, while another person noted that the assistant or 
practice nurse ensured that sufficient time was scheduled. 
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Table 5 Facilitators and barriers for diabetes health care providers in addressing psychosocial needs 
during diabetes consultations
Organisational factors
Q40 F HCP7 (practise nurse): When I mention it to the general practitioner, he says “Go ahead. Just let 
me know if you need any help. See how far you get.” It’s a question of discussion.
Q41 B HCP3 (practice nurse): I have to say that it would be a relief if more tasks could be delegated, 
because it takes up a lot of my time to have regular conversations with those patients, even though 
I like taking the time to listen to them. In fact, there is so much pressure from here [= refers to the 
managed care organisation - CS] – all the things I have to include in such a consultation ‒ that it’s 
sometimes rushed, and that’s a shame.
Q42 B Pt18: I think that general practitioners are always in a hurry these days. They all want to get 
things done very quickly. Pt20: they don’t give you as much attention. Pt18: Yes, they give you less 
attention compared with the practice nurse, at least that’s how I see it. [...] They just have to go 
on and on, like a conveyor belt. 
Health care provider factors
Q43 B HCP10: When do you really call it depression? Everyone has a day now and then that he’s a bit 
down, and that’s what I find very difficult to assess. Of course, I don’t have much experience 
though, but when do you call it depression, you know what I mean? When I record it as that, then 
that’s what it is.
Q44 F HCP14: And at a certain moment, when you get to know people better, there are consultations 
when you don’t talk about diabetes at all but about what’s on their mind. 
Factors related to the person with diabetes
Q45 B Pt1: “How are you feeling?” That’s a general practitioner’s standard question, isn’t it? I can imagine 
that anyway, and then it is up to whoever’s on the other side of the table to say “well, it is like this 
or that”. So it’s my responsibility, if I don’t talk freely […], then you can ask as many questions as 
you like, use all kinds of subtle ways and means, it’s up to me to decide how open I am going to be, 
including about whether or not I need psychosocial health care. I don’t want to be dependent on 
the medical health care system. They should support and not the other way round.
Q46 B HCP18: And not talking about it. HCP17: Yes, not mentioning it. HCP18: Not right away, that’s 
true. HCP14: Not with the practice nurse either, that’s what I notice. Then I read in the medical 
chart what medication is being used now and then, HCP13: and all of a sudden it mentions Viagra. 
HCP14: Yes, exactly
Q47 F/B Pt1: Well, I would like to turn it around. I am responsible for my own body and I think that 
most people should take the initiative when they are not feeling well. I don’t want the health 
professionals to be responsible for all that. I don’t want to be so dependent. When I need 
psychological care I am still able to read, to make a phone call and do a lot of things, and I will take 
whatever initiative I think necessary. So I don’t let my fate depend on the level of knowledge of 
someone else. I want to be responsible for myself.
Q48 F Pt15: Yes, but you get to hear that from the practice nurse. If she suggests that it’s time to go there 
[mental health care provider], [...] then you do what she says.
Q = Quote. F = Facilitator. B = Barrier. Pt = person with type 2 diabetes. HCP = health care provider
 HCP factors. Important factors influencing whether HCPs addressed psychosocial needs 
were whether or not they viewed these as part of their job, and the degree to which they felt 
competent to address these issues. For example, not knowing how to differentiate between 
normal ups and downs and a depressed mood was mentioned as a barrier (Q43). Some HCPs 
described that they did not want to stigmatise or offend patients and, therefore, sometimes 
avoided discussions on psychosocial issues. Yet, only a few HCPs questioned the utility of 
addressing psychosocial issues, for example, some HCPs noted the possible down side of 
PSYCHOSOCIAL HEALTH CARE NEEDS OF PEOPLE WITH DIABETES
99
6
making a problem of normal ups and downs. These factors influenced whether they asked 
about distress or the situation at home and whether they recognised emotional problems. 
Some HCPs experienced personal barriers in addressing psychosocial issues. Besides not 
feeling competent, sensitive issues, such as sexual problems, were described as topics that 
were generally more difficult to discuss. A feeling of trust between the HCP and the person 
with diabetes facilitated discussing personal issues (Q44). A suggestion made by HCPs to 
increase competence and awareness was to integrate diabetes and psychosocial problems 
during professional training.
 Factors related to the person with diabetes. The characteristics of a person with diabetes 
also determined whether psychosocial issues were addressed by the HCP. Participants 
identified the proactiveness and willingness of a person with diabetes to discuss psychosocial 
issues as facilitators (Q45), but HCPs noted that feelings of embarrassment on the part of 
the person with diabetes might hamper the discussion of psychosocial issues, for example, 
with regard to sensitive topics (Q46). Some HCPs noted that when a person had just been 
diagnosed, a huge amount of information and advice was given by various HCPs and, 
therefore, they thought it would be too much to expect a person with diabetes to address 
psychosocial issues and start psychosocial counselling. 
 People with type 2 diabetes also discussed who was responsible for initiating a 
conversation on psychosocial well-being. For example, one person with diabetes thought 
it exclusively his responsibility (Q47) and described HCPs’ attention for psychosocial well-
being as ‘patronising’, while others opined that it was the responsibility of the HCP to ask 
about well-being and to indicate that extra help was needed (Q48).
Factors that facilitate or impede an open attitude towards psychosocial health care
Barriers and facilitators to having an open attitude towards psychosocial health care in 
people with diabetes were divided into organisational factors, HCPs factors, and factors 
related to the person with diabetes (Table 6).
 Organisational factors. Easy access to care reduced barriers for people with diabetes. 
Few barriers were experienced when care was provided by an HCP with whom the person 
with diabetes was familiar (e.g., practice nurse or GP) (Q49). Several general practices 
had a practice nurse for psychosocial health care working in the practice, and HCPs noted 
that a referral to this practice nurse was relatively easily accepted. Internet interventions 
were also mentioned as being potentially easily accessible. For example, when a person 
feels embarrassed about his problems, web-based support is often anonymous and 
can be accessed at times and places of choice. HCPs experienced that internet forums 
offered a place to express feelings, share experiences, and also to receive peer support. 
However, participants mentioned a lack of personal interaction as a downside to internet 
interventions. In the case of individuals with functional limitations, proximity and ease of 
entrance to where the care is being provided were preconditions. Flexibility within the 
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organisation was requested by people with diabetes. For example, the possibility to switch 
HCPs in order to obtain the most harmonious match could facilitate being open (Q50). The 
costs of specialised psychosocial health care were mentioned as a barrier by participants 
(Q51).
Table 6 Factors related to being open to a psychosocial health care offer in people with diabetes
Organisational factors
Q49 Easily accessible care F HCP3: I refer them to the general practitioner. (HCP7: me too) 
because that’s normally the first thing you do. That’s what people 
are used to [the GP]. I inform the general practitioner in advance, 
preferably on the same day, […] so that they can’t go home and 
change their minds. That works fine. 
Q50 Flexibility organisation F Pt14: So the social worker as well as the organisation need to, or 
the person himself needs to, accept that sometimes you run into 
people you don’t get on with. If that happens, you have to take the 
step to go to someone else. 
Q51 Costs B HCP12: Costs are also a barrier for some people. […] In those cases, 
the practice nurse specialised in mental health care is a good 
alternative; but I understood that the compensation for primary 
care psychologists is going to change in 2013, and that patients’ 
contributions will go up.
Health care provider factors
Q52 Reducing barriers F HCP2: I notice that if things are discussed with me, so when people 
discuss their sexual problems with me, I can more easily motivate 
them to discuss these with their general practitioner. I have noticed 
that you can lower that threshold. 
Q53 HCP characteristics B Pt14: But to say straight away that that social worker is useless. Pt9: 
I wouldn’t do that, I am not saying that he isn’t useless, but just that 
I wouldn’t choose him. I wouldn’t give myself away. 
Q54 F Pt6: No, but if you have a psychologist, you have to make sure 
that she’s experienced and is able to discuss things with you. Not 
the other way around. She has to advise me what to do. [...] I just 
wanted to say that it didn’t work out and I don’t want it any more. 
Factors related to the person with diabetes
Q55 Readiness to change F HCP18: You must be aware that not everything is going to go well, 
you have be open for this and also have the understanding to 
accept that something is going to change.
Q56 Burden B HCP13: I also think you have to be easily accessible, because in my 
experience, people already have so much to do. For many people, it 
is simply one step too far to have to see a psychologist and discuss 
your disease.
Q57 Positive attitude/experience F Pt3: When you consult a psychologist, I think you have to realise 
that she only wants what’s best for you. If you are open to that, 
everything will work out fine. 
Q58 Negative attitude/experience B Pt5: Well, that could be too late. It’s the same as when you’re in 
hospital and they’ve finished treating you but they won’t discharge 
you yet, and you end up leaving on an argument. 
Q = Quote. F = Facilitator. B = Barrier. Pt = person with type 2 diabetes. HCP = health care provider
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 HCP factors. Diabetes HCPs could play a role in reducing the barriers for discussing 
psychosocial problems and accepting help by proactively addressing these issues and by 
guiding people towards the appropriate care (Q52). However, one HCP thought that the 
fact that she was discussing psychosocial problems increased the barrier for accepting 
external help. People with diabetes identified several HCP characteristics that facilitated 
an open attitude towards psychosocial health care, including sufficient time being taken, 
being competent, and being knowledgeable about diabetes. The type of provider (e.g., 
psychologist or social worker) could influence whether or not help was accepted (Q53). 
For example, a diabetes HCP was preferred in issues related to diabetes distress (Table 3, 
Q30). A feeling of trust between the HCP and person with diabetes was also mentioned as 
important in stimulating an open attitude towards psychosocial health care. Moreover, the 
method used by the HCP should match the expectations of the person with diabetes. For 
example, whether group or individual sessions were used, concrete advice was given, or a 
coaching strategy used. A mismatch could result in disappointment and a reduced chance of 
being open in the future (Q54).
 Factors related to the person with diabetes. It was also mentioned that the ease with 
which help was accepted also depended on factors relating to the person with diabetes. HCPs 
mentioned the readiness to change in people with diabetes and a clear request for help as 
facilitating factors (Q55), and the busy schedule of a person with diabetes as a barrier against 
visiting additional HCPs (e.g., a psychologist) (Q56). In focus groups of people with type 2 
diabetes, it was observed that personal positive or negative experiences with psychosocial 
health care, or those of acquaintances, influenced whether a person had a positive (Q57) or 
a negative (Q58) attitude towards psychosocial health. Some HCPs mentioned that people 
with diabetes usually focused on the somatic aspects of diabetes, such as blood glucose 
levels, and less on the psychosocial aspects.
DISCUSSION
Both in focus groups of people with type 2 diabetes and in those of HCPs, opinions differed 
considerably as to whether there was a need for psychosocial care. Not perceiving diabetes 
as a serious disease, effective coping, and the perception of receiving adequate social 
support were reported to diminish the need for psychosocial health care. The needs that 
were expressed focused predominantly on distress related to diabetes and its management, 
such as help in incorporating lifestyle advice into daily life, and additional diabetes education 
when a person feels insecure about the condition. These needs also included being treated 
by an HCP who is aware of the personal position of the person with diabetes, who listens 
to emotional problems, and provides support. Some participants mentioned this as a 
precondition for adequate diabetes care. According to most participants, these types of 
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care could be provided by diabetes HCPs as part of regular diabetes care. A minority of the 
participants mentioned the need for a referral to a specialised psychosocial HCP. 
 In general, people with diabetes were satisfied with the attention they received from 
their HCP for their well-being. However, suggestions for improvements were made, such 
as tailoring advice to the personal situation, which could reduce frustration with regard to 
treatment. For HCPs to be able to meet the psychosocial health care needs of people with 
type 2 diabetes, the following factors were identified as being important: (1) having adequate 
communication skills; (2) having up-to-date knowledge of diabetes and its treatment; and 
(3) knowing the personal position of the person. Since participants acknowledged the 
importance of the role of the diabetes HCP in addressing psychosocial issues, a precondition 
is that HCPs should be sufficiently skilled for this task. However, not all HCPs were convinced 
of their competence with regard to addressing psychosocial needs. 
 One technique that incorporates a patient-tailored approach and provides a tool for 
HCPs to target (distress related to) changes in behaviour is motivational interviewing [33]. 
The results of a systematic review of eight studies in primary care (two of which studies 
included people with diabetes) indicated the effectiveness of this technique in improving 
lifestyle [33]. However, a Dutch study specifically focusing on the effect of motivational 
interviewing by practice nurses on diabetes outcomes in people with type 2 diabetes in 
primary care did not show motivational interviewing to be any more effective than routine 
care [34]. It is known that practice nurses often experience difficulties in applying this 
technique [35,36]. Thus, coaching of the practice nurse by a psychologist, or using video-
feedback training with videotaped consultations, could assist the practice nurse in putting 
motivational interviewing skills into practice [37]. HCPs in the focus groups mentioned that 
a mental health care nurse could assist when psychosocial problems occurred or when 
lifestyle adjustments were difficult to achieve. 
 Several barriers were identified that impeded HCPs when addressing psychosocial 
problems. These included organisational factors (e.g., health care policy focussing on 
somatic diabetes indicators that needed to be addressed), factors related to the HCP (e.g., 
not seeing the addressing of psychosocial issues as a (primary) task, or not feeling sufficiently 
competent), and factors related to the person with diabetes (e.g., feeling ashamed of talking 
about certain topics, such as sexual problems). 
 A solution mentioned by HCPs in order to help increase their competence, confidence 
and awareness, was to provide additional professional trainings on, for example, how to 
discuss and treat emotional problems and how to provide integrated care for psychosocial 
problems in people with diabetes. However, it should be noted that results from the 
Hampshire Depression Project clearly showed that a clinical-practice guideline and practice-
based education on how to recognise and treat depression did not actually improve 
depression outcomes in primary care [38]. 
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 Increased awareness and communication could also be facilitated by having a set of 
questions easily available for discussing these topics. One study in a secondary care setting 
found that regular assessment of well-being by a specialist diabetes nurse, and discussion of 
the results, increased the well-being of people with diabetes [39]. In that study, the diabetes 
nurses received half a day of training, including general counselling skills and how to discuss 
emotional well-being using the results of a computerised assessment that utilised a short 
well-being questionnaire [39]. 
 The attitude of people with diabetes regarding psychosocial health care is also important. 
Several factors were mentioned during the focus groups as potential barriers. Participants 
described organisational factors, such as the accessibility of psychosocial health care; for 
example, whether this was provided within the diabetes care setting or by a specialised 
psychosocial HCP outside the diabetes care setting. Personal factors were also revealed, 
such as previous positive or negative experiences with psychosocial health care, or personal 
beliefs about this type of care. People with diabetes noted that a mismatch can exist between 
expectations regarding psychosocial health care and the actual care received. This can result 
in a negative attitude towards specialised psychosocial health care. During the focus groups, 
it was also noted that diabetes HCPs could play an important role in reducing barriers; for 
example, by initiating a conversation about sensitive topics, such as sexual complications. 
In addition, HCPs could create realistic expectations about psychosocial health care, discuss 
referral, and help find an HCP who supports the needs of the patient.
 Barriers that may be experienced with regard to face-to-face interventions, may not 
be an issue when using internet interventions. This type of intervention could overcome 
barriers, such as time limitations and mobility problems and, due to the relatively anonymous 
setting of an internet intervention, could also facilitate disclosure. There is an effective 
internet intervention aiming at people with diabetes and a depressed mood [40]. Internet 
interventions appear to be especially effective when they include personal coaching [41].
 Another theme that emerged during the focus groups was responsibility for initiating 
discussion on psychosocial problems and the usefulness of additional psychosocial health 
care. People with diabetes had various preferences; while some explicitly stated that they 
themselves preferred to make the decisions about the necessity of care, others preferred the 
HCP to be responsible and take the lead. A comparable diversity in opinions was identified 
among HCPs. Some HCPs expected the person with diabetes to mention any psychosocial 
problems that needed help, while others felt it was the task of HCPs to initiate a discussion 
on psychosocial problems. The discussion on the responsibility for initiating a conversation 
on psychosocial needs taps into the current discussion on patient empowerment and shared 
decision-making. Currently, diabetes care is changing from the directive role of the HCP to 
increasing empowerment of patients and shared decision-making [42]. However, based on 
the discussion in the focus groups, it should be noted that people with diabetes differ in 
CHAPTER 6
104
their preference for either a directive approach or an approach with a more prominent role 
for the patient, also in the case of psychosocial health care support. 
 The major strength of the present study is that the perspectives of both people with 
diabetes and HCPs were explored, which provided a more complete view on psychosocial 
health care needs and the provision of psychosocial health care. This study also has several 
limitations. Firstly, although every effort was made to select a diverse sample in order to 
obtain a varied range of opinions on this topic, the inclusion of participants from an ethnic 
minority group was low (one person = 5%). This low number was to be expected, given 
the low percentage of persons belonging to ethnic minority groups in the area where the 
present study took place (approximately 7%). Since the focus group sessions were conducted 
in Dutch, only individuals with sufficient mastery of the Dutch language could participate. 
Based on our study, no conclusions can be drawn regarding psychosocial health care needs 
in ethnic minority groups. It is likely that psychosocial health care needs differ between 
native Dutch persons and those belonging to ethnic minorities. For example, the literature 
has shown that, among Surinamese persons living in the Netherlands, talking about having 
diabetes is taboo, and that diet recommendations conflicted with far-reaching cultural 
beliefs about food and eating patterns [43,44]. Secondly, recruitment took place in primary 
care practices in the south-east of the Netherlands, with participants mainly residing in rural 
or semi-rural areas and one small city. This means that it may not be possible to generalise 
the results with regard to the needs of persons in secondary care residing in large cities, 
other areas of the Netherlands, or other countries. 
 In conclusion, opinions differed on whether or not there was a need for psychosocial 
health care in people with type 2 diabetes in primary care. The needs that were expressed by 
the participants focused predominantly on diabetes-related distress, and could be addressed 
during regular diabetes care. In general, attention for psychosocial problems was appreciated 
and was regarded as the task of diabetes HCPs. However, not all HCPs felt competent enough 
to be able to address psychosocial problems. Improving the communication and counselling 
skills of HCPs, for example, by providing a tool (questionnaire) to aid in the discussion of this 
topic, could help to optimise the provision of psychosocial support within diabetes care. 
Another solution would be to include a psychosocial HCP in the standard diabetes team, 
either in order to coach diabetes HCPs or to provide care to people with diabetes first-
hand. When people with diabetes experience barriers with regard to accepting help by a 
specialised psychosocial HCP, their diabetes HCPs could play an important role in reducing 
these barriers.
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In this chapter the main findings of the thesis are summarised. Furthermore, methodological 
considerations, clinical implications, and future research directions are discussed.
SUMMARY OF THE MAIN FINDINGS
This thesis focused on emotional distress in people with type 2 diabetes who are treated in 
primary care. The aims of present thesis were:
1) to evaluate the effectiveness of a stepped care intervention in the Disease Management 
model for Comorbid Depression and Anxiety (DiMaCoDeA) trial (Chapter 2 and 3), 
2) to explore the response to a screening procedure for symptoms of anxiety and depression 
and subsequent participation in the DiMaCoDeA trial (Chapter 4), 
3) to compare levels of diabetes-specific emotional distress (diabetes distress) between 
people with type 2 diabetes treated in primary care and those treated in secondary care 
and examine factors explaining a potential difference (Chapter 5), and 
4) to examine (a) psychosocial health care needs of people with type 2 diabetes in primary 
care, (b) factors that facilitate or impede having an open attitude towards psychosocial 
health care, and (c) factors that facilitate or impede the extent to which psychosocial 
issues are currently addressed by health care providers (Chapter 6). 
Investigating the DiMaCoDeA intervention
The rationale and design of the DiMaCoDeA trial for people with type 2 diabetes were 
described in Chapter 2. This randomised controlled trial evaluated the effectiveness of a 
12-month disease management program in reducing symptoms of depression and/or 
anxiety. People were invited for participation in the trial when they experienced elevated 
levels of depression and/or anxiety symptoms on a screening questionnaire. The DiMaCoDeA 
intervention involved stepped care and monitoring of symptoms of both depression and 
anxiety. The rationale behind stepped care is that the first step consists of a low intensive, 
least costly intervention, and when treatment goals are not met, a more intensive treatment 
is offered in the next step [1]. The first step of the DiMaCoDeA intervention comprised four 
weekly meetings of psycho-education. The second step included the ten-weekly course 
“Coping with depression” or “Coping with anxiety” [2,3]. The third step consisted of booster 
sessions (six times during a maximum of six months) and the advice to discuss the option 
of treatment with psychotropic medication with the general practitioner (GP). At the end 
of each step, symptoms of anxiety and depression were assessed to evaluate whether 
symptoms had decreased or whether a next step was indicated. Monitoring of symptoms 
was continued in all cases, also after remission of symptoms. When a relapse occurred, 
continuation with the next step of the stepped treatment was offered. The control group 
received usual care and, for research purposes, symptoms of anxiety and depression were 
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monitored. For ethical reasons, the GP was notified when a participant of the study had two 
consecutive scores ≥ 15 on either questionnaire, indicating (moderately) severe symptoms 
of anxiety or depression, or when possible suicidal thoughts were identified.
 Chapter 3 described the results of the randomised controlled trial investigating the 
DiMaCoDeA intervention. This 12-month disease management program was tested not 
only in people with type 2 diabetes, but also in people with asthma or COPD. In total, 3559 
people were invited for screening of whom 1336 (38%) completed the questionnaire. A 
total of 286 persons met the inclusion criteria of whom 46 persons (16%) agreed with 
participation and were randomised. The outcome variables were symptoms of anxiety and 
symptoms of depression 12 months post screening (the end of the disease management 
program) and 18 months post screening. The analyses were first adjusted for condition 
(diabetes or asthma/COPD) and baseline symptom scores, and subsequently also for age, 
sex, and education. The group that was allocated to the DiMaCoDeA intervention reported 
significantly less symptoms of anxiety after the 12-month program than the control group 
(Cohen’s d = 0.61; partly adjusted model p = 0.02, fully adjusted model p = 0.048). This 
effect was still present six months later (18-month measurement; Cohen’s d = 0.74; partly 
adjusted model p = 0.003, fully adjusted model p = 0.007). Also less symptoms of depression 
were reported in the intervention group compared to the control group at the end of 
the 12-month program (Cohen’s d = 0.63); however, this difference was only statistically 
significant in the partly adjusted model (p = 0.03), but not in the fully adjusted model (p = 
0.10). This difference seemed to remain after 18 months (Cohen’s d = 0.61, large effect size), 
but was not statistically significant in either the partly or fully adjusted model. 
Screening for anxiety and depression and subsequent participation in the DiMaCoDeA 
trial
Although the DiMaCoDeA intervention appeared to be effective in reducing symptoms of 
anxiety and depression, the participation in the treatment trial was substantially lower 
than initially expected. Therefore, we took a closer look at the flow from screening for 
symptoms of anxiety and depression to participation in the DiMaCoDeA trial in people with 
type 2 diabetes. In Chapter 4, we explored the response to the screening questionnaire and 
differences on demographic and clinical variables between people who did and did not fill 
out the screening questionnaire. In addition, we explored how many people with elevated 
symptoms of anxiety and/or depression decided to participate in the trial, and whether 
participants differed from non-participants on demographic, clinical, and psychological 
variables. Forty-two percent of the 1837 invited persons completed the screening 
questionnaire (n = 798). Non-responders were more often female (53% vs 44%, p < 0.001) 
and had slightly less optimal LDL cholesterol levels (2.4 ± 0.9 vs 2.3 ± 0.8, p = 0.001) and 




percent of the people with an elevated depression and/or anxiety score (27/130) decided 
to participate in the randomised controlled trial, which is 1.5% of all people invited for 
screening. Compared to non-participants, trial participants had less often a low educational 
level (46% vs 69%, p = 0.03), had a higher level of diabetes distress (Problem Areas In 
Diabetes (PAID) total score 21 ± 18 vs 30 ± 14, p = 0.003), and reported more often that they 
had experienced psychological problems in the past (74% vs 48%, p = 0.01).
Diabetes distress: Primary and secondary care compared
The low participation rate in the trial also suggested that diabetes might be less of a burden 
and cause less emotional distress in people treated in a primary care setting than initially 
expected, and might be more of a burden to people with complex diabetes such as those 
treated in secondary care. About 90% of Dutch people with type 2 diabetes are treated in 
primary care. Indications for referral to secondary care include uncontrolled glucose levels, 
therapy resistant cardiovascular risk factors (e.g., persistent dyslipidaemia or hypertension), 
difficulties with the treatment of complications, such as nephropathy or painful neuropathy, 
or comorbidities that require specialised care [4]. Therefore, we expected that less diabetes-
specific emotional distress (diabetes distress) would be experienced in people with type 
2 diabetes treated in primary care compared to those treated in secondary care. This 
hypothesis was tested in Chapter 5 by comparing our data to data that previously had been 
collected in three outpatient clinics in the Netherlands. Demographic and clinical factors 
were explored that could explain potential differences in diabetes distress levels. This 
comparison of care settings confirmed our hypothesis. The prevalence of elevated diabetes 
distress was considerably lower in the primary care sample (4%) than in the secondary care 
sample (19%; odds ratio (OR) = 4.51, 95% confidence interval (CI) 3.51-5.81, p < 0.001). 
Demographic and clinical factors substantially attenuated the association between care 
setting and diabetes distress. The demographic variables age, sex, ethnic minority status, 
single status, and education level attenuated the odds from 4.51 to 2.97 (95% CI 2.26-3.91, 
p < 0.001). Adding the clinical variables diabetes duration, diabetes treatment (insulin yes/
no), BMI, and HbA1c further attenuated the association between care setting and diabetes 
distress from 2.97 to 1.71 (95% CI 1.19-2.45, p < 0.01). Surprisingly, having micro- or 
macrovascular complications only slightly attenuated the association between diabetes 
distress and care setting compared with the model including demographic variables (from 
OR = 2.97 to OR = 2.49, 95% CI 1.85-3.36, p < 0.001). In the fully adjusted model, the odds 
of having higher levels of diabetes distress in secondary care compared to primary care 
decreased to 1.53 (95% CI 1.05-2.22, p < 0.05). This study is the first to directly compare 
diabetes distress levels within one country and to show that levels of diabetes distress differ 
substantially between primary care and secondary care.
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Psychosocial health care needs 
Although diabetes guidelines advocate attention for psychosocial aspects, the exact 
psychosocial health care needs of people with type 2 diabetes have rarely been studied. Also, 
factors that could possibly be related to provision of psychosocial health care and accepting 
a psychosocial health care offer have hardly been studied. These topics were investigated 
from the perspective of people with type 2 diabetes and health care providers (HCPs; general 
practitioners, practice nurses, and diabetes nurses) in primary care using a qualitative study 
design (Chapter 6). Both in focus groups of people with type 2 diabetes (n = 20) and in focus 
groups of HCPs (n = 18) opinions differed considerably as to whether there was a need 
for psychosocial care. Not perceiving diabetes as a serious disease, effective coping, and 
the perception of receiving adequate social support diminished the need for psychosocial 
health care. The needs that were expressed focused predominantly on diabetes-specific 
issues, additional diabetes education when a person feels insecure about the condition, 
help with the acceptance process, and help in incorporating lifestyle advice into daily life. 
From that perspective, education how to deal with a hypoglycaemic event or individual 
tailored lifestyle advice could play an important role in diminishing or preventing emotional 
distress. Only a few people with diabetes reported a need for specialised psychosocial 
care. In general, people with diabetes were satisfied with the attention they received from 
their HCP for their well-being. However, several suggestions for improvements were made, 
such as “HCP’s should take more time (longer consultations) and take the context of the 
person into consideration”, and “HCP’s should also improve their communication skills”. 
A positive attitude of people with diabetes regarding psychosocial health care seemed to 
depend on several factors including previous experiences with psychosocial health care, 
but also prioritising a visit to the care provider in their busy schedule or personal beliefs 
about psychosocial care and the care provider. Few barriers were experienced when care 
was provided by an HCP with whom the person with diabetes was familiar (e.g., practice 
nurse or general practitioner). During the focus groups, it was also noted that the diabetes 
health care providers could play an important role in reducing barriers towards psychosocial 
health care.
COMPARISON OF THE CURRENT INTERVENTION WITH OTHER STUDIES 
Comparison with other stepped care models
The stepped care intervention that was tested in the present thesis appeared to be successful 
in reducing symptoms of anxiety and depression in people with type 2 diabetes, asthma, 
and/or COPD. To our knowledge, a basic stepped care intervention has not been evaluated 
before in these groups. Other basic stepped care interventions targeting symptoms of 




results [5-7]. Differences in the number of people (a) randomised to the intervention group 
(b) who actually started and (c) completed the treatment may be an important factor in 
explaining these mixed results. Randomised controlled trials are commonly analysed 
according to the intention-to-treat principle, meaning that participants are analysed in 
the group to which they were randomised (intervention or usual care), irrespectively of 
whether they started or completed the track to which they were allocated. A stepped care 
prevention trial by Van ‘t Veer-Tazelaar et al. targeting symptoms of depression and anxiety 
in elderly who did not fulfil the criteria for having a mood or anxiety disorder successfully 
halved the 12-month incidence of depressive and anxiety disorders [7]. In that trial, 92% of 
people allocated to the intervention group started the first treatment step [7]. In contrast, 
a stepped care trial by Van der Weele et al. aiming at reducing depressive symptoms in 
elderly actually found that care as usual was more effective than the stepped care treatment 
[6]. In the latter trial, the acceptance of the first treatment step was much lower (18%) 
[6]. Both trials were analysed according to intention-to-treat principles. In our trial, 96% 
started the first treatment step. In line with the results of the former trial [7], we found 
that the stepped care intervention resulted in significant improvements in depression/
anxiety. A stepped care trial by Seekles et al. found that 86% accepted the first treatment 
step, comprising of a self-help book or self-help internet course [5]. However, these authors 
found no beneficial effects of the stepped care intervention compared to the control group. 
This might have to do with the completion of the intervention. Seekles et al. were unable 
to determine how many lessons of the self-help treatment were followed, but thought that 
adherence to this treatment might have been low given the high drop-out rate after this first 
step (52%). The total stepped care program was completed by only 37% of all participants 
randomised to the treatment arm [5]. In the effective prevention trial of Van ‘t Veer-Tazelaar 
et al. 72% completed the stepped care program: 62 out of 86 people in the treatment arm 
still participated after 12 months. In our trial, 74% completed the stepped care program 
until (first) remission was reached. However, the reuptake of the intervention after a relapse 
occurred appeared to be rather low (3 out of 13; 23%). The acceptability of the treatment 
offered seems of crucial importance when interpreting treatment effectiveness. 
Basic stepped care versus collaborative stepped care models
An extended version of the stepped care model is the ‘collaborative’ stepped care model. 
The collaborative stepped care model involves not only stepped care, but also the use of a 
multidisciplinary team and a care manager [8]. This model has more often been evaluated 
in people with a chronic disease than the basic stepped care model [9]. For example, the 
Pathway study has tested the effectiveness of this collaborative stepped care model in people 
with type 2 diabetes in a US primary care setting. That study found that the collaborative 
care intervention resulted in a significant reduction of depressive symptoms, compared to 
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the usual care intervention, although the difference between both groups in the percentage 
of people with a 50% reduction in depressive symptoms did not reach statistical significance. 
Because there is evidence for both the effectiveness of the ‘basic’ stepped care model and 
the ‘collaborative’ stepped care model, one might ask what the added value is of having 
‘collaborative’ stepped care. It might be that in certain subgroups the extended version is 
more effective than the basic stepped care model. For example, in the National Institute of 
Health and Care Excellence (NICE) guideline from the United Kingdom it is hypothesised that 
the addition of a coordinated multidisciplinary team might be a particularly useful addition 
in people with severe or complex depression [9]. Future studies should determine when a 
collaborative stepped care model is to be preferred over a basic stepped care model. This 
could be accomplished by a randomised controlled trial comparing the (cost-) effectiveness 
of both models in the same country (i.e. within the same health care system). 
METHODOLOGICAL CONSIDERATIONS
External validity
The primary care practices that were taking part in the present studies were all located 
in one region of the Netherlands (Southeast-Brabant). This area is mainly rural and semi-
rural and therefore our results might not be easily generalisable to urbanised regions. For 
example, the number of people from ethnic minority groups is much higher in urbanised 
areas in the Netherlands. In Chapter 5, we have found that persons from ethnic minority 
groups reported higher levels of diabetes distress. Previous research has shown that in some 
ethnic minority groups, for example, Surinamese, having diabetes is often a taboo [10]. It 
could be hypothesised, therefore, that psychosocial health care needs might be perceived 
differently in ethnic minority groups.
 The low participation rate in the treatment trial might also limit the external validity 
of the results. However, based on the results of Chapter 4, it seems unlikely that a strong 
selection bias has occurred. There we showed that people who did and those who did not 
complete the screening questionnaire did not differ statistically significantly in terms of age, 
diabetes duration, HbA1c levels, systolic blood pressure, triglycerides and body mass index. 
However, non-responders were more often female (53% vs 44%, p < 0.001) and had slightly 
less optimal albumin/creatinine ratio (4.1 ± 15.4 vs 2.9 ± 11.6, p = 0.01) and LDL cholesterol 
levels (2.4 ± 0.9 vs 2.3 ± 0.8, p = 0.001). Unfortunately, we had no information about the level 
of emotional well-being in the group that did not complete the screening questionnaire. 
Participants and non-participants in the DiMaCoDeA trial did not differ regarding clinical 
variables and most demographic variables, except for education level. Participants had 
on average a higher education level. Furthermore, participants reported higher levels of 




finding might suggest that anxiety and depression symptoms are of a more chronic and 
recurrent nature in people who agree to participate in a treatment trial compared with non-
participants.
Blinding
When investigating a psychological intervention, it is often impossible to blind participants 
to the condition to which they are randomised. The fact that participants in both groups 
were not blinded might have inflated the effectiveness of the intervention [11]. For example, 
persons in the control group might have become disappointed, when they expected to 
receive additional help for psychological problems. However, persons in the control group 
were allowed to discuss the need for additional support for psychological problems with 
their primary care physician and our impression is that these disappointment effects have 
not occurred. Although we cannot exclude that some bias may have occurred, the large 
effect size suggests that even in the situation where a potential bias is taken into account, 
the DiMaCoDeA treatment group is likely to show greater benefit than the control group. 
Control group received more than just care as usual
Similar to the intervention group, the control group received a questionnaire every three 
months to assess symptoms of depression and anxiety: they received care as usual plus 
monitoring of symptoms. For ethical reasons, the GP was informed when a person in the 
control group had two consecutive scores ≥ 15 (moderately severe to severe symptoms) 
on the Patient Health Questionnaire (PHQ-9), assessing depression, or Generalised Anxiety 
Disorder Questionnaire (GAD-7), assessing anxiety. Three persons in the control group met 
this criterion. In case of possible suicidal thoughts (a score > 0 on the ninth item of the PHQ-
9) the person received a phone call and the GP was notified. The same procedure in case of 
possible suicidal thoughts was followed in the intervention group. Hence, people with such 
thoughts received more personal attention than people without these thoughts. During 
the 12-month DiMaCoDeA program, this procedure had to be followed for nine persons in 
the intervention group and for nine persons in the control group. The fact that the control 
group received more than just care as usual, particularly in people having possible suicidal 
thoughts (a symptom of depression), may be important in the interpretation of the results 
of the trial (as discussed below).
 The course of symptoms of depression and anxiety over time (PHQ-9 and GAD-7 total 
scores) for the intervention and control groups is displayed in Chapter 3 in Figure 4 and 5. 
The percentages of people having elevated symptoms of anxiety (GAD-7 ≥ 8 [12]) and/or 
depression (PHQ-9 ≥ 7 [13]) are displayed in Figure 1 below. In Figure 2 and 3 these results 
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Figure 1 Percentage of people with a GAD-7 score ≥ 8 and/or PHQ-9 score ≥ 7 in the intervention and 
control group. 
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Figure 3 Percentage of people with a PHQ-9 score ≥ 7 in the intervention and control group




 An inclusion criterion was having elevated scores on the GAD-7 and/or PHQ-9. Thus, 
100% has a heightened score on at least one of the two questionnaires at baseline (Figure 
1), but not all participants had heightened scores on both questionnaires at baseline (Figure 
2 and 3). In Figure 1 it can be observed that the percentage of positive cases decreased in 
both the control group (from 100% at baseline to 78% after 12 months and 47% after 18 
months) and the intervention group (from 100% at baseline to 67% after 12 months and 
37% after 18 months). The number needed to treat to have one additional person without 
elevated symptoms of anxiety and depression after following the 12-month DiMaCoDeA 
intervention was three.
 Regarding symptoms of anxiety, the percentage of positive cases at the end of the 
program (12 months post screening) and 6 months later (18 months post screening) was 
considerably smaller in the intervention group than in the control group (Figure 2). However, 
this difference was less pronounced for depression (not statistically significant at either 12 
months, p = 0.18, or 18 months, p = 0.09, Figure 3). As previously mentioned, in case of 
persistently high anxiety or depression scores in participants in the control group the GP 
was notified, but the participant was not contacted. However, the extra attention given to 
people in the control group experiencing possible suicidal thoughts (related to depression) 
and the notification of the GP about these thoughts, may partly explain why the stepped 
care intervention appeared less effective in reducing symptoms of depression. This suggests 
that monitoring in people with depression, including having direct contact with the patient 
by telephone in case of possible suicidal thoughts, might already have a beneficial effect. 
 An alternative explanation for the reduction in percentage of positive cases in both 
groups is the regression-to-the-mean effect [14]. A measured score contains the true mean 
score (feelings of anxiety/depression) and random error (e.g., random measurement error 
or random fluctuations in symptoms). Because people are selected based on a cut-off score, 
this means that the group scoring above the cut-off contains both people with true elevated 
symptoms of anxiety/depression and people who score above the cut-off due to random 
error (by chance). Measuring a second time the extreme scores are more likely to be closer 
to the true mean, and therefore less individuals will score above the cut-off [14].
Method of recruiting participants for the treatment trial
For the recruitment of participants for the DiMaCoDeA trial, a screening procedure was used 
based on two widely used and validated self-report questionnaires (PHQ-9 and GAD-7). An 
advantage of using such a screening procedure to identify people with elevated symptoms 
of depression and anxiety is that this method also reveals cases with currently unrecognised 
symptoms.
 However, only 27 persons with diabetes participated in the trial. This was only 21% of 
people with elevated symptoms (27/130) and 1.5% of those invited for screening (27/1837). 
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This means that the number needed to screen to have one participant in the trial is 68. 
Several other treatment trials targeting emotional distress in people with diabetes also 
showed similar low percentages (4-6%) of people invited for screening [15-18]. This 
suggests that it might be useful to consider other potentially more efficient methods to 
recruit people. 
 One alternative method might be case finding: focusing on high risk groups for mental 
health problems. One particular group at high risk of depression or anxiety are people who 
have experienced these symptoms in the past [19-21]. The results in Chapter 4 showed 
that among participants of the DiMaCoDeA trial, a considerable number had experienced 
previous psychological problems (74%), compared to non-participants with elevated 
symptoms (48%). This suggests that focusing on this high risk group might be useful.
 Another alternative is not to screen, but to recruit participants via referral by their 
primary health care provider. In their qualitative study, Van der Weele et al. [22] identified 
reasons for not starting the allocated treatment. Some participants stated that they 
missed the involvement of their GP in the process of deciding whether or not to start the 
treatment. In our focus group study, it has been mentioned that health care providers could 
play an important role in reducing certain barriers, for example, unrealistic expectations or 
irrational views regarding psychosocial health care. Thus, involving the primary health care 
provider (practice nurse or general practitioner) in the recruitment process might increase 
the participation rate. It is important to note that a meta-analysis about the effectiveness of 
psychological treatment of depression in primary care found larger treatment effects when 
participants were referred by their GP (d = 0.43; 95% CI 0.28-0.58) than when participants 
were identified through screening (d = 0.13; 95% CI -0.08-0.34) [23]. Similar results have 
been found in a meta-analysis on psychological treatment of anxiety in primary care, showing 
that the effect size of trials where participants were recruited through referral by their GP 
was d = 0.71 (95% CI 0.36-1.07) and lower (not statistically significant) when participants 
were recruited using a screening questionnaire, or both using a screening questionnaire 
and referral by the GP (d = 0.21; 95% CI -0.06-0.47) [24]. However, the major problem of 
this alternative is that it is well known that in general practice depression and anxiety are a 
commonly overlooked problem by health care providers which ultimately will not result in 
referral [25,26]. 
Change of the protocol
Originally, funding had been obtained from ZonMw to test the stepped care intervention in 
people with diabetes or COPD. When additional funding had been obtained, we changed 
our original plan and aimed to test stepped care separately in diabetes and asthma/COPD 
[27,28]. However, after substantial screening efforts, the number of participants in the trial 




being eligible and willing to participate in the trial (n = 27), we had to combine the two 
samples to be able to have sufficient power to analyse the effectiveness of the intervention. 
Even after combining both samples, the total number of persons that participated in the 
randomised controlled trial (n = 46) did not reach the required 128 that we had calculated 
to be necessary to have sufficient power to detect differences between the intervention and 
control group. Because of the relatively large effects of the intervention (Cohen’s d > 0.6), 
the sample size, however, appeared to be large enough to show a statistically significant 
effect, at least regarding symptoms of anxiety.
Continuous monitoring of symptoms
One particular element of our intervention that may have contributed to the effectiveness 
is the monitoring of symptoms of depression and anxiety. In the intervention group, 
monitoring of these symptoms was not only used for the assessment of symptoms between 
steps (to decide whether more intensive treatment was needed), it was also used after 
remission of symptoms in order to be able to detect relapse and offer treatment when 
relapse occurred. Because anxiety and depression are often recurrent [19-21], monitoring 
after remission could signal relapse, and facilitate the opportunity to quickly intervene when 
symptoms recur. 
 In (mental) health care settings the use of routine outcome monitoring (regular 
assessments of symptoms during the treatment process) has been shown to have favourable 
effects on treatment outcomes; especially when feedback was given both to practitioners 
and patients [29,30]. Previous research has shown that clinicians are often not accurate in 
judging progress and even less accurate in judging deterioration of symptoms [30]. Assessing 
symptoms during the treatment process using a questionnaire could aid clinicians to decide 
on treatment strategies and modifications. 
 Furthermore, a study in people with diabetes treated in secondary care that investigated 
the effect of monitoring on well-being in all people with diabetes (with and without 
elevated levels of emotional distress) showed beneficial effects. In that study, the diabetes 
nurse specialist discussed outcomes of the well-being questionnaire with the person with 
diabetes, and if needed subsequent treatment by a medical psychologist was offered [31]. 
Possible future improvements of the treatment model
Although the stepped care intervention (DiMaCoDeA) was effective in reducing symptoms 
of anxiety and depression, relapse of symptoms frequently occurred during the 12-month 
intervention period (13 out of 16 individuals). Relapse of anxiety and depression is common 
[19-21], but it would be worthwhile aiming at reducing the number of people who relapse. 
A possible solution might be to address relapse prevention during the first step of the 
stepped care programme. In the current model, specific attention for relapse prevention 
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was incorporated in step 2. Yet, more people will probably be reached when this topic is 
already discussed during step 1. In the DiMaCoDeA trial, most participants only completed 
the first step, because symptoms were in remission after the first step and, moreover, only 
a few were interested in following step 2 when a relapse occurred (3 out of 13 persons). 
 In contrast, the majority of participants for whom step 2 was indicated directly after step 
1, started and also completed step 2 (6 out of 7 people). This might suggest that the need 
for psychological support of people who have a recurrence of symptoms differs from people 
who did not yet improve after the first step. Reasons for not starting step 2 were: (a) not 
being interested, (b) having the believe that the intervention will not be helpful, (c) having 
an alternative explanation for complaints that required a different approach (e.g., financial 
problems), (d) having difficulties with reading, (e) cognitive problems, or (f) having started 
with specialised mental health care. Unfortunately, the DiMaCoDeA treatment model did not 
have the flexibility to offer other treatment options, for example, when people believed that 
the treatment modality in the next step was not suitable for them. To facilitate flexibility, the 
continued monitoring after remission could be performed by the primary diabetes health 
care provider including discussion of the results and preferred treatment options which 
could either be continuation with former treatment, start with other treatment, or only 
continuing with monitoring [31]. Our results suggest that a stepped care approach is useful 
in treat current symptoms of anxiety or depression, but an adapted stepped care approach 
may be needed in case a relapse occurs.
INTERPRETATION OF THE FINDINGS AND CLINICAL IMPLICATIONS
This thesis showed that the prevalence of emotional distress was highly dependent on the 
care setting in which it is investigated. We found a low prevalence rate of diabetes distress 
in people with type 2 diabetes treated in primary care compared with those treated in 
secondary care (Chapter 4) [32]. Other studies showed similar results regarding symptoms 
of depression [20,33]. In case people with type 2 diabetes experienced symptoms of anxiety 
and/or depression, we found that a stepped care intervention with continued monitoring 
of symptoms (the DiMaCoDeA intervention) was effective in reducing these symptoms in a 
primary care setting. However, we also noted that a minority of people with type 2 diabetes 
who were experiencing symptoms of anxiety and/or depression was actually interested 
in participating in the trial. The focus groups revealed that even though a minority may 
have specialised psychosocial health care needs, attention for psychosocial well-being in 
regular diabetes care and taking the personal situation into account to tailor treatment 
were appreciated and were described by some participants as preconditions for adequate 
diabetes care. Together, the findings of the present thesis lead to several important insights 





1. Psychosocial health care needs: An important role for the diabetes health care provider
Although focus groups acknowledge that the diabetes health care provider has an important 
role in addressing psychosocial issues and providing support, not all health care providers 
were confident in being sufficiently skilled for this task. Hence, improving competence of 
health care providers might be a useful starting point for improving psychosocial health 
care within primary diabetes care. Regardless of the prevalence of severe emotional 
problems, it is important that health care providers are aware of the negative interaction 
between psychosocial problems and diabetes. If more support is needed than the support 
provided by the diabetes health care provider, the DiMaCoDeA stepped care program could 
be an effective treatment option. Because some people expressed resistance in accepting 
psychosocial health care, their diabetes health care provider could play an important role 
in reducing these barriers; for example, by helping to create realistic expectations about 
specialised psychosocial health care, helping with referral, and stimulating the readiness to 
change.
2. Monitoring of symptoms of emotional distress during regular diabetes care
Even though the prevalence of elevated diabetes distress was low, focus groups revealed 
that attention for psychosocial well-being was appreciated and according to some, necessary 
for person-tailored care. This suggests that monitoring (regular discussion of emotional 
well-being) should be integrated in routine diabetes care. This could be achieved by 
regularly asking all people with diabetes about psychosocial well-being. Special awareness 
for emotional well-being is warranted in a subgroup, i.e. people with a known history of 
psychosocial problems. “Have you ever experienced psychological problems in the past?” 
is a simple question that could be added to the standard general medical history interview 
when a person enters into the diabetes care program to be able to identify people at risk for 
emotional problems. When diabetes distress, anxiety, or depression is identified, it seems 
prudent to intensify monitoring of symptoms, because of the chronic and recurrent nature 
of the symptoms [19-21,34,35]. Because people with type 2 diabetes in primary care are 
frequently visiting a practice nurse (approximately three times a year), these health care 
providers could play an important role in monitoring emotional well-being. However, focus 
groups revealed that not all diabetes health care providers consider themselves sufficiently 
competent to optimally address psychosocial issues. To facilitate discussing psychosocial 
problems and to aid monitoring of symptoms, an easily available and short set of questions 
could be a helpful communication tool. For discussing symptoms of depression and anxiety, 
the 4-item PHQ-4 could be used. This brief questionnaire consists of the first two items of 
the PHQ-9 (depression scale) and the first two items of the GAD-7 (anxiety scale) [36,37]. In 
addition, a question could be asked about the wish for help, for example, “is this something 
with which you would like help?” [38]. To assess diabetes distress, a one-item (“worrying 
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about the future and the possibility of serious complications”) and a 5-item version of the 
PAID have been developed [39]. Whether this selection of items is also the most optimal 
set to be used in Dutch primary care still needs to be evaluated. Also the 5-item well-
being questionnaire (WHO-5) could be a useful tool to monitor and facilitate discussion 
of emotional well-being [31,40]. This questionnaire consist of five positively formulated 
questions, for example, “I have felt cheerful and in good spirits”.
3. Role of specialised psychosocial health care providers within regular diabetes care
For optimal integration of psychosocial support within diabetes care, adding a mental health 
care professional to the diabetes team could be valuable. Within the general practice, this 
could be a mental health care nurse and/or a psychologist. Because some diabetes health 
care providers in the qualitative study were insecure about their competence regarding 
addressing psychosocial issues, the mental health care nurse or psychologist could coach 
the diabetes health care providers. Additionally, if support by the diabetes health care 
provider does not suffice, the mental health care professional could provide psychosocial 
care to the person with type 2 diabetes. Because some people experience resistance 
towards specialised psychosocial health care, the diabetes health care provider could play 
an important role in reducing barriers. When the diabetes health care provider is actively 
involved in discussing psychosocial well-being and discussing referral, more people might be 
willing to start with (stepped) treatment. 
CONCLUSIONS 
The present thesis focused on emotional distress in people with type 2 diabetes treated in 
primary care. Diabetes guidelines advocate addressing psychosocial issues within diabetes 
care, because of the heightened prevalence of depression, anxiety, and diabetes distress 
found in people with diabetes. This thesis revealed that people with type 2 diabetes treated 
in primary care experienced substantially lower levels of diabetes distress than those treated 
in secondary care, which may suggest that guidelines should make a distinction between care 
settings regarding their recommendations for emotional problems in diabetes. A stepped 
care intervention for symptoms of depression and anxiety that also included continued 
monitoring of symptoms was evaluated in the present thesis and appeared to be effective in 
reducing symptoms of depression and anxiety with large effect sizes. Although effective, this 
model can probably still be further improved, for example, by incorporating techniques that 
reduce the risk of relapse and by increasing treatment uptake after relapse. The method of 
general screening might not be optimal for trial inclusion, since screening efforts yielded only 
a few participants. Moreover, results from previous meta-analyses showed convincingly that 




their HCP (instead of detection after screening). Case finding and/or a greater involvement 
of the diabetes health care provider in this process might thus increase the effects and 
the reach of the intervention. The diabetes health care provider could play an important 
role in reducing barriers that may impede acceptance of a psychosocial health care offer. 
However, implementation of the DiMaCoDeA model does not seem to be the best starting 
point for improving psychosocial health care within primary diabetes care. The focus group 
study revealed that psychosocial support and taking the personal context into account 
were generally appreciated by people with diabetes who expected this to be part of regular 
diabetes care. However, not all diabetes health care providers considered themselves 
sufficiently competent for providing psychosocial support. This suggests that a conceivable 
next step in integrating psychosocial health care within current primary diabetes care is 
increasing the competence of the diabetes health care providers to engage in this task. The 
optimal way of enhancing these competences should be further investigated.
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In Nederland hebben ongeveer één miljoen mensen diabetes mellitus, ook wel diabetes 
of suikerziekte genoemd. Diabetes is een chronische aandoening waarbij het lichaam geen 
of onvoldoende insuline aanmaakt.  Insuline is nodig om glucose (suiker), de belangrijkste 
energiebron van ons lichaam, op te kunnen nemen in de lichaamscellen. Als glucose niet 
goed wordt opgenomen door de lichaamscellen, wordt de hoeveelheid glucose in het bloed 
hoog. Dit kan schade opleveren aan de bloedvaten en daarmee ook aan organen. Zo kan 
verhoogde glucose in het bloed leiden tot schade aan de ogen, nieren, zenuwen en hart, 
wat uiteindelijk kan leiden tot blindheid, nierfalen, amputatie van voet of been en een 
hartaanval. 
 De meest voorkomende vormen van diabetes zijn type 1 en type 2. Bij diabetes type 
1 raken bèta cellen in de alvleesklier beschadigd door een auto-immuun reactie van het 
lichaam. Hierdoor is het lichaam niet meer in staat om insuline te produceren. Bij diabetes 
type 2 is er sprake van een verminderde gevoeligheid van het lichaam voor insuline en 
produceren de bèta cellen onvoldoende insuline om aan de verhoogde vraag te kunnen 
voldoen. Ongeveer 90% van de mensen met diabetes heeft diabetes type 2 en deze vorm van 
diabetes staat centraal in dit proefschrift. Bij de meeste mensen ontwikkelt diabetes type 
2 zich op middelbare of oudere leeftijd. Naast een belangrijke genetische component heeft 
ook leefstijl (ongezond eten en weinig bewegen) invloed op het ontstaan van diabetes type 2. 
 De behandeling van diabetes is er op gericht om de complicaties van diabetes te 
voorkomen of te vertragen. Een belangrijk aspect daarbij is het onder controle houden 
van de glucosewaardes in het bloed. Dit kan worden bereikt door het verbeteren van de 
leefstijl (bewegen en gezond eten), het innemen van tabletten die de hoeveelheid glucose 
in het bloed verminderen, en/of het spuiten van insuline. De meerderheid van de mensen 
met diabetes type 2 wordt behandeld in de huisartsenpraktijk. Het grootste deel van de 
dagelijkse zorg voor diabetes wordt echter verricht door de persoon met diabetes zelf. 
Deze moet zorgen voor een gezonde leefstijl, zorgen dat de medicatie wordt ingenomen en 
mogelijk ook zelf de bloedwaarde in de gaten houden. 
 Het hebben van diabetes kan een zware emotionele belasting betekenen. De stress 
en negatieve emoties die specifiek gerelateerd zijn aan het leven met diabetes worden 
‘diabetesstress’ genoemd. Ook depressie en angstklachten komen vaker voor bij mensen 
met diabetes dan bij mensen zonder deze aandoening. Deze emotionele problemen zijn 
gerelateerd aan een ongunstig verloop van diabetes, zoals hogere bloedglucosewaardes, 
meer complicaties en een hogere sterfte. Ook hangen ze samen met een slechtere kwaliteit 
van leven.
Behandelen van angst- en/of depressieklachten bij mensen met diabetes type 2 
In dit proefschrift is onderzocht of een behandeling bestaande uit ‘getrapte’ psychologische 
zorg effectief is bij het behandelen van angst- of depressieklachten bij mensen met diabetes 
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type 2. Getrapte zorg houdt in dat met een eenvoudige behandeling wordt begonnen en 
als dat tot onvoldoende verbetering leidt, vervolgens een intensievere behandeling wordt 
aangeboden. In het behandelmodel dat door ons werd onderzocht bestond de eerste stap uit 
vier wekelijkse bijeenkomsten waarin psychoeducatie over angst- en/of depressieklachten 
werd gegeven, de tweede stap uit de cursus ''omgaan met angst/depressie'' (tien weken) 
en de derde stap uit een advies de wenselijkheid van medicatie tegen angst/depressie met 
de huisarts te bespreken en uit gesprekken voortbordurend op de cursus ''omgaan met 
angst/depressie'' (zes keer gedurende maximaal zes maanden). Na elke stap werd met 
een vragenlijst de ernst van angst- en depressieklachten gemeten. Aan de hand van die 
uitkomst werd bepaald of een volgende stap was geïndiceerd of dat de klachten alleen in 
de gaten zouden worden gehouden (monitoring fase). In de monitoring fase werden elke 
drie maanden angst- en depressieklachten gemeten. Als iemand terugval liet zien, dan werd 
opnieuw behandeling aangeboden. De interventie (getrapte zorg en monitoren) duurde in 
totaal 12 maanden. 
 Om de effectiviteit te bepalen van dit behandelmodel werden mensen met diabetes type 
2 en angst- en/of depressieklachten willekeurig ingedeeld in een groep die de interventie 
kreeg of een groep die gebruikelijke zorg ontving, de controlegroep. In de controlegroep 
werden ook elke drie maanden de angst- en depressieklachten gemeten. Om ethische 
redenen werd de huisarts op de hoogte gesteld als een deelnemer uit de controlegroep 
twee keer achter elkaar een hoge mate van angst- en/of depressieklachten rapporteerde. 
Ook werd de huisarts geïnformeerd over mogelijke suïcidale gedachten en werd in dat geval 
tevens contact op genomen met de betreffende persoon. In de interventiegroep werd bij 
mogelijke suïcidale gedachten dezelfde procedure gevolgd.
Effectiviteit van het behandelmodel 
Het behandelmodel werd niet alleen onderzocht bij mensen met diabetes type 2, maar ook 
bij mensen met de longaandoeningen astma en/of COPD wat staat voor chronic obstructive 
pulmonary disease. De reden dat bij de evaluatie ook mensen met een longaandoening 
werden meegenomen, was dat er onvoldoende deelnemers waren met diabetes om het 
behandelmodel apart in deze groep te evalueren. Mensen met diabetes type 2, astma en/
of COPD uit de deelnemende huisartsenpraktijken ontvingen een screeningsvragenlijst 
om de mate van angst- en depressieklachten te bepalen. Bij verhoogde klachten werden 
ze uitgenodigd om deel te nemen aan ons onderzoek naar de effectiviteit van het 
behandelmodel. Van de 3559 vragenlijsten die waren verstuurd kwamen 1336 exemplaren 
(38%) ingevuld terug. In totaal hadden 286 mensen een verhoogde score, van wie 46 
personen (16%) daadwerkelijk meededen aan ons onderzoek. 
 Aan het eind van de twaalf maanden durende interventie bleek de interventiegroep 
minder angst- en depressieklachten te rapporteren dan de controlegroep. Dit effect was in 
NEDERLANDSE SAMENVATTING 
131
termen van klinische relevantie behoorlijk groot, al was het verschil in depressieklachten 
tussen de interventie en controlegroep niet in elke analyse statistisch significant. Zes 
maanden na het einde van het behandelprogramma (18 maanden na het invullen van 
de screeningsvragenlijst) bleek dat de interventiegroep nog steeds minder angstklachten 
rapporteerde dan de controlegroep. Dit klinisch relevante verschil was ook zichtbaar bij 
depressieklachten, maar niet statistisch significant.
De weg van screeningsvragenlijst naar deelname aan het onderzoek
Opvallend was dat ondanks het grote aantal screeningsvragenlijsten dat was verstuurd 
maar relatief weinig mensen deelnamen aan het onderzoek naar de effectiviteit van 
het behandelmodel (46 deelnemers in totaal, waarvan 27 deelnemers met diabetes). 
Oorspronkelijk was berekend dat 64 mensen nodig waren in zowel de interventie- als de 
controlegroep (128 in totaal). Rekening houdend met mogelijk uitval van mensen vormde 
het werven van 160 deelnemers het uitgangspunt. Ondanks het lage deelnemersaantal (46) 
bleek dit aantal vanwege de grote verschillen tussen de interventie- en controlegroep na 12 
maanden toch voldoende om de effectiviteit van de interventie aan te kunnen tonen. Het 
lage aantal deelnemers riep echter wel een aantal nieuwe onderzoeksvragen op. Zo waren 
we benieuwd of er verschillen bestonden tussen mensen die de screeningsvragenlijst wel of 
niet terugstuurden, en tussen mensen met een verhoogde angst/depressiescore die wel of 
niet deelnamen aan het onderzoek.
 De weg van de screeningsvragenlijst naar deelname aan het onderzoek werd nader 
bekeken bij mensen met diabetes type 2. In totaal waren 1837 screeningsvragenlijsten 
verstuurd naar mensen met diabetes type 2. Daarvan kwam 42% ingevuld terug. Mensen 
die de vragenlijst niet terugstuurden waren vaker vrouw (53% vs. 44%) en hadden een 
iets ongunstiger LDL cholesterol niveau (risicofactor voor aderverkalking) en ongunstigere 
albumine/creatinine ratio, die iets zegt over het functioneren van de nieren. Er waren dus 
verschillen tussen mensen die de lijst wel en die deze niet terugstuurden, maar de verschillen 
waren niet groot.
 Van de mensen die een ingevulde vragenlijst hadden teruggestuurd had 21% (130 
personen) verhoogde angst- en/of depressieklachten. Van hen deden 27 mensen mee aan 
het onderzoek. Dat komt neer op 1,5% van het aantal mensen naar wie een vragenlijst 
was verstuurd. In vergelijking met niet-deelnemers (die wel verhoogde angst- en/of 
depressieklachten hadden) waren deelnemers hoger opgeleid en hadden ze meer last van 
diabetesstress. Ook gaven de deelnemers vaker aan in het verleden last te hebben gehad 
van psychische klachten dan niet-deelnemers. Het lage percentage mensen dat uiteindelijk 
deelnam aan het onderzoek suggereert dat het selecteren van deelnemers via het versturen 
van screeningsvragenlijsten niet de meest effectieve wervingsmethode is. 
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Diabetesstress: de huisartsenpraktijk en het ziekenhuis vergeleken
Het lage deelnemersaantal kan er op wijzen dat de diabetes geen grote stressfactor 
vormt voor mensen die in de huisartsenpraktijk onder behandeling zijn. Het zou kunnen 
zijn dat in een andere setting, het ziekenhuis, diabetes veel sterker gerelateerd is aan 
stress. De meeste mensen met diabetes type 2 (ongeveer 90%) worden behandeld in de 
huisartsenpraktijk. Verwijzing naar het ziekenhuis vindt plaats a) wanneer men er niet in 
slaagt om bloedglucosewaardes onder controle te houden, b) als bijkomende risicofactoren 
voor hart- en vaatziekten niet verbeteren door de gegeven behandeling (zoals bloeddruk 
en cholesterol), c) als complicaties van de diabetes specialistische zorg nodig hebben 
(bijvoorbeeld nierfalen of zenuwpijnen), d) als andere aandoeningen in combinatie 
met de diabetes gespecialiseerde zorg nodig hebben, of e) bij een zwangerschapswens. 
Doordat mensen die in het ziekenhuis worden behandeld complexere diabetes hebben, 
zou je kunnen verwachten dat die mensen meer stress ervaren door het leven met de 
diabetes (diabetesstress) dan mensen die in de huisartsenpraktijk onder behandeling 
zijn. In ons onderzoek hebben we de mate van diabetesstress vergeleken tussen deze 
twee groepen en we vonden inderdaad dat de mate van diabetesstress lager was in de 
huisartsenpraktijk dan in het ziekenhuis. Het was echter opvallend dat het verschil zo groot 
was. In de huisartsenpraktijk ervoer 4% een grote mate van diabetesstress, tegenover 
19% in het ziekenhuis. Demografische verschillen tussen mensen die behandeld werden 
in de huisartsenpraktijk en het ziekenhuis konden deels het verschil in diabetesstress 
verklaren. Jongere leeftijd en het behoren tot een etnische minderheidsgroep hingen 
ook onafhankelijk van setting (huisartsenpraktijk of ziekenhuis) samen met meer ervaren 
diabetesstress. Klinische factoren konden het verschil in diabetesstress verder verklaren, 
waarbij het gebruik van insuline, een hogere body mass index (verhouding tussen gewicht 
en lengte) en hogere bloedglucose waardes onafhankelijk van setting samenhingen met 
meer diabetesstress.  Opvallend was dat het hebben van complicaties maar een klein deel 
kon verklaren van het hogere percentage van diabetesstress in het ziekenhuis.
Behoefte aan psychosociale hulp
Richtlijnen binnen de diabeteszorg onderschrijven het belang van aandacht voor 
psychosociale aspecten bij mensen die diabetes hebben. Er is echter maar weinig onderzoek 
gedaan naar de behoeftes die mensen met diabetes type 2 hebben op het gebied van 
psychosociale hulp. Door middel van focusgroepen met mensen met diabetes type 2 en 
met hulpverleners (praktijkondersteuners en huisartsen) hebben wij dit nader onderzocht. 
De behoeftes waren divers. Weinig behoefte aan psychosociale hulp was er bijvoorbeeld 
als mensen hun diabetes niet zagen als een ernstige aandoening, als ze aangaven goed 
met de aandoening om te kunnen gaan of aangaven voldoende steun te ontvangen uit hun 
omgeving. De behoeftes die werden genoemd in de focusgroepen richtten zich voornamelijk 
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op de diabetes zelf, zoals behoefte aan meer uitleg over de diabetes (bijv. hoe kan je een 
hypoglykemie - te lage bloedglucosewaarde - voorkomen), hulp bij het accepteren van de 
aandoening en hulp op maat bij het inpassen van de behandeladviezen  in het dagelijks leven 
(bijv. meer bewegen en afvallen). Deze hulp kan helpen bij het voorkomen en verminderen 
van (diabetes) stress. Slechts een enkeling gaf aan behoefte te hebben aan gespecialiseerde 
psychosociale hulp naast de hulp van de diabetes hulpverlener. Velen gaven aan tevreden 
te zijn over de (psychosociale) hulp die ze ontvingen van hun diabetes hulpverleners. Er 
werden echter ook diverse verbeterpunten genoemd, zoals meer tijd nemen, meer de 
persoonlijke situatie in ogenschouw nemen, en verbeteren van communicatievaardigheden. 
Niet alle hulpverleners voelden zich voldoende zeker over hun vaardigheden in het bieden 
van psychosociale hulp.
 De mate waarin mensen met diabetes openstonden voor het accepteren van hulp door 
een psychosociale hulpverlener verschilde. Een positieve houding werd beïnvloed door 
eerdere positieve ervaringen met psychosociale hulpverlening of door positieve verhalen 
die ze erover  hadden gehoord.  De drempel om psychosociale steun te ontvangen bleek 
lager als het ging om een diabetes hulpverlener in vergelijking met een psychosociale 
hulpverlener (bijv. een psycholoog of maatschappelijk werker). Ook werd gesuggereerd 
dat diabetes hulpverleners de drempel konden verlagen om de stap te zetten naar een 
psychosociale hulpverlener, bijvoorbeeld door een verwijzing bespreekbaar te maken.
 De punten die werden genoemd door mensen met diabetes en door hulpverleners 
kwamen vaak overeen. Een in het oog springend verschil was dat mensen met diabetes 
frustraties rondom de zorg noemden als een stressfactor en daarmee ook als aandachtspunt 
om de stress te verminderen, terwijl dit niet door hulpverleners werd genoemd. Hulpverleners 
noemden nog dat seksuele problemen en eet-/alcoholverslaving bij mensen met diabetes 
extra aandacht nodig hebben. Ook gaven hulpverleners aan dat een psychosociale 
hulpverlener behulpzaam zou kunnen zijn bij het bewerkstelligen van gedragsverandering 
(zoals eet- en beweeggewoontes) bij mensen met diabetes.
CONCLUSIES
Stressklachten gerelateerd aan het leven met diabetes type 2 komen in de huisartsenpraktijk 
in veel mindere mate voor dan in het ziekenhuis. Toch geven mensen met diabetes type 
2 aan dat aandacht voor de gehele persoon, inclusief het psychosociaal welzijn, gewenst 
is. De diabeteshulpverlener heeft een belangrijke rol bij de psychosociale zorg en het 
voorkomen of wegnemen van stress. Dit kan gerealiseerd worden door extra aandacht 
te besteden aan de kennis en de beleving van diabetes. Ook is gerichte aandacht voor de 
persoon zelf belangrijk, zoals het regelmatig informeren naar de thuissituatie. Omdat een 
deel van de hulpverleners onzeker was over de eigen vaardigheden en capaciteiten op het 
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gebied van communicatie en het bieden van psychosociale hulp, zou het verbeteren van 
die vaardigheden een startpunt kunnen zijn om beter aansluitende psychosociale zorg aan 
mensen met diabetes te bieden. Als extra begeleiding voor angst- of depressieklachten 
wenselijk is, dan is een behandelmodel bestaande uit getrapte zorg en het monitoren van 










Het zit erop. Het proefschrift is af! 
Tijdens mijn studie stelde ik mij promoveren voor als vier jaar lang alleen in een kamertje 
achter een computer je verdiepen in één vierkante millimeter. Dat leek mij niet direct een 
droombaan en daar heb ik na mijn studie dan ook niet gelijk voor gekozen. Onderzoek doen 
dat praktisch toepasbaar was, dat sprak mij wel aan. Alleen bij onderzoek doen, kom je toch 
al snel bij promoveren uit. Gelukkig bleken er ook promotietrajecten te zijn die zich richtten 
op de praktijk. Toen ik vijf jaar geleden dit onderzoek voorbij zag komen, heb ik de stap 
aangedurfd. Dat lichaam en geest elkaar beïnvloeden vond ik fascinerend en daar paste het 
onderzoek naar psychische klachten bij diabetes goed bij. 
Het promoveren zelf bleek afwisselend. Het was helemaal niet in je eentje in een kamertje 
verpieteren achter een computer. Daarbij ben ik dankbaar voor de mogelijkheden die 
mij tijdens het promotietraject werden geboden. De combinatie universiteit, zorggroep 
en huisartsenpraktijk paste goed bij mij. Bij de universiteit vond ik gedegen kennis over 
methoden en statistiek en wat er in de wetenschappelijke literatuur bekend is over 
psychische aspecten bij mensen met een chronische aandoening; bij de zorggroep PoZoB 
kreeg ik meer van de praktijk mee, zoals hoe de zorg in de eerstelijn is georganiseerd en 
wat de belangen zijn voor de praktijk; en de huisartsenpraktijken boden inzicht hoe het er 
op de werkvloer aan toe gaat en stelden me in staat om verdere ervaring op te doen met 
het geven van behandelingen. Via interviews, focusgroepen en behandelingen hoorde ik 
van mensen met diabetes, astma en/of COPD hoe zij hun aandoening ervoeren. Behoorlijk 
afwisselend. En ja, alleen in een kamer achter de computer zitten kwam ook voor. Tijdens 
het promoveren sta je er echter niet alleen voor. Er zijn veel mensen die direct of indirect 
hun bijdrage hebben geleverd.
Allereerst wil ik alle deelnemers en huisartsenpraktijken bedanken die aan de onderzoeken 
hebben meegewerkt. Dit onderzoek is voor jullie, en zonder jullie medewerking was dit 
proefschrift nooit tot stand gekomen.
Aan de universiteit stonden de volgende (co)promotoren voor me klaar om me te begeleiden 
bij het promotieonderzoek: Professor dr. Pouwer, Professor dr. Pop en dr. Nefs. Beste Frans, 
bedankt voor het vertrouwen dat je me hebt geschonken. Ik bewonder jouw enthousiasme 
voor de wetenschap en je kennis over het onderwerp. Dank voor je begeleiding. Beste 
Victor, ik heb me erg gesteund gevoeld door het feit dat ik wist dat ik bij je terecht kon als het 
nodig was en dat je signaleerde wanneer begeleiding nodig was. Ik heb wel met verbazing 
gekeken hoe je als een wervelwind een kamer binnen kwam, snel kon schakelen tussen 
de verschillende aio’s met hun verschillende projecten en even snel weer uit de kamer 
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verdwenen kon zijn. Bedankt voor je vertrouwen, steun en begeleiding. Gouden Giesje! 
Wat super fijn dat je het laatste jaar bij mijn proefschrift werd betrokken! Ik kon altijd bij 
je binnenlopen, en met een kamer naast die van mij was dat heel gemakkelijk. Heel erg 
bedankt voor je kritische en nauwkeurige blik en je luisterend oor.
Nog meer mensen van de universiteit ben ik dankbaar voor hun bijdrage. Viola, jou wil ik 
nog even noemen. Jij bent aan het begin van het traject betrokken geweest als co-promotor. 
Bedankt voor toen! Brenda, bedankt voor je advies bij het kwalitatieve onderzoek. In soms 
slechts een paar minuten wist je me alweer stappen verder te helpen. Als ik even het spoor 
bijster was en alleen nog maar de bomen zag, wist jij me het bos te tonen. Dank daarvoor! 
Marion, voor vragen over Excel en het maken van syntaxen was ik bij jouw aan het goede 
adres. Ook bij het opzetten van de logistiek van de trial was je een welkome vraagbaak. Dank 
je wel! En ook dank voor de gezellige kletspraatjes J. Overige collega’s, en in het bijzonder 
Wobbe (bedankt voor je statistische advies!), de ‘wandelclub’ en vele kamergenootjes 
(Antoinette, Erla, Fleur, Giesje, Helma, Jenny, Mariëlle, Marion, Mariska, Moniek, Lianne, 
Olga, Simone, Mirela, Corline, Hester, Marleen P, Anke en Kim) bedankt voor jullie adviezen, 
gezelligheid en wandelingen door het bos. Het bos waar we in de pauze een rondje liepen 
noemde ik vaak wel even als mensen me vroegen naar mijn werk aan de universiteit. De 
wandelingen, de konijntjes die langs het raam hupten en de vogels en eekhoorntjes die 
langs kwamen verhoogden het werkplezier. 
Antoinette en Lianne, fijn dat jullie mijn paranimfen zijn! Lieve Antoinette, wat een 
geluk dat we samen waren aangenomen op het DiMaCoDeA project. Het klikte goed en 
de samenwerking verliep op rolletjes (al was dat met het project zelf soms wat anders). 
Daarnaast vond ik het waardevol om zo betrokken te zijn bij elkaars leven. Voor grote vragen 
of kleine vragen (tips voor campings in Frankrijk, of waar ik het beste een jurkje zou kunnen 
kopen) kon ik bij je terecht. Victor noemde ons wel de siamese tweeling. Bedankt  voor de 
samenwerking, de gezelligheid en je wijze woorden. Lieve Lianne, we waren al collega’s 
bij het Trimbos-instituut, daarna ben ik je achterna gegaan naar Tilburg. Aan jouw heb ik 
te danken dat ik dit promotieonderzoek ben begonnen. En nu zijn we weer collega’s bij 
PoZoB. Bedankt voor het me wegwijs maken in de nieuwe functies, je adviezen, je steun en 
gezelligheid. 
PoZoB, bedankt voor de plezierige samenwerking! Arnold en Niels, bedankt voor het bieden 
van de mogelijkheid om dit project in nauwe samenwerking met PoZoB uit te voeren, 
en bedankt voor het meedenken over het onderzoek. Colette, jij zorgde ervoor dat het 
onderzoek bij PoZoB zo goed mogelijk kon verlopen. Daarnaast ook dank voor het bieden 
van de kans om als projectmanager bij PoZoB aan de slag te gaan. Ruud en Martha, bedankt 
voor het meedenken bij het opzetten van de interventie.
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ZonMw en het Center of Research on Psychology in Somatic diseases, dank voor de financiële 
middelen om dit proefschrift tot stand te laten komen.
Ook dank aan andere mensen die bij het promotieonderzoek betrokken waren. Asha, 
bedankt dat je me de kneepjes van psychologische gesprekvoering hebt bijgebracht, en voor 
je supervisie gedurende dat proces. Lara, bedankt voor je assistentie bij de focusgroepen en 
de uitwerking van de transcripten. Antoine en Saffira, bedankt voor jullie invoerwerk. Co-
auteurs, dank voor jullie waardevolle feedback. 
Leden van de promotiecommissie, dank voor jullie tijd om mijn proefschrift kritisch te lezen 
en voor het stellen van vragen tijdens de verdediging van mijn proefschrift.
Lieve vrienden, bedankt voor de welkome afwisseling naast het werk. Elske en Marieke, 
twee toffe huisgenootjes, wat super om met jullie een huishouden te hebben mogen delen 
en natuurlijk lief en leed. Nu weet ik ook dat je met andijvie veel meer kan doen dan alleen 
stampot maken; wokken bijvoorbeeld, of door de soep doen. Ik vond het mooi om te zien wat 
een (voor mij nog verborgen) talenten jullie bleken te hebben; wat kan jij mooi portretten 
tekenen, Elske; en Marieke, het op en neer fietsen naar Berlijn zullen maar weinigen je 
na doen. Dank voor jullie vriendschap! Vrienden van het koor (en orkest), wat heerlijk om 
naast het werk lekker te kunnen zingen. Bedankt voor de gezellige momenten samen! Ik ga 
niet iedereen persoonlijk bij naam noemen, maar twee wil ik er nog even uitlichten. Meike, 
fijn om tips en trucs uit te kunnen wisselen rondom het promoveren en in het bijzonder 
het plannen. Ik heb er bewondering voor hoe jij dat doet. Barbara, wat leuk om ook even 
collega’s te worden en dat je ons bij PoZoB kwam versterken. Onze autoritjes van Utrecht 
naar Veldhoven heb ik waardevol gevonden. Tineke, Franka en Sita, dank voor de gezellige 
bijkletsmomenten! Mariëtte, je voelt al haast familie, zo lang zijn we vriendinnen. Dat er nog 
velen jaren van vriendschap mogen volgen!
Lieve pap, mam, Evert-Jan, Martijn, opa en oma, bedankt voor jullie interesse, steun en 
gezelligheid. Pap en mam, ik heb me altijd gesteund gevoeld bij de keuzes die ik heb gemaakt. 
Fijn dat ik altijd bij jullie terecht kan. Evert-Jan, bedankt dat je tussen al jouw activiteiten 
door het logo voor ons DiMaCoDeA project hebt ontworpen. Martijn, allebei hebben we 
dit jaar een mijlpaal bereikt; ik heb mijn promotieonderzoek afgerond, jij je studie. Ik ben 
trots op je! Jules en Mitrees, wat een mooi plekje hebben jullie gevonden in Udenhout. Wat 
worden we daar verwend met culinaire hoogstandjes en een eigen logeerhuisje. Bedankt 
voor jullie warme onthaal.
DANKWOORD
140
Lieve Caspar, de laatste woorden zijn voor jou. Ik voel me dankbaar dat ik jou ben tegen 
gekomen. Gedurende de laatste maanden van mijn promotietraject (tevens de eerste 
maanden van ons samenwonen) was ik misschien ietwat minder gezellig door de vele uren 
die ik achter de computer doorgebracht, maar nu is het af. Ook jij hebt daar je steentje 
aan bijgedragen. Je hebt zelfs voor een artikel de citaten van spreektaal Nederlands naar 
spreektaal Engels vertaald. Dank daarvoor! Ik geniet van onze tijd samen, de fietstochtjes, 
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